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6-OHDA - 6-hydroxydopamine 
AAV - adeno-associated virus 
ANT - adenine nucleotide transporter 
AD - Alzheimer’s disease 
ADP - adenosine diphosphate  
ATP - adenosine triphosphate 
BAX - bcl-2-associated X protein 
bGH - bovine growth hormone derived polyadenylation site 
bp - base pairs 
BPB - bromphenol blue sodium salt  
BSA - bovine serum albumine 
cAMP - cyclic adenosine monophosphate 
CNS - central nervous system 
COMT - catechol-O-methyltransferase  
CPu - caudate putamen (striatum) 
Cx - cortex 
DA - dopaminergic 
DAPI - 4',6-diamidino-2-phenylindole 
DIV - day in vitro 
DMEM - Dulbecco’s modified Eagle’s medium 
DNA - desoxyribonucleic acid 
DsRed - red fluorescent protein 
DTT - dithiothreitol 
EDTA - ethylenediaminetetraacetic acid 
EGFP - enhanced green fluorescent protein 
ELISA - enzyme-linked immunosorbent assay 
ERK - same as MAPK 
FA - formaldehyde 
FCS - fetal calf serum 
FG - fluorogold 
FPLC - fast protein liquid chromatography 
GABA - γ-aminobutyric acid 
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GDNF - glial cell line-derived neurotrophic factor 
GFAP - glial fibrialy acidic protein 
GFL - GDNF family ligands 
GFR - GDNF family receptor 
GP - globus pallidus 
GPe - globus pallidus externum 
GPi - globus pallidus internum 
GPI - glycosyl phosphatidylinositol  
GSH - glutathione 
HNC - hippocampal neuron cultureshSyn1 – human synapsin 1 gene promoter 
HRP - horse reddish peroxidase 
HSPG - heparan sulfate proteoglycan 
Int - intron 
LB - Luria broth  
L-DOPA - 1-3,4-dihydroxyphenylalanine  
MAPK- mitogen-activated protein kinase, same as ERK 
MAO-A - monoamine oxidase A 
MAO-B - monoamine oxidase B 
mCMV - murine cytomegalovirus immediate early promoter 
MFB - medial forebrain bundle 
MPTP - 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin 
MWCO - molecular weight cut off  
NBM - neurobasal medium 
NCAM - neural cell adhesion molecule 
NDD - neurodegenerative disorders 
NIA - National Institute on Aging (United States of America) 
NGS - newborn goat serum 
NS - nervous system 
nsP - non-structural protein 
ORF - open reading frame 
PAGE - polyacrylamide gel electrophoresis 
PBS - phosphate buffered saline 
PCR - polymerase chain reaction 
PD - Parkinson’s disease 
PDGFR - platelet-derived growth factor receptor 
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PFA - paraformaldehyde 
PI3K- phosphatidylinositol 3-kinase 
PLCγ - phospholypase-Cγ  
PNS - peripheral nervous system 
PS (-N) - penicillin-streptomycin (-neomycin) 
PTP - permeability transition pore 
RET - receptor tyrosine kinase 
RGC - retinal ganglion cell 
ROS - reactive oxygen species 
RT - room temperature 
RT-PCR - real time PCR  
SDS - sodium dodecylsulfate  
SFV - Semliki-Forest virus 
SN - substantia nigra of the midbrain 
SNpc - substantia nigra pars compacta 
STN - subthalamic nucleus 
SV40 - simian virus 40 polyadenylation site 
TB - synthetic transcription blocker 
TBS - tris-buffered saline 
TBS-T - TBS-tween 
TCA - tricyclic aminoacids 
TEMED - tetraeminethylendiamine  
TH - tyrosine hydroxylase 
TH-IR - TH immunoreactive  
TNF - tumour necrosis factor 
TRAIL - tumour necrosis factor-related apoptosis-inducing ligand  
VTA - ventral tegmental area of the midbrain 
WPRE - woodchuck hepatitis virus posttranscriptional regulatory element 
WB - western blotting 









1.1. Neurodegeneration  
Nervous system disorders are a major cause of morbidity in the western society, 
which impair quality of life to a degree rarely affected by other diseases. More than 1% of the 
population suffer from Parkinson’s disease after reaching 55 years of age (de Rijk, M. C. et al., 
1997) and nearly half of those who reach the age of 85 years and older suffer from Alzheimer’s 
disease (excerpt from NIA's Progress Report on Alzheimer's Disease, 1998: NIA). Among the 
factors contributing to the burdensome cost of managing neurodegenerative diseases is the fact 
that only few symptomatic and no causative therapies are currently available. Despite 
considerable efforts in basic research, novel diagnostic approaches and effective therapies have 
yet to be developed. 
The majority of human neurodegenerative diseases is not related to inherited mutations 
of specific proteins but develops with aging as a multifactorial pathology. It is often 
characterized by features of oxidative stress (Tretter, L. et al., 2004) and axonal degeneration 
preceding neuronal cell loss, as demonstrated for Alzheimer’s disease (Stokin, G. B. et al., 
2005), Parkinson’s disease (Dauer, W. et al., 2003), Huntington’s and other polyglutamine 
diseases (Gunawardena, S. et al., 2005;Li, H. et al., 2001). Various experimental animal 
models of neurodegenerative diseases have been developed to provide a better understanding 
of the complex mechanisms involved in neurodegeneration and to serve for the preclinical 
evaluation of prospective diagnostic tools and therapies. However, every model can reflect 
only certain aspects of the complex aetiology of respective diseases in humans. Thus, the 
evaluation of neuroprotective strategies aiming at generalized inhibition of neurodegeneration 
should be performed in more than one particular model system. Furthermore, considering the 
diversity of mechanisms leading to neurodegeneration, effective human therapy may 
necessitate targeting of more than one neurodegenerative pathway.  
 
1.2. Parkinson’s disease (PD) 
1.2.1. Prevalence and symptomatology of PD  
Parkinson’s disease is the second most common neurodegenerative disorder, which 
affects more than 1% of 55-year-old individuals and more than 3% of those over 75 years of 
age (de Rijk, M. C. et al., 1997). The overall age- and gender-adjusted incidence rate is 13.4 
per 100,000, with a higher prevalence among males (19.0 per 100,000) than females (9.9 per 
100,000)(Van Den Eeden, S. K. et al., 2003). It was initially described by James Parkinson in 
1817 and characterized by a typical triad of symptoms: 1) poverty and slowness of movement 
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without paralysis (bradykinesia), 2) changes in posture and muscle tone towards rigidity and 3) 
resting tremor. In most cases these symptoms are sufficient for the diagnosis of the disease 
(Hughes, A. J. et al., 2001). Psychological symptoms and autonomic nervous system 
dysfunction typically develop as the disease progresses and often become a major cause of 
disability.  
 
1.2.2. Morpho-pathological background of PD 
The pathological basis of the disease remained unknown for over 100 years, although 
the clinical features have been well-described. The importance of the substantia nigra (SN) was 
emphasized by Tretiakoff in 1919, who studied the substantia nigra in thirteen cases of 
parkinsonism and found lesions in this nucleus in all cases. The SN, named so because of the 
native content of the neuromelanin pigment, was noted to show depigmentation, loss of nerve 
cells, and gliosis. Tretiakoff also confirmed the earlier observation of Lewy (1914), who had 
found the presence of lipophylic cytoplasmic inclusions in Parkinson’s disease, now referred to 
as Lewy bodies and recognized as the pathologic hallmark of the disorder. In 1959, at the 
International Catecholamine Symposium, Carlsson suggested that Parkinson’s disease was 
related to brain dopamine. In 1960, Ehringer and Hornykiewicz, using Carlsson’s 
methodology, measured greatly reduced DA concentrations, to about one-tenth of normal, in 
the caudate, putamen and substantia nigra in brains from parkinsonian patients. The underlying 
key morphopathological feature is the progressive loss of dopaminergic (DA) neurons in the 
substantia nigra pars compacta (SNpc) of the midbrain, with intracytoplasmic inclusions (Lewy 
bodies) in the remaining intact nigral neurons (Braak, H. et al., 2000;Forno, L. S., 1996). It is 
believed that the disease becomes symptomatic when 50-60% of DA neurons in SNpc and 
more than 70-80% of their projections in the striatum are lost (Deumens, R. et al., 2002). 
Moreover, the severity and the stage of the disease are correlated with the extent of 
neurodegeneration (Riederer, P. et al., 1976;Fearnley, J. M. et al., 1991;Foley, P. et al., 1999). 
DA neurons of SNpc also have a tendency to degenerate with aging at a rate of approximately 
5% per decade (Fearnley, J. M. et al., 1991). In PD patients, however, both the rate and the 
pattern of DA neurodegeneration significantly differ from that observed during normal aging. 
Thus, the DA neuronal loss in PD in contrast to normal aging is uneven and occurs mainly in 
the ventro-lateral part of SNpc. While during normal aging the rate of neurodegeneration is 






1.2.3. Genetic clues to the etiology of PD 
Despite the early descriptions of clinical and pathomorphological features of PD the 
etiology of the disease remains unclear. Several genes which are implicated in rare familial 
forms of PD have been identified over the last decade and revealed novel proteins and 
pathways that may induce parkinsonism as a result of nigral neurodegeneration. The genetic 
load of known mutations in PD is small, accounting for less than 5% of the overall PD 
population. However, the typical and extremely consistent phenotype of both idiopathic and 
familial PD suggests that one common molecular mechanism may underlie PD. Similar 
pathways underlying familial forms of the disease might be strongly implicated in the 
pathogenesis of the sporadic forms. Understanding the pathogenesis of the sporadic form of PD 
will have the greatest impact on advancing novel therapies for this common incurable 
neurodegenerative disorder. Five disease genes (SNCA, PARK2, PINK1, DJ-1, LRRK2) have 
been conclusively implicated in PD (Abou-Sleiman, P. M. et al., 2006), out of which the most 
studied are the mutations in the gene encoding for α-synuclein. This protein has also been 
detected as a major component of the Lewy bodies suggesting its unequivocal role in DA 
neurons degeneration. The only genetic evidence associating a single mutation in UCHL1 gene 
with PD was not sufficient for the conclusive linkage (Abou-Sleiman, P. M. et al., 2006;Leroy, 
E. et al., 1998). 
Data obtained from studies on DJ-1 and PINK1 mutations may serve as an indirect 
evidence of the seminal role of mitochondrial dysfunction and oxidative stress in PD 
pathogenesis. Endogenous DJ-1 is localised to the mitochondrial matrix and the mitochondrial 
intermembrane space in addition to its cytoplasmic pool (Zhang, L. et al., 2005), and may act 
as an antioxidant since it can be oxidized at the cysteine residue C106. Furthermore, a 
quantitative proteomic study of the SN of mice treated with MPTP revealed a significant 
increase in the protein DJ-1 in mitochondrial fraction of the SN (Jin, J. et al., 2005). These data 
suggest that DJ-1 may be involved in neuroprotection of DA neurons from oxidative damage. 
Another protein implicated in PD, PINK1, consists of a highly conserved kinase domain 
(Unoki, M. et al., 2001;Nakajima, A. et al., 2003) and a mitochondrial targeting motif 
(Valente, E. M. et al., 2004). Together with the study showing localization of PINK1 to 
mitochondria in transfected cells (Beilina, A. et al., 2005), this data may suggest that PINK1 
may also act as a protein protecting from oxidative stress (Valente, E. M. et al., 2004). 
Mutation and polymorphism in another gene, encoding the mitochondrial protease HtrA2/ Omi 
have been recently associated with PD (Strauss, K. M. et al., 2005).  
In addition, possible susceptibility genes (e.g. NR4A2, SNCAIP) that may increase, or 
decrease the risk of an individual to develop PD have been identified. However, since only a 
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minor group of PD patients reveal a genetic predisposition, external factors influencing the 
initiation and progression of the disease must be examined.  
 
1.2.4. Environmental contribution to the etiopathogenesis of PD 
One of the earliest hypotheses of PD pathogenesis was based on the finding that three 
inhibitors of mitochondrial complex 1, namely MPTP, rotenone and paraquat, were able to 
reproduce parkinsonism with selective DA neuronal loss in mice and primate models (Seniuk, 
N. A. et al., 1990). The first toxic models of PD did not fully reproduce the features of the 
disease, mainly because of the absence of one of the major pathological hallmark of PD, the 
Lewy body. Later, a chronic infusion of either rotenone (Betarbet, R. et al., 2000) or MPTP 
(Fornai, F. et al., 2005) in rodents was shown to induce the formation of α-synuclein positive 
aggregates. These data support the theory that sporadic PD may be caused by a combination of 
genetic predisposition and environmental toxins, which act via inhibition of the mitochondrial 
complex I to produce selective DA cell loss. Inhibition of complex I may result in the depletion 
of ATP leading to impairment of all ATP dependent cellular processes, and in generation of 
free radicals responsible for oxidative stress damage. Clear evidence of increased oxidative 
stress was found in postmortem PD brains, as compared to the age-matching controls 
(Andersen, J. K., 2004;Sian, J. et al., 1994). Furthermore, a reduced activity of complex I was 
found in the brains of idiopathic PD patients (Schapira, A. H. et al., 1990;Parker, W. D., Jr. et 
al., 1989).  
 
1.2.5. Mechanisms of cell death in PD 
The loss of dopaminergic neurons in SNpc is a characteristic feature of PD. However, 
mechanisms underlying this neurodegeneration are not very well understood. Different modes 
of cell death, apoptotic, necrotic and autophagic have been described to contribute to the 
neuronal loss occurring in PD (von Bohlen und Halbach O. et al., 2004;Blum, D. et al., 2001). 
Several pathogenetic mechanisms have been proposed to be implicated in cell death observed 
in PD: mitochondrial dysfunction and oxidative stress, defective proteolysis and proteotoxic 
stress, excitoxicity, and inflammation (Gandhi, S. et al., 2005;von Bohlen und Halbach O. et 
al., 2004;Blum, D. et al., 2001). It is likely that PD pathogenesis is multifactorial and all 
mechanisms listed above to a certain extent contribute to the PD associated degeneration of 
nigrostriatal neurons. However, one of the single mutations described above, being present in 
all cells of the body, affects specifically DA cells in SNpc and results in clinico-pathological 
characteristics of PD.  Furthermore, the fact that mutations described in PD affect the proteins 
remote from each other structurally and functionally suggests the native susceptibility of DA 
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neurons to various types of cellular stress.  In other words, independently on the original 
trigger, all pathogenetic pathways mentioned above may sequentially be involved in the 
process of neurodegeneration of SN neurons.  Conversely, if various pathogenetic mechanisms 
may ultimately lead to the same PD phenotype, the evidence of molecular convergence of these 
pathways must exist. The cellular “powerhouse organelle” mitochondria is a good candidate 
for a subcellular localization of such a convergence (Gandhi, S. et al., 2005;Beal, M. F., 2005). 
 
1.2.6. Oxidative stress and mitochondrial dysfunction in PD 
Mitochondria are important intracellular organelles that play a crucial role in various 
cellular processes including energy production via pyrimidine biosynthesis, fatty acid 
oxidation, calcium homeostasis and cell survival (Wang, H. Y. et al., 1991;Elston, T. et al., 
1998;Thress, K. et al., 1999;Newmeyer, D. D. et al., 2003;Melov, S., 2004).  
Oxydative phosphorylation, occuring in the mitochondria through tricyclic aminoacid 
(TCA) cycle and proton gradient, is the main source of high energy compounds (e.g. ATP) in 
the cell. Electrons derived from metabolic utilization of glucose in TCA enter the respiratory 
electron transport system at the inner mitochondrial membrane (Fig. 1.1). Driven by high 
potential energy they induce a series of oxidation-reduction reactions resulting in the final 
reduction of oxygen to produce water. Electron transport chain consists of 4 complexes, which 
use the potential energy of electrons to pump the protons through the inner mitochondrial 
membrane into the intermembrane space, thus increasing energy potential across the inner 
membrane (Δψ). Energy created by a charge difference across the inner membrane is stored as 
ATP via ATP synthesis through the F0F1-ATPase (complex V) or used directly for 
transmembrane transport.  Blocking the electron transport system or reducing the availability 
of final acceptors like cytochrome c or oxygen can lead to excessive reduction of ubiquinone 
and ubisemiquinone (Staniek, K. et al., 2002). These accumulated reduced quinones can 
directly interact with oxygen when it becomes available thus creating free oxygen radicals, 





Fig.1.1. The mitochondrial electron transport chain, represented in the context of processes 
and proteins that may play a role in neuronal cell death. In the inner membrane of the double 
membrane system of mitochondria, the four respiratory chain components are shown: complexes I 
(yellow), II (light green), III (brown), and IV (green), with their substrates, cofactors, and the paths of 
electron flow (black arrows). The ATP synthase (complex V, blue) is shown using the proton gradient to 
drive ATP synthesis. Radical oxygen species (ROS) are indicated to be produced at the level of 
complexes I and III where ubiquinol (UQH2), and ubisemiquinol are formed. In the outer membrane, the 
pore protein, VDAC (voltage dependent anion channel) is shown interacting with various cytosolic and 
mitochondrial proteins, including the ADP/ADP translocator (or ANT). The latter interaction is 
represented as forming the permeability transition pore often associated with loss of the inner 
membrane potential during apoptosis. UQ, ubiquinone; NAD+, nicotinamide adenine dinucleotide; FMN, 
flavin mononucleotide; FAD, flavin adenine dinucleotide; Qo, outer quinone binding site; Qi, inner 
quinone binding site; Cyt.bL, Cyt. bH, low and high potential cytochrome b; Cyt.c1, Cyt.c, cytochrome 
c1, c; Fo and F1, membrane and soluble domains of ATP synthase, with subunits designated; Baxn = 
polymeric form of Bax, inserted in the outer membrane, and similarly for Bakn. Bax, Bak Bcl-xL, Bcl-2, 
tBID, AIF: apoptosis inhibitor factor. (Newmeyer, D. D. et al., 2003) 
 
Dopaminergic neurons of SNpc are more likely to be susceptible to the oxidative 
stress due to the highly oxidative intracellular environment (Lotharius, J. et al., 
2002b;Lotharius, J. et al., 2002a). The neurotransmitter dopamine is degraded in the DA cells 
of SNpc either by monoamine oxidase A (MAO-A)(Gotz, M. E. et al., 1994) or by 
autooxidation (Fig.1.2). Oxidation of dopamine by MAO-A results in the production of 
hydrogen peroxide, which after conversion to the hydroxyl radical, leads to oxidation of 
cellular compounds. Autooxidation of dopamine generates both dopamine-quinones and 
hydrogen peroxide inside the cell (Graham, D. G. et al., 1978;Sulzer, D. et al., 2000). 
Dopamine quinones can directly modify proteins by reacting with their sulfhydryl groups and 
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reduce the level of intracellular antioxidant glutathione (Graham, D. G. et al., 1978;Stokes, A. 
H. et al., 1999). The conversion of hydrogen peroxide to highly reactive hydroxyl radical 
(Fenton reaction) requires Fe2+ ions (Fig. 1.2, 1.3). Interestingly, the Fe2+ level in the SNpc is 
natively higher than in the other areas of the brain and, moreover, was found to be increased in 
PD (Sofic, E. et al., 1988;Dexter, D. T. et al., 1989b).  
 
            
 
Fig.1.2. Oxidation of dopamine. Oxidation of dopamine by MAO or by autooxidation leads to 
the production of H2O2, which when converted to OH  radicals can lead to the oxidization of 
proteins, lipids, and nucleosides. Autooxidation of dopamine also leads to the generation of 
dopamine quinone, which may covalently bind to proteins or further be converted to neuromelanin. 
The modification of biomolecules by OH  or dopamine quinone may exert toxic effects on 
dopaminergic neurons. (Hald, A. et al., 2005) 
 
 
Excess of dopamine was reported to inhibit the complex I function in the brain (Ben 
Shachar, D. et al., 1995). The reduced activity of the complex I of the respiratory chain was 
also found in PD (Schapira, A. H., 1994). Selective vulnerability of DA neurons of SNpc to the 
toxins (MPTP, rotenone, 6-OHDA) acting through the inhibition of the complex I activity, 
even when systemically applied (MPTP), suggests that these neurons are intrinsically more 
sensitive to the oxidative damage and mitochondrial dysfunction.  
Abundant evidences of the major role of oxidative stress in the pathogenesis of PD 
have accumulated over the recent decades. Additionally to increased iron level, reduced levels 
of glutathione (GSH) and GSH-peroxidase expression (see also Fig 1.3) (Sofic, E. et al., 
1992;Kish, S. J. et al., 1985), decrease in immunoreactivity of the reduced form of complex I 
(Schapira, A. H. et al., 1989), and multiple signs of protein and lipid oxidation, such as 2-fold 
increase in  carbonyl protein modifications (Floor, E. et al., 1998), increased levels of 
thiobarbituric acid-reactive compounds (as an indicator of lipid peroxidation) and 
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malondialdehyde, and 8-hydroxy-2’deoxyguanosine (a nucleoside oxidation product)(Zhang, J. 
et al., 1999;Dexter, D. T. et al., 1989a) were found in SN of PD-affected brains in comparison 




Fig.1.3. Factors leading to oxidative stress in the SNpc: (A) a deficiency in glutathione (GSH), 
thereby diminishing the capability to clear H2O2; (B) an increase in reactive iron, which can promote 
OH* formation; (C) auto-oxidation of DA into toxic dopamine-quinone species. GSSG: oxidized 
gluthation; SO: dopamine-quinone species.(von Bohlen und Halbach O. et al., 2004)  
 
 
Beside ROS generation, mitochondria are also important regulators of Ca2+ 
signalling. They actively and sensitively respond to the local increase in Ca2+ concentration by 
transient but massive uptake of the ion into the organelle (Rizzuto, R. et al., 1999).  Ultimately, 
this may lead to the loss of mitochondrial membrane potential, energy deprivation and cell 
death. The fluctuations of intracellular Ca2+ are observed in glutamate excitotoxic damage, 
which was suggested as one of the factors involved in DA cell death in PD, and may serve as 
an additional link between mitochondrial dysfunction and SNpc pathology. 
 
1.2.7. Basal ganglia physiology 
Development of new treatment strategies as well as appropriate model systems for the 
evaluation of their therapeutic value require a better understanding of the basal ganglia 
physiology, since a dysbalance in their functional circuits results in a typical for PD 
symptomatology. The basal ganglia consist of several interconnected nuclei which send their 
projections to different cortical motor areas, thalamus, certain brainstem nuclei, and indirectly 
to the cerebellum. The principal four nuclei of basal ganglia are the striatum, the globus 
pallidus (GP), subdivided into the external (GPe) and internal (GPi) segments, the substantia 











Fig.1.4. Shematic depiction of the basal ganglia of the human brain. Oblique 
frontal section. (Bear, M. F. et al., 2001) 
 
 
Most of the intrinsic connections of the basal ganglia are GABA-ergic inhibitory. The 
only excitatory glutaminergic projection originates in STN. Striatum receives excitatory input 
from the cortex, thalamus, raphe nuclei and SN. Two major inhibitory output pathways are 
distinguished in the striatum: direct and indirect pathways (Fig. 1.5). The direct pathway runs 
from the striatum to the GPi, whereas the indirect one first passes to the GPe, then to the STN 
and only then to the GPi. Activation of the direct pathway, excitatory in their nature, leads to 
the active inhibition of the GPi output, thus reducing the thalamus inhibition and facilitating 
movements. Activation of the indirect pathway on the contrary, leads to the inhibition of 
movements. Dopamine released by nigrostriatal neurons binds to the D1 receptors facilitating 
the transmission through the direct pathway as well as to the D2 receptors inhibiting the 
transmission through the indirect pathway (Fig. 1.5). Reduction in dopamine supply in the 
striatum due to the loss of DA neurons in SNpc will lead to the inhibition of the direct and 
facilitation of the indirect pathway resulting in the hypokinetic movement disorder, of which 





Fig.1.5. The anatomic connections of the basal ganglia-thalamocortical circuity, indicating 
the parallel direct and indirect pathways from the striatum to the basal ganglia output nuclei. Two 
types of dopamine receptors (D1 and D2) are located on different sets of output neurons in the 
striatum that give rise to the direct and indirect pathways. Inhibitory pathways are shown as gray 
arrows, excitatory pathways, as pink arrows. GPe, external segment of the globus pallidus; GPi, 
internal segment of the globus pallidus; SNc, substantia nigra pars compacta; STN, subthalamic 
nucleus. (Kandel, E. R. et al., 2000) 
 
 
1.2.8. Animal models of PD: complete unilateral 6-hydroxydopamine rat model 
Modelling human neurological disorders in animals is common practice used for the 
study of the underlying pathogenetic mechanisms and evaluation the novel therapeutic 
approaches. However, they generally can only partly reproduce specific pathological and 
behavioural features of the particular disease. Various animal models of PD that are currently 
used can be subdivided into two groups: 1) genetic and 2) pharmacological (toxic) models. 
First group continuously enlarges due to the discovery of new mutations in PD related genes as 
well as due to the successful transgenic technologies, the use of different model systems 
(ranging from Drosophila to primates) and gene transfer approaches. Thus, α-synuclein 
transgenic Drosophila flies (Feany, M. B. et al., 2000) and rats (Klein, R. L. et al., 2002;Kirik, 
D. et al., 2002) have been created, however transgenic mouse models remain the most 
extensively used models of α-synucleinopathy (Fleming, S. M. et al., 2005). The 
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pharmacological models of PD remain a widely employed alternative, since they are easy to 
create and are able to reproduce the major etiopathologic features of PD induced by oxidative 
stress and inhibition of complex I. Several different neurotoxins, 6-hydroxydopamine (6-
OHDA), MPTP, and rotenone are commonly used to this purpose (Blum, D. et al., 2001;von 





Fig. 1.6.  Schematic depiction of the unilateral lesion of the nigro-striatal projections (MFB) 




The first toxic model of PD was established by unilateral injection of 6-OHDA into 
the caudate-putamen, or striatum, or into the medial forebrain bundle (MFB) in close proximity 
to the SNpc of rat brain (Ungerstedt, U., 1968). Remarkable degeneration of the whole 
nigrostriatal dopamine neuron system associated with significant motor asymmetry was 
observed after the injection of the toxin into the SNpc. Usually, dopamine content in the 
striatum is reduced by more than 97% after this lesion (Schmidt, R. H. et al., 1983;Rioux, L. et 
al., 1991;Kirik, D. et al., 1998). The expression of D1 and D2 receptors was shown to be 
upregulated in the lesioned caudate-putamen (Gagnon, C. et al., 1991;Cadet, J. L. et al., 
1992;Dawson, T. M. et al., 1991). Quantification of drug-induced rotations was later used as a 
simple behavioural test for estimation of the degree of the produced lesion (Ungerstedt, U. et 
al., 1970). Typically, two drugs are used for induction of the rotational behaviour in 
unilaterally lesioned animals: amphetamine and apomorphine. Amphetamine acts as an agonist 
of dopamine inducing the fast and almost complete release of the neuromediator dopamine 
from the presynaptic terminals (Sulzer, D. et al., 2005). Apomorphine, a short-acting dopamine 
D1 and D2 receptor agonist, functions postsynaptically (Picada, J. N. et al., 2005). An animal 
subjected to the injection of either of the drugs will rotate away from the site of a greater 
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activity. This can be explained by the anatomical structure of the mammalian CNS, particularly 
the fact of crossing of the afferent tracts to the contralateral side at the level of either brainstem 
or spinal cord.  However, due to the difference in mechanisms of action of the drugs, the rat 
exposed to amphetamine will rotate ipsilaterally, while the apomorphine-injected rat will 
exhibit contralateral to the lesion turns. Drug-induced rotational behaviour is often used to 
select the animals with complete lesions, since only those rats with complete degeneration of 
the nigrostriatal projections will exhibit robust turning behaviour induced by the drug. 
 
  1.3. Therapeutic approaches for PD treatment 
1.3.1. Current therapeutical strategies and limitations 
The pharmacological standard for the treatment of PD remains a replacement of 
dopamine. This is typically accomplished with the precursor of dopamine, 1-3,4-
dihydroxyphenylalanine (L-DOPA). The clinical effects of L-DOPA on akinesia in 
parkinsonism were first presented in 1967 by Birkmayer and Hornykiewicz. L-DOPA is 
typically administered in a combination with carbi-dopa, an inhibitor of DOPA-decarboxylase 
which reduces the peripheral conversion of L-DOPA to dopamine thus allowing for 
considerable amount of the drug to cross the blood brain barrier and undergo decarboxylation 
to DA in the brain. Although the initial therapeutic effects of L-DOPA are excellent, patients 
develop drug-related side effects over the course of the disease, which include motor 
fluctuations (the so-called "wearing-off" and "on–off" phenomena) and dyskinesias (Lang, A. 
E. et al., 1998). Other medications including anticholinergic agents, inhibitors of catechol-O-
methyltransferase (COMT) or monoamine oxidase-B (MAO-B) provide only mild-to-moderate 
benefit (Lang, A. E. et al., 1998;Hristova, A. H. et al., 2000;Olanow, C. W. et al., 
2004;Marjama-Lyons, J. M. et al., 2001). Eventually, L-DOPA or dopamine agonists are 
required for management of progressive disability. However, dopamine agonists usually take 
longer than L-DOPA to reach effective doses, and also require co-administration of L-DOPA 
for supervening disability after varying periods of time.  
At the later stages of the disease patients developing resistance or severe side effects 
to pharmacological therapy may benefit from neurosurgical procedures such as pallidotomy or 
deep brain stimulation of the subthalamic nucleus (STN) (Esselink, R. A. et al., 2004). 
Nevertheless, none of the currently available treatments has been proven to slow the 






1.3.2. Neuroprotective gene therapy: achievements and perspectives 
Different strategies have been employed to inhibit neurodegenerative processes: early 
studies aimed at blocking the executioners of apoptotic cell death, cysteine proteases of the 
caspase family, however, no sustained neuroprotection could be achieved (Kermer, P. et al., 
1999;Perrelet, D. et al., 2000;Rideout, H. J. et al., 2001). Most pro-apoptotic signals converge 
on breakdown of mitochondrial membrane potential, followed by release of pro-apoptotic 
factors and subsequent caspase activation (Chang, L. K. et al., 2002). Thus, several studies 
focused on the maintenance of mitochondrial integrity by overexpression of anti-apoptotic 
members of the bcl-2 family of proteins (Azzouz, M. et al., 2000;Malik, J. M. et al., 
2005;Wong, L. F. et al., 2005). This strategy proved to be significantly more efficient than 
caspase inhibition, although in long-term studies substantial neuronal cell loss was still 
observed (Malik, J. M. et al., 2005;Kim, R., 2005).  
Neurotrophic factors in several paradigms could only shortly postpone neuronal 
degeneration (Cheng, H. et al., 2002;van Adel, B. A. et al., 2003). Glial cell line-derived 
neurotrophic factor (GDNF) appears to be an exception and remains a promising candidate in 
the treatment of Parkinson’s disease.  
 
1.3.3. Glial cell line-derived neurotrophic factor (GDNF) 
GDNF was originally identified as a trophic factor promoting the survival of 
embryonic midbrain dopaminergic neurons (Lin, L. F. et al., 1993). Subsequently, it was found 
to be a potent trophic factor for noradrenergic neurons of the CNS (Arenas, E. et al., 1995) as 
well as for the moto- and sensory neurons of the PNS (Henderson, C. E. et al., 1994;Ramer, M. 
S. et al., 2000). GDNF was purified from a glioma cell line supernatant and then found to be 
expressed in several glial cell types of the NS (Schaar, D. G. et al., 1993;Strelau, J. et al., 
1999). In toxicity animal models of PD, GDNF was proven to rescue DA neurons of SNpc 
from the neurotoxic damage and promote behavioural recovery (Grondin, R. et al., 1998). 
However, lentiviral delivery of GNDF to SNpc failed to prevent neurodegeneration in α-
synuclein transgenic rat model of PD (Lo, Bianco C. et al., 2004). Furthermore, recent clinical 
trials demonstrated divergent outcomes (Gill, S. S. et al., 2003;Nutt, J. G. et al., 2003;Patel, N. 
K. et al., 2005). GDNF has also been shown to induce resprouting of the lesioned nigrostriatal 
neuron system and thus may have beneficial effects on deafferentiated neurons in general 
(Björklund, A. et al., 1997;Love, S. et al., 2005). 
Together with three other neurotrophic factors (neurturin, artemin, persephin) GNDF 
comprises a family of proteins, the so-called GDNF family ligands (GFLs). GFLs are distantly 
related to the transforming growth factor-beta superfamily, containing seven cysteine residues 
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with the same relative spacing and acquiring similar conformation as the other members of this 
superfamily (Ibanez, C. F., 1998). The main signalling pathway of GFLs is mediated by RET-
receptor tyrosine kinase (Sariola, H. et al., 2003), which was initially discovered as a 
protooncogen (Takahashi, M., 2001). RET is activated upon binding of GDNF dimer to 
GFRα1 receptors linked to the plasma membrane via a glycosyl phosphatidylinositol (GPI) 
anchor (Fig. 1.7). Dimerization of RET triggers its autophosphorylation, thus initiating various 
intracellular signalling cascades, that regulate cell survival, proliferation, differentiation, 
neurite outgrowth, synaptic plasticity and morphogenesis (Airaksinen, M. S. et al., 2002). For 
example, MAPK and phosphatidylinositol 3-kinase (PI3K) may be involved in neurite 





Fig. 1.7. GDNF interaction with its receptors. A dimer of GDNF brings together two molecules 
of GFR 1. This complex dimerizes two molecules of Ret leading to transphophorylation of their 
tyrosine kinase domains. GFR  proteins are attached to the plasma membrane through a GPI-
anchor and consist of three globular cysteine-rich domains joined together by adapter 
sequences.(Sariola, H. et al., 2003) 
 
  
GDNF may also signal independently of RET but involving the same receptor 
GFRα1. In RET-deficient cells GDNF may act through the Src family kinases, inducing 
sustained activation of the Ras/ERK and PI3K/Akt pathways,  cAMP response element-
binding protein phosphorylation, and increased c-fos expression (Trupp, M. et al., 1999). In the 
absence of RET, Src-mediated cellular events may also promote neuronal survival and neurite 






Fig. 1.8. Non-RET signalling for GDNF through NCAM. NCAM interacts with a GDNF-
GFR  dimer leading to activation of Fyn, a Src-like kinase, for instance. It is not known whether 
Fyn activates Met in NCAM-mediated GDNF signalling.(Sariola, H. et al., 2003) 
 
 
NCAM has been proposed as an alternative signalling receptor for GDNF (Paratcha, 
G. et al., 2003). When GFRα1 is absent, GFL associates with NCAM with low-affinity. In 
turn, in the presence of GFRα1, GDNF may bind to the p140-NCAM and activate cytoplasmic 
Src-like Fyn and FAK kinases (Fig. 1.8) (Paratcha, G. et al., 2003). Interestingly, both in vivo 
and in vitro effects of GDNF, such as DA neuron survival, neurite outgrowth, DA turnover, 
and locomotor activity in rats were inhibited by anti-NCAM antibodies (Chao, C. C. et al., 
2003).  
 
1.3.4. BclXL, an antiapoptotic member of the bcl-2 family proteins 
 The antiapoptotic member of the bcl-2 protein family, BclXL plays an important role 
in the inhibition of mitochondria-dependent cell death pathways. Mouse embryos deficient in 
BclXL show massive cell death of immature neurons of the CNS and dorsal root ganglia 
(Motoyama, N. et al., 1995). Co-deletion of BAX largely rescued the BclXL knockout 
phenotype providing evidence that BclXL serves as a negative regulator of BAX -mediated cell 
death in vivo (Shindler, K. S. et al., 1997). Together with bcl-2, BclXL is considered a 
prominent native inhibitor of apoptosis and BAX and BAK function. The latter belong to the 
pro-apoptotic proteins of the bcl-2 family, which are believed to induce permeabilization of the 
mitochondrial membrane in response to both internal and external apoptotic triggers (Kim, R., 
2005).  
Several models have been proposed to explain the mechanism for the formation of 
such permeability transition pore (Hengartner, M. O., 2000). Truncated Bid, the caspase-
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activated form of a "BH3-domain-only" bcl-2 family member, triggers the 
homooligomerization of "multidomain" conserved proapoptotic family members BAK or 
BAX. This interaction may lead to the formation of a channel pore, through which cytochrome 
c and other mitochondrial intermembrane proteins can escape. The recruitment of the voltage-
dependent anion channel (VDAC) located at the outer leaflet of the mitochondria and the 
adenine nucleotide transporter (ANT) of the inner mitochondrial membrane for the formation 
of the permeability transition pore was also suggested (see also Fig. 1.1). Both bcl-2 and BclXL 
might prevent the interaction of BAX/BAK via heterodimerization, which is achieved when the 
BH3 domain of one molecule binds into a hydrophobic pocket formed by the BH1, BH2 and 
BH3 domains of another family member (Sattler, M. et al., 1997;Cheng, E. H. et al., 2001).  
The ability of BclXL and bcl-2 to inhibit mitochondrial permeability transition pore 
(PTP) formation and cytochrome c release rendering cells more resistant to the oxidative stress 
makes these proteins attractive candidates for neuroprotective therapy. In contrast to bcl-2, 
BclXL was shown to possess a C-terminal mitochondrial targeting motif which ensures its 
more effective localization to mitochondria and may in part explain the higher potential of 
BclXL to inhibit the loss of mitochondrial membrane potential as compared to bcl-2 
(Kaufmann, T. et al., 2003;Kim, R., 2005). Also, overexpression of BclXL, but not bcl-2 
suppressed TNF-induced cell death in tumour cells (Marini, P. et al., 2003).  
 
1.4. AAV vectors as tools for gene therapy 
In order to express transgenic proteins in the lesioned CNS, effective gene transfer 
tools, such as viral vectors, are needed. Adeno-associated virus (AAV) is a small dependovirus 
from the Parvoviridae family, which is replication deficient in the absence of adenovirus, 
herpesvirus or vaccinia virus (Buller, R. M. et al., 1981). Wild-type AAV is not known to be 
associated with any disease in humans or mammals, which makes it an attractive tool for 
human gene therapy. AAV harbours a linear single-stranded genome of 4,675 nucleotides in 
length and contains inverted terminal repeats (ITRs) of 145 nucleotides, the first 125 
nucleotides of which form a palindromic sequence (Srivastava, A. et al., 1983). AAV genome 
possesses two large open reading frames (ORF) that do not overlap. One (cap) encodes for 
virus coat proteins, the other (rep), for the proteins necessary for virus replication and 
transcription of the viral genes.  To date, ten different AAV serotypes (AAV-1 – AAV-9, and 
AAV-Rh10) have been identified (Cearley, C. N. et al., 2006). While most AAV serotypes 
share certain sequence homology in cap genes, AAV-5 appears to be the most distantly related 
serotype to the other parvoviruses (Bantel-Schaal, U. et al., 1999).  
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AAV vectors used for gene therapy are typically devoid of 96% of their genome with 
the exception of ITRs, the only cis elements which are required for packaging (Samulski, R. J. 
et al., 1989). Therefore, recombinant AAV vectors are considered to have one of the highest 
biosafety ranking among the viral vectors.  
Different transduction properties of the AAV serotypes have been employed using 
“pseudotyping”, the generation of hybrid AAV vectors which contain the genome of one 
serotype (typically AAV-2) packaged into the capsid of another serotype (Duan, D. et al., 
2001;Auricchio, A. et al., 2001;Hildinger, M. et al., 2001). The other technique exploiting the 
different serotype properties of capsid proteins is generation of chimeric rAAV vectors by 
cross-dressing of the virion (Hauck, B. et al., 2003). By mixing helper plasmids of different 
AAV serotypes at different ratios, the final contribution of the serotype-specific capsid 
components to the mature virion can be controlled (Rabinowitz, J. E. et al., 2004). Except for 
variations in cellular tropism, the capsid proteins of different serotypes may also influence the 
onset and the intensity of gene expression (Auricchio, A. et al., 2001;Chao, H. et al., 
2000;Rabinowitz, J. E. et al., 2004).  
Recombinant AAV vectors are lacking the wild-type rep gene, which is responsible 
for the site-specific integration in the chromosomal DNA, and thus persist mainly in an 
episomal form (Duan, D. et al., 1998). They can, nevertheless, mediate stable transgene 
expression for more than one year (Woo, Y. J. et al., 2005;Stieger, K. et al., 2006). Among 
other beneficial features of the AAV for gene transfer is the ability to infect both dividing and 
non-dividing cells (Flotte, T. R. et al., 1994;Flotte, T. R. et al., 1992). Recombinant AAV 
vectors have been reported to be non-toxic, non-inflammatory and inducing only a very limited 
immune response without any noticeable decrease in transgene expression after injection into 
the brain (Mastakov, M. Y. et al., 2002)  
Apart from the fact that neutralizing antibodies to AAV have been found in 
circulation of certain individuals (Moskalenko, M. et al., 2000), a relatively small packaging 
capacity (less than 5 kb) has limited the application of rAAV for gene therapy (Dong, J. Y. et 
al., 1996). However, by exploring a unique feature of AAV biology, the possibility of viral 
DNA heterodimerization and formation of head-to-tail concatemers, the expression of genes 








1.5. Semliki Forest virus (SFV) vectors 
Semliki Forest virus (SFV) is a positive-stranded enveloped RNA virus that belongs 
to the alphavirus genus of the Togaviridae family. The single-stranded, around 12 kb long 
genome of SFV functions directly as an mRNA encoding its own replicase, being capped at 
the 5’ terminus and polyadenylated at the 3’terminus. The SFV genome is divided into two 
open reading frames (ORF). The first ORF encodes four non-structural proteins (nsP1-4) 
responsible for transcription and replication of viral RNA. The second ORF codes for the 
structural proteins required for the encapsidation of the viral genome and the assembly into 
enveloped particles under the control of a 26S subgenomic promoter (Lundstrom, K., 
2005;Lundstrom, K. et al., 2003).  
Alphavirus gene expression is transient by nature due to the cytoplasmic replication 
and strong cytotoxicity leading to the shutdown of endogenous gene expression of the host 
cell. This property of alphaviruses can serve as an advantage for application in cancer gene 
therapy. However, the same feature makes SFV vectors non-useful for long-term gene therapy 
as well as for functional studies.  
Alphaviruses possess certain advantages for gene transfer, known to have a very 
broad host range and replicating efficiently to high titres in many cells of both vertebrates and 
invertebrates (Strauss, J. H. et al., 1994). Principally, three types of SFV vector systems have 
been developed so far: 1) replication-competent viral particles, 2) replication-deficient RNA 
vectors (replicons), and 3) DNA-based vectors. Most applications of alphavirus vector systems 
have been attributed to the replicon vectors, in which the genome for the viral structural 
proteins has been replaced by a multiple cloning site (Liljestrom, P. et al., 1991). However, 
they retain the entire non-structural region as well as the natural subgenomic promoter. 
Considerable efforts have been made over the recent years to generate novel alphavirus vectors 
with reduced cytotoxicity and prolonged expression profiles. Thus, the SFV(PD) vector, which 
bears two point mutations in nsP2, shows lower host cell toxicity, probably due to the 
decreased replication (Lundstrom, K. et al., 2003). On the basis of SFV(PD) vector, a triple 
mutant which substantially prolongs transgene expression in cell cultures for more than 20 
days was generated (Lundstrom, K. et al., 2003). Typically, SFV vectors infect both neurons 
and glial cells in the CNS (Atkins, G. J. et al., 1999). However, generation of novel vector 
based on the avirulent A7 strain exhibit a temperature dependent expression pattern in 
organotypic hippocampal cultures in that  the expression pattern was mainly restricted to glial 
cells at 37°C, and was neuron-specific at 31°C (Ehrengruber, M. U. et al., 2003).  
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Taken together, these novel rapid-to-generate mutant SFV vectors with reduced 
cytotoxicity are excellent tools for fast evaluation of epitope tags applicability for in vivo 
transgene tracing in the brain.  
 
1.6. Epitope-tagging  
In the post-genomic era it will be a major task to assign cellular functions to proteins.  
Recent estimations of the number of protein-coding genes in complex eukaryotic organisms 
like mice and humans have been between 25,000 to 35,000 (Ewing, B. et al., 2000) which 
would be only one-third more than that of simple organisms like C. elegans with 19,000 genes. 
Alternative splice variants of genes and posttranslational modifications of proteins may thus 
significantly contribute to the higher complexity of higher eucaryotes (Liu, S. et al., 2003). 
Assessing the functional diversity of proteins may require the ability to trace multiple variants 
of a protein. This task may be one of the major applications for epitope tagging techniques, 
which allow for a specific recognition of short peptides (epitopes), fused to a protein under 
investigation, by commercially available antibodies. This will greatly facilitate studies in fields 
such as sub-cellular tracing, protein-protein interactions, or the effects of dominant negative 
mutants in vitro and in vivo. Another prominent field for using epitope tagging technology is 
the evaluation of proteins to which no antibodies for immunodetection exist yet. Furthermore, 
gene transfer studies seeking to overexpress a protein, or its dominant-negative mutants, may 
encounter an intrinsically expressed equivalent in either the transduced cell type or in cells near 
to the site of transduction. Therefore, unequivocal identification of the overexpressed transgene 
is required and benefits substantially from an epitope tag.  
While epitope tagging is frequently used for in vitro applications (Terpe, K., 2003), 
no attempt has been made so far to elucidate the properties of the different available epitope 
tag / antibody combinations in tissue sections derived from animals expressing respectively 
tagged proteins. In the present study we approached this question by overexpressing several 
epitope tags fused to the fluorescent reporter protein EGFP in different areas of the central 
nervous system, e. g. striatum, retina and primary hippocampal cultures, by means of viral 







2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals 
Applichem: 2-Propanol, Acetone, Agarose, Ethanol absolute, Boric acid, Glycine, HEPES, LB 
medium (powder), LB agar (powder), Magnesium chloride (MgCl2), Methanol, 
Paraformaldehyde, PBS (1x Dulbecco’s, powder), Potassium chloride (KCl), Sodium chloride 
(NaCl), Sodium dodecylsulfate (SDS), Sodium hydroxide pellets, D(+)-Sucrose, Tris.  
BIO-RAD: Avidin-HRPO. 
Calbiochem: Moviol, Sodium citrate. 
Gibco: B27 Supplement, DMEM, DMEM: F12 (1:1), Neurobasal medium (NBM), OptiMEM, 
PS-N 
Fluka: Chloral hydrate, Coumaric acid, Sodium acetate, Tween 20. 
Merck: Agar, Ammonium peroxide, Formaldehyde, Hydrogen peroxide (H2O2). 
PAA (cell culture company): NGS, FCS, penicillin/streptomycin (PS).  
QIAGEN: QIAGEN Plasmid Maxi Kit, QIAprep spin MiniPrep kit, QIAquick Gel Extraction 
Kit, RNeasy QIAGEN Kit 
Roche: DNAse I 
Roth: Glycerol, Milk powder, Rothiphorese. 
Riedel-deHaen: Diethylether. 
Seromed: L-glutamine 
Serva: Bromphenol blue sodium salt (BPB), TEMED. 
Sigma: 2-mercaptoethanol, 6-hydroxydopamine hydrochloride, α-chymotrypsin, Ampicillin 
(Sodium salt), Bactotryptone, Bezonase, Biotinylated SDS Molecular Weight Standard 
Mixture for SDS-PAGE (Molecular Weight Range 14,300 - 97,000 Da),  Bradford reagent, 
BSA D(+)-glucose, Dithiothreitol (DTT), EDTA, Ethidium bromide, Laminin, L-ascorbic acid, 
Luminol, MOPS, Poly-L-Ornithine, Sodium azide, Sodium bicarbonate (Na2CO3), 
Streptavidin-Peroxydase, Transferrin, Triton X-100, Trypsin, Yeast extract. 
 
2.1.2. Antibodies  
Anti-HA, mouse monoclonal (Covance, # MMS-101R) 
Anti-FLAG M2, mouse monoclonal (Sigma, # F3165) 
Anti-c-Myc, rabbit polyclonal (Cell Signalling Technologies, # 2272) 
Anti-EE (Glu-Glu), rabbit polyclonal (Covance, # PRB-115C) 
Anti-AU1, mouse monoclonal (Covance, # MMS-130R) 
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Anti-IRS, mouse monoclonal (Covance, # MMS-166R) 
Anti-TH, rabbit polyclonal (Advanced Immunochemicals, RATH 4-6b) 
Anti-BclX, rabbit polyclonal (BD Transduction Laboratories, # 610211) 
Anti-cabindin D28K, rabbit polyclonal (Swant, # CB38a) 
Anti-GFP, rabbit polyclonal (Clontech, # 8367-1) 
Anti-GFAP, rabbit polyclonal (DAKO A/S, #Z0334) 
Anti-NeuN, mouse monoclonal (Chemicon, # MAB377) 
Anti-Tubulin, rabbit polyclonal (Sigma, #T3526) 
Secondary antibodies for immunofluorescence were Cy3-coupled anti-mouse or anti-
rabbit IgGs (Dianova), for western blotting - HRP-coupled anti-mouse and anti-rabbit IgGs 
(Santa Cruz Biotechnology). 
 
2.1.3. Plasmids 
pAAV-6p1-TB, kindly provided by S. Kügler 
pAdV-hGDNF, kindly provided by S. Kügler 
pBluescript-II-KS (Stratagene) 
pDG, kindly provided by Kleinschmidt 
pDP5, kindly provided by Kleinschmidt 
pDsRed2 (Clontech) 
pEGFP (Clontech) 
pMH4 (Microbix Biosystems) 
pSFV-PD, a generous gift of K. Lundström 
pSFV-helper2, a generous gift of K. Lundström 
 



































RT- calbindin D28K: 
GATACAATGTATCACTAGCAAGTGG 
5’-calbindin D28K -cDNA: 
CTCTAACTAGCCGCTGCACCATGG 



















2.1.5. Cell lines and electrocompetent cells 
BHK-21 (Sigma) 
HEK 293 (ATCC) 
AAV-293 (STRATAGENE) 
DH5α and SURE E. coli strains (STRATAGENE) 
 
2.1.6. Buffers and Solutions 
Blocking solution for IHC: 10% NGS, 0.3% Triton X-100 in PBS. 
Blocking solution for WB: 10% Milk in TBS-T (see below). 
Citric saline (1 x): 135 mM potassium chloride, 15 mM sodium citrate. 
DNA loading buffer (6 x):  2% glycerol, 60 mM Na2EDTA, pH 8; 0.6% SDS, 0.003% BPB 
ECL-1: 2.5 mM Luminol, 0.4 mM  p-Coumar acid, 0.1 M Tris-HCl, pH 8.5. 
ECL-2: 18% H2O2, 0.1 M Tris, pH 8.5. 
Electrophoresis buffer: 192 mM Glycine, 0.1% SDS, 25 mM Tris-HCl, pH 8.3. 
HBS (2 x): 280 mM NaCl,1.5 mM Na2HPO4, 50 mM HEPES, pH 7.1. 
Incubation solution -1 for immunofluorescence (IF): 2% NGS, 0.3% Triton X-100 in PBS 
Incubation solution -2 for immunofluorescence (IF): 2% NGS in PBS. 
Lysis buffer I (cell culture): 0.5% SDS, 1 mM DTT, 50 mM Tris-HCl, pH 8.0. 
Lysis buffer II (tissue): 150 mM NaCl, 1% Triton X-100, 50 mM Tris-HCl, pH 8.0. 
MOPS (10x): 0.2 M MOPS, 50 mM Na acetate, 10 mM EDTA, pH 7.0. 
PBS: 9.55 g of PBS powder in 1 L millipore H2O, autoclaved. 
RNA loading buffer: 62.5% Formamide, 8% Formaldehyde, 12.5% 10xMOPS, 0.025% 
BPB, 0.017% Ethidium bromide. 
SDS-Sample buffer (2x): 0.125 M Tris-HCl, pH 6.8, 4% SDS, 0.15 M DTT, 20% 
Glycerol, 0.01% Bromphenolblue.  
TE: 0.01 M Tris-HCl, pH 7.4, 1 mM EDTA, pH 8.0. 
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TBE:  42 mM Boric Acid, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0. 
TBS: 150 mM NaCl, 10 mM Tris-HCl, pH 9.0 (for antigen retrieval).  
TBS-T: 0.1% Tween in TBS, pH 7.6 (for WB). 
Transfer buffer: 192 mM Glycine, 20% Methanol, 25 mM Tris-HCl, pH 8.3. 
Trypsin solution (0.25%) for primary culture: 25 mg Trypsin, 10 ml CMF. 
 
2.2. Methods 
2.2.1. Cloning procedures 
Primer design and all major cloning steps were first simulated using SECentral 
software. Restriction sites, necessary for cloning of the DNA fragments into respective 
plasmids, as well as epitope sequences were added to the cDNA by using corresponding 
primers via PCR. All basic DNA procedures were essentially performed according to the 




Before amplification of the cDNA sequences of interest, the most suitable PCR 
conditions were checked. Thus, different concentrations (2 mM, 4 mM and 6 mM) of 
magnesium sulfate salt (MgSO4) in the buffer and annealing temperatures (usually 50°C and 
60°C) were used for initial amplification. Those conditions that resulted in the best yield of 
PCR-product were chosen for further amplification. PCR reaction mix typically contained: the 
ThermoPol Reaction Buffer (20 mM Tris-HCl, pH 8.8, 10 mM (NH ) SO , 10 mM KCl, 
2 mM MgSO , 0.1 % Triton X-100; BioLabs
4 2 4
4 ), 2-6 mM of MgSO4, 400 nM of sense and 
antisense primers, 200 µM of dATP, dCTP, dGTP, dTTP (BioLabs), 5-10ng of the template 
DNA, 0.5 unit of the Vent DNA Polymerase (2,000 units/ml; BioLabs), and millipore H20 to 
achieve a total volume of 50 µl. The amplification was performed on PCR machine from MJ 
Research Biozym (Hessisch Oldendorf, Germany). The amplification was started with 1 min 
incubation at 95°C followed by 30 cycles of amplification (annealing – 30 sec at 50°C or 60°C, 
elongation – 45 sec at 72°C, separation of DNA strands – 30 sec at 95°C). The amplified 
fragments were purified from the 1% agarose gel by DNA electrophoresis using the Gel 
Extraction Kit (QIAGEN).  
 
2.2.1.2. In vitro transcription 
Calbindin D28K cDNA was obtained through reverse transcription amplification from 
total RNA extract from a rat brain. RNA was extracted using RNA Extraction Kit (QIAGEN) 
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according to the protocol of the manufacturer. 500 ng of total RNA, 2 pmol of RT-calbindin 
D28K primer, 1 µl of dNTP mix (10 mM each; BioLabs) and RNAse-free sterile H2O were 
mixed in a total volume of 12 µl, heated to 65°C for 5 min and quickly chilled on ice. After 
collecting the content of the tube by a brief centrifugation 4 µl of 5 x First-Strand Buffer (250 
mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl2, Invitrogen) and 2 µl of 0.1 M DTT were 
added, and the reaction mix was incubated at 42°C for 2 min.  SuperScript II reverse 
transcriptase (1 µl or 200 units; Invitrogen) was added and mixed with the content of the tube 
by gentle pipetting up and down. The final reaction mix was incubated for 50 min at 42°C. The 
transcription reaction was stopped by heating at 72°C for 15 min. To remove RNA 
complementary to the cDNA 1µl of E. coli RNase H (Invitrogen) was added and the mix was 
incubated at 37°C for 20 min.  
 
2.2.1.3. Sequencing of PCR-amplified DNA 
The sequencing reactions were carried out using the ‘ABI PRISM® BigDyeTM 
Terminator Cycle Sequencing Ready Reaction Kit’ (Perkin Elmer Applied Biosystems 
Division, Foster City, CA) according to the manufacturer’s protocol. The Terminator Ready 
Reaction Mix contained the four dNTPs with different fluorescence labels (BigDyeTM 
Terminators), unlabeled dNTPs, AmpliTaq DNA Polymerase FS, MgCl2, Tris-HCl buffer (pH 
9.0). Template DNA (10 ng) and 3.2 pmol of the sequencing primer (universal T7 or T3 
promoter primers for sequencing of cDNA inserted in pBluescript vector) and 8 µl of the 
Terminator Ready Reaction Mix were used in a 20 μl sequencing reaction. The sequencing 
reaction mixes were subjected to 25 linear amplification cycles. Each cycle consisted of 30 sec 
at 95°C, 45 sec at 50°C and 1 min at 60°C. The amplified probes were then precipitated as 
described in DNA precipitation section (3.2.1.4.), resuspended in 20 µl of template suppression 
reagent (Applied Biosystems) and subjected to DNA capillary electrophoresis on the ABI 
PRISMTM 310 Genetic Analyzer. Sequence analysis and alignment with reference cDNA were 
performed using ABI PRISMTM (Applied Biosystems) 3100 and SECentral softwares. 
 
2.2.1.4. DNA precipitation 
One tenth volume of 3 M Sodium Acetate buffer (pH = 5.0 -5.3) was added to the 
DNA solution to equalize ion concentrations. Two volumes of ice-cold 100 % ethanol were 
added to the mix, then the mix was briefly vortexed and left on dry ice for 5 min. The sample 
mix was then centrifuged for 30 min at highest speed in a 4°C microcentrifuge. The 
supernatant was removed and 200 µl of ice-cold 70 % ethanol were added to the precipitate. 
The mix was centrifuged again for 10 minutes in a 4°C centrifuge. The supernatant was 
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carefully removed and the precipitate left for drying at room temperature for 5-10 min. The 
DNA pellet was resuspended in desired volume of water or TE buffer. 
 
2.2.1.5. DNA restriction, electrophoresis, gel extraction, concentration determination 
For restriction digest 5-10 µg of plasmid DNA and 0.5-3 µg of PCR product were 
used. Appropriate endonucleases in corresponding buffers (BioLabs) were mixed with DNA 
and left for (us. 1 - 1.5 h) restriction digest at the temperature specified for each enzyme in the 
instruction manual of BioLabs. Analysis of the DNA size was performed by agarose gel 
electrophoresis. To prepare the gel 1% agarose was dissolved in TBE buffer in a microwave 
oven and 0.3µg/ml ethidium bromide solution was added then. DNA samples were mixed with 
DNA loading buffer and millipore sterile water to reach a final volume of 12.5 µl for loading 
the gel. The gel was run in 1 x TBE buffer. The DNA bands were visualized by UV-light of 
302 nm at Gel Documentation 2000TM UV-transilluminator (Bio-Rad) using the Quantity One 
software (version 4.2.1). DNA extraction after gel electrophoresis was performed in 
accordance with QIAquick Gel Extraction Kit (QIAGEN) protocol. To increase the purity and 
the concentration of DNA in the final solution DNA precipitation step typically followed the 
extraction procedure. The concentration of DNA in the final solution was measured at the 
Biophotometer (Eppendorf) at 260 nm.   
 
2.2.1.6. DNA ligation and transformation in E. coli 
For ligation vector DNA and cDNA fragment were mixed in a molar ratio of 1:1 and 
1:3 with ligation buffer (10 mM MgCl , 1 mM ATP, 10 mM dithiothreitol, 25 µg/ml BSA, 
50 mM Tris-HCl, pH 7.5 @ 25°C
2
), millipore sterile water and T4 DNA ligase (1µl = 2 000 
units, BioLabs) in a total volume of 10 µl. The ligation reaction was performed for 1 h at room 
temperature. The DNA ligation product (3 - 5 ng DNA) was added to 50 µl of de-frozen and 
kept on ice electrocompetent E.coli cells. The mixture was transferred to a prechilled on ice 
cuvette and subjected to the electroporation pulse procedure at Bio-Rad Gene Pulser II 
(Voltage = 1.8 kV, pulse controller- low resistance = 200 Ohm, capacitance = 25 µF). 
Immediately after the pulse 1 ml SOC medium (2% bacto-tryptone, 0.5% yeast extract, 10 mM 
NaCl, 10 mM KCl, 20 mM MgCl2 and 2 mM glucose) was added and the cells transferred to a 
sterile culture tube. The transformed cells were incubated for 40 min with moderate shaking at 






2.2.1.7. Plasmid Mini- and Maxi - Preps 
Small- and large-scale DNA plasmid extractions were performed using the QIAGEN 
Plasmid Mini and Maxi kits according to the protocol of the manufacturer. Briefly, the 
procedure consists of alkaline lysis of the bacterial cell wall, removing the cell debris while 
keeping the supernatant containing the nucleic acids, degradation of RNA by RNase, binding 
of plasmid DNA to a silica-gel matrix and washing with high-salt solution (to remove the 
chromosomal DNA and proteins) and elution of plasmid DNA.  
 
2.2.1.8. Preparation of electrocompetent E. coli  
One liter of LB medium was inoculated with 10 ml of a fresh overnight culture of E. 
coli (DH5α or SURE strains). The cultures were grown at 37 °C with shaking to an O.D. 600 = 
0.5 - 0.8 and chilled on ice for 1 h. The cells were transferred to a prechilled centrifuge bottles 
and harvested by centrifugation (10 minutes, 5,000 x g, 4°C). The pellets were resuspended in 
the original culture volume of ice-cold water. After a second centrifugation step (15 minutes, 
5,000 x g, 4°C) the pellets were resuspended again in a 10 ml of ice-cold water and washed 
with an original culture half-volume of ice-cold water. The cells were centrifuged again (15 
minutes, 5,000 x g, 4°C). Bacterial pellets now were re-suspended in 30 ml ice-cold 10% 
Glycerol in water and transferred to 30 ml centrifugation tubes (Beckmann). Following the last 
centrifugation (15 minutes, 5,000 x g, 4°C), the pellets were now re-suspended in 1.5 ml of ice-
cold 10% Glycerol in water, aliquoted and quickly frozen in dry ice-ethanol bath and stored at 
–80 °C. The cells were kept ice-cold during the entire procedure.  
 
2.2.1.9. Cloning into pSFV-plasmid 
Epitope tags were fused to EGFP by PCR based cloning. The following amino acid 
sequences were used for the tags: HA = YPYDVPDYA; c-Myc = EQKLISEEDL; FLAG = 
DYKDDDDK; AU1 = DTYRYI; EE (also called Glu-Glu) = EYMPME; IRS = RYIRS. N-
terminal tags were separated by one glycine residue from the initiator methionine and by two 
glycine residues from EGFP. C-terminal tags were separated by two glycine residues from 
EGFP (Fig. 2.1). BamHI and XhoI restriction sites were inserted in the primers at the N- and C-
terminus respectively to allow subcloning into pSFV-PD plasmid (Fig. 2.2) as well as into 
pBluescript-II-KS vector (Fig. 2.3) for sequencing of the subcloned PCR product.   All primers 














Fig.2.1. Schematic depiction of the epitope tag peptides fused to EGFP and calbindin D28K. 
The amino acids sequences of various tags fused to EGFP and calbindin D28K via glycine linkers 
(GG), shown in one letter code. All C-terminal fusion proteins retain the genuine EGFP start codon, 
while in N-terminal fusions the initiator methionine of EGFP or calbindin D28K is replaced by the 























      


























































































































2.2.1.10. Cloning into pAAV-2 plasmid 
Construction of adeno-associated virus (AAV) vectors has been described previously 
(Kügler, S. et al., 2003b). For this study we employed a bi-cistronic vector expressing the 
functional transgene and a fluorescent reporter from two independent human synapsin 1 gene 
promoters (Fig. 2.4). We used pAAV-6p1-TB plasmid (Fig. 2.5) as a backbone for subsequent 
cloning.   
 
 TR     hSyn1        BclXL       Intron   SV40  TB    hSyn/mCMV    EGFP      WPRE    TR 
 
Fig.2.4. Shematic depiction of AAV vector genomes. TR, inverted terminal repeats; hSyn1, 
human synapsin 1 gene promoter; mCMV, immediate early murine cytomegalovirus promoter; BclXL, rat 
BclXL; EGFP, enhanced green fluorescent protein; SV40, SV40 polyadenylation site; TB, synthetic 
transcription blocker; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element.  
 
 
First, BclXL cDNA was substituted by GDNF and calbindin D28K cDNA. GDNF was 
amplified with 5’-MfeI-GDNF and 3’-NotI-GDNF primers from pAdV-hGDNF by PCR. 
Calbindin D28K cDNA was obtained via reverse transcription from a rat brain lysate (see 
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reverse transcription). For this, RT- calbindin D28K primer was used initially, followed by 
specific amplification of caldindin cDNA using 5’-calbindin D28K-cDNA and 3’-calbindin 
D28K-cDNA primer set. Finally the required restriction sites and AU1-epitope tag were inserted 
through the third amplification step with 5’-hSyn1-MfeI-AU1-calbindin D28K and 3’-NotI-
calbindin D28K primer set. The sequences of the PCR products were verified in the modified 
version pBluescript-II-KS (pBS-II-KS) plasmid. Since original pBS-II-KS vector (Fig. 2.3) 
does not contain MluI and SpeI restriction sites, we designed the oligo (pBS-woMCS-oligo), 
which bore these sites. The obtained pBluescript-modified (pBS-m) vector was devoid of a 
large part of MCS, but included MluI and SpeI restriction sites (Fig. 2.3). First expression 
cassette of the bi-cistronic AAV-6p1-TB vector (hSyn1-FLAG-BclXL-Intron-SV40pA) was cut 
out by MluI and SpeI and inserted into pBluescript-modified version. The obtained plasmid 
was cut with EcoRI and NotI to allow for the insertion of the PCR products cut with the same 
enzymes or with MfeI and NotI, since MfeI and EcoRI generate compatible ends upon cut. The 
ligated into pBS-m fragments were subjected to sequencing procedure to verify the absence of 
any mutations generated through PCR amplification. After the sequencing the whole 
expression cassette was cut out by MluI and SpeI and transferred to AAV-6p1-TB cut at the 
same restriction sites. Thus, we obtained pAAV-GDNF-EGFP and pAAV-calbindin D28K-
EGFP vectors. 
Second, we replaced EGFP in the second expression cassette of pAAV-6p1-TB by 
DsRed-2 cDNA to obtain pAAV-6pRed plasmid. DsRed2 was amplified from DsRed2 plasmid 
(Clontech) using 5’-BamHI-AgeI-DsRed2 and 3’-HindIII-BsrgI-DsRed2 primers. The PCR 
product was subcloned via BamHI and HindIII restriction sites into pBS-II-KS vector and 
sequenced and then inserted into pAAV-6p1-TB vector through ligation at BsrgI and AgeI 
sites.  
Finally, we substituted hSyn-1 promoter in the second expression cassette of the bi-
cistronic AAV vector by mCMV promoter (Addison, C. L. et al., 1997;Gerdes, C. A. et al., 
2000). To this purpose we amplified mCMV from pMH4-I vector using 5’-SpeI-mCMV and 
3’-NotI-MfeI-mCMV primers. The plasmid for sequencing was prepared as follows: the first 
expression cassette was inserted into pBS-m as described above and then the fragment was cut 
out by SpeI and NotI endonucleases and replaced by mCMV cut at the same restriction sites. 
After confirming the sequence the promoter was cut out by SpeI and MfeI and inserted into 
AAV-vector backbone after cutting pAAV-6p1-TB with SpeI and EcoRI. Thus, the obtained 
AAV-mCMV-EGFP vector contained only one expression cassette where EGFP was driven by 









































Fig.2.5. Schematic depiction of pAAV-6P1-TB 
 
 
We also constructed the control vector, which expressed only a reporter EGFP, but no 
functional transgene. For this, we amplified Intron-SV40pA fragment from pBS-m-hSyn-
BclXL-Int-SV40pA via PCR using 5’-PstI-Intron-SV40pA-w/oEcoRV and 3’-EcoRI-Intron-
SV40pA-w/oEcoRV primers. The PCR product was then cut with PstI and EcoRI and inserted 
on the place of hSyn-1 promoter, which was cut out with the same enzymes from pBS-m-
hSyn-BclXL-Int-SV40 plasmid. The first expression cassette in the pAAV-6p1-TB vector was 
replaced by the fragment which was cut out from resulted pBS-m-Int-SV40-BclXL-Int-SV40 
plasmid with MluI and SpeI. Thus, the control vector retained only one active expression 
cassette of the reporter EGFP. 
AAV vectors are characterized by inherently high recombination probability due to 
the presence of ITRs. Therefore all AAV plasmids were propagated in the SURE strain of E. 
coli, and the integrity of AAV vector genome was confirmed by a SmaI digest (cutting the 
vector plasmid in the ITR regions) was performed before using it for AAV vector production. 




2.2.2. Viral vectors production and purification 
2.2.2.1. SFV vectors 
Recombinant Semliki-Forest virus (SFV) vectors with reduced cytotoxicity and 
conditionally infective particles were generated as described (Lundstrom, K. et al., 2003). 
pSFV-PD vector, containing epitope-tagged EGFP was linearized with NruI, while pSFV-
helper2 plasmid was lineraized with SpeI endonuclease. Linearization of the plasmids was 
necessary for in vitro transcription step that followed. The reaction conditions were following: 
3-5 µg DNA was mixed with 5 µl of rNTPs (10 mM each), 5 µl of Cap structure (Ribo m7G 
Cap Analog, Promega), 5 µl of 10 x SP6-transcription buffer, 1.5 µl of RNasin, 3.5 µl of SP6 
polymerase (Promega) and millipore sterile water to achieve a volume of 50 µl, and the 
reaction mix was incubated for 1 h at 37°C. RNA was purified using RNeasy QIAGEN Kit, 
precipitated as described above for DNA, and run in the denaturing RNA agarose gel (1% 
agarose, 20 mM MOPS , 5 mM Na acetate, 1 mM EDTA, pH 7.0; 2% Formaldehyde) to check 
for the purity. RNA concentration was determined at a photometer as described above for 
DNA. Each vector production run required 30 µg of SFV-RNA , 15 µg of SFV-helper2 RNA 
and only 2 x 107 BHK-21 cells, which after electroporation (Bio-Rad Gene Pulser II: voltage = 
0.36 kV, pulse controller- high resistance = 500 Ohm, capacitance = 75 µF) were seeded in one 
6-well plate (Sarstedt) and cultured for 24 h at 31°C. Electroporation medium contained 1:1 
DMEM/F12, 10% FCS, 4 mM glutamate, 1% PS. The supernatants containing the virus 
particles were collected twice at 24 (2 ml/well) and 48 h (1 ml/well) after the transfection, 
sterile filtered to remove the cell debris and stored at -20°C until processed further. Viral 
particles were precipitated by ultracentrifugation of the activated by addition of α-
chymotrypsin treatment supernatants in a Beckman SW41 rotor (39,000 rpm, 1 h, 4°C) and 
resuspended in a small volume of phosphate buffered saline (PBS). Titration of transducing 
units was performed on BHK-21 cells by counting EGFP positive cells.  
 
2.2.2.2. AAV vectors 
AAV-293 cells were harvested after they reached ca. 50% confluency in 175 cm2 
culture flasks and then seeded in cell factories (Nunc) at 1.1 x 108 cells per factory in 700 to 
800 ml of medium (see cell culturing). Typically 6 culture flasks are required for seeding of 
one cell factory. When the cells reached 50-60% confluency (ca. 24 h), they were subjected to 
calcium-phosphate transfection. Cells were first washed with ca. 400 ml of DMEM. The 
transfection mix contained 265 µg of AAV-plasmid, 1 mg of helper plasmid (pDG for AAV-2 
and pDP5 for AAV-5), 0.25M CaCl2 in 16.5 ml of deionized sterile water. 16.5 ml of 2 x HBS 
(pH 7.05) were added to 16.5 ml of transfection mix and incubated for 1 min at 25°C. The 
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mixture was added to 315 ml of DMEM/ 2%FCS and the obtained transfection medium was 
equally distributed through the layers of the cell factory. For the transfection the cell factories 
were incubated overnight (12-14 h) at 37°C, 5% CO2, 95% humidity. The medium was 
changed then to 10% FCS/ 1% PS/ DMEM (ca. 750 ml/ cell factory). At ca. 36-40 h after 
transfection the cells were checked for reporter fluorescence at the microscope and then 
harvested. After removing the medium from the cell factory, the cells were briefly washed 300 
ml with citric saline (CS). Then 200 ml of CS were added and the cells incubated at 37°C for 
several min until detached and then collected to a sterile bottle. The remaining cells were 
collected by a second rinse with ca. 100 ml of CS. Collected cells were centrifuged then for 5-
10 min at 1,300 rpm at RT. The cell pellets (the volume of the pellet was noted) were 
resuspended in total volume of 20 ml of Tris-buffered saline (150 mM NaCl, 50 mM Tris, pH 
8.5) and stored at -80°C until further processing. For virus gradient centrifugation the virus-
containing cells were first thawed and frozen 3 times in an ethanol/ dry ice bath. 1.6 µl of 
Bezonase (300 U/ml) was added to the cells and incubated for 30 min at 37°C water bath. The 
cell mix was slightly shaken every 5-10 min during incubation.  Following incubation, the cell 
mix was centrifuged at 4000 rpm 18°C for 30 min. The supernatants were carefully transferred 
to new 50 ml falcon tube and adjusted to a 30 ml volume by addition of ca. 10 ml of Tris-
buffered saline. After washing the pump catheter connected to a 20G needle placed into a 50 
ml falcon tube pump with millipore sterile water, the iodixanol (Opti PrepTM Fresenius Kabi, 
Norge, Axis-Shield, Oslo, Norway) step gradient was performed. For this, the following 
solutions were prepared first: 
 
B = 10 x PBS-MK (80g NaCl + 2 g KCl + 14.4 g Na2HPO4 + 2.4 g KH2PO4 dissolved in 990 
ml millipore sterile water, pH 7.4; and then 5 ml 2,5 M KCl and 5 ml 1 M MgCl2 were added 
and the solution sterile filtered). 
C = 1x PBS-MK (500 µl 2.5 M KCl; 500 µl 1M MgCl2 in 499 ml PBS) 
D = 2 M NaCl in 1x PBS-MK  
E = 54 % working solution: (45 ml iodixanol + 5 ml B). 
 
For obtaining different iodixanol gradient solutions the solutions C, D, E, iodixanol and phenol 
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The diluted supernatant containing the virus particles was transferred to "Quick Seal 
Tubes" (Beckmann; 1x 3.5 inch [25x 89 mm]) in a volume of 15 ml per tube, by using a 20 ml 
a syringe connected to the spinal needle (20G x 23/4). Using the pump, the iodixanol gradient 
solutions were added consequentially (10 ml of the 15% gradient, 6 ml of the 25% gradient, 4 
ml of the 40% gradient, 6 ml or more of the 60% gradient to fill up the tube) into the 
Beckmann tubes underneath the virus solution. Every next gradient solution was placed 
underneath the previous one. The tubes were heat-sealed and the gradients were run at the 
ultracentrifuge (SORVALL® Discovery 90SE). The settings for ultracentrigation were: speed 
68,000 rpm (310,000 g), 1 h 15 min, 18 °C, acceleration was set to “5”, deceleration to “0”. 
After centrifugation the phase containing the concentrated and relatively pure virus solution 
was removed by inserting the needle connected to a 5 ml syringe slightly underneath the border 
between 40% and 60% iodixanol gradient and aspirating the 40% gradient solution containing 
the virus vectors (3-4 ml). The virus-containing gradient solution was collected in a 50 ml 
falcon tube and stored frozen at -20°C. The virus was further purified and concentrated by 
collecting the “peak” elution phase on Äkta-FPLC system FPLC using HiTrapTM Heparin HP 1 
ml column for rAAV-2 (Amersham) and HiTrapTM QFF 1 ml column (Amersham) for rAAV-5 
vectors. Further concentration and purification of rAAV-2 particles was done by dialysis using 
Slide-A-Lyzer, (MWCO = 10,000, before using) in 1 L PBS for 1 h. The final virus solution 
was subjected to real-time PCR (RT-PCR) quantification of the rAAV-vector genome titre. 
Purity of the vectors was determined by SDS-gel electrophoresis and infectious titres by 
transduction of cultured primary hippocampal neurons. Genome particles to transducing units 
(t.u.) ratio typically was 25:1 - 35:1. The AAV vectors were aliquoted and stored at -80°C until 
required. During all procedures dealing with AAV vectors, 0.5% SDS solution in water was 





2.2.3. Cell culturing 
2.2.3.1. Continuous cell culture 
Working with continuous cell culture was always performed under sterile conditions. 
Mammalian AAV-293 were cultured in DMEM supplemented with 10% FCS and 1% PS and 
BHK-21 cells in DMEM/F12 1:1 supplemented with 10% FCS, 4 mM glutamine, 1% PS in 
175 cm2 culture flasks (Sarstedt) at 37°C, 5% CO2 supply, 95 % humidity. After reaching 
approximately 70% confluency, the cells were split 1:4 (every 2-4 days). For this, the medium 
was removed, 4 ml of pre-warmed to 37°C 0.05% trypsin/ 0.02% EDTA solution were added 
to the culture and left in the incubator at 37% for 5-12 min until detached from the flask.  
Trypsin activity was stopped by addition of 7 ml of the cell culture medium to the flask. The 
mix containing detached cells was carefully transferred to a 15 ml Falcon tube and spun down 
at 4,000 g, 4°C, 5 min. After removing the supernatant a cell pellet was resuspended in 100 ml 
of the fresh medium and seeded in 4 (175cm2) flasks. 
 
2.2.3.2. Primary culture of hippocampal neurons 
Coating of 24-well plates (Nunc) or coverslips with polyornithine/ laminin is 
particularly useful for culturing CNS neurons. For this, ethanol-soaked and flamed coverslips 
(∅10 mm) incubated with polyornithine solution (500 µl/well, 100 µg/ml in millipore sterile 
water) for 12-24 h at RT, then washed twice with 1 ml/well of millipore sterile water and 
coated with laminin (500 µl/well, 1µg/ml in NBM) by incubation at 37°C, 5% CO2, 95 % 
humidity overnight. Before the preparation of the hippocampi, the coverslips were washed 
twice with NBM and then 500 µl of hippocampus medium (1% PS-N, 0.5 mM L-glutamine, 
0.05% Transferrin, 2% B27 Supplement in NBM) was added and the plates kept at 37°C. To 
obtain primary hippocampal neurons, hippocampi were dissected from Wistar rat embryos 
(embryonic day 18) and further processed for establishing dissociated cell cultures. All surgical 
procedures were performed on ice. In brief, hippocampal tissue pieces were collected in ice-
cold hippocampus medium and centrifuged at 1,000 rpm for 4 min. The medium was removed 
and the tissue pellet was incubated in 750 µl trypsin (0.25%, 15 min, 37°C). Trypsin was 
inactivated by addition of 750 µl ice-cold FCS. The pellet was then dissociated by gentle 
trituration using a fire-polished Pasteur pipette. After centrifugation at 1,000 rpm for 4 min, the 
pellet was resuspended in warm hippocampus culture medium. Cells were seeded in poly-L-
ornithine/laminin 24-well culture plates (Nunc) at a density 250,000 cells/well. Cultures were 





2.2.3.3. SFV-transduction and cell lysis for western blotting 
After reaching 70% confluency HEK-293 cells seeded in a 6-well plate were 
transduced by addition of 5 x 105 SFV t.u. per well in a 500µl volume of OptiMEM and kept at 
31°C, 5% CO2, 95% humidity for 1 h. Then 1.5 ml of OptiMEM was added to each well and 
the plates were transferred to a 35°C, 5% CO2, 95% humidity for overnight incubation (12-13 
h). After removing the medium the cells were washed twice with PBS, the lysis buffer for cells 
was added (250µl/well) and the cells scraped from the plate and transferred to a 1.5 ml 
eppendorf tube. The lysates were boiled for 5 min and chilled on ice. After addition of protease 
inhibitor mix the lysates were centrifuged at 4°C at maximum speed for 20 min. The 
supernatant was collected, aliquoted and frozen at -20°C. 
 
2.2.3.4. Indirect immunofluorescence on primary neurons 
For transduction of primary hippocampal neurons seeded in 24-well plates 1 x 108 t.u. 
of AAV-2 vector in 500 µl of hippocampal medium were used per well. After the reporter gene 
fluorescence (either EGFP or DsRed2) could be clearly detected by microscopy (us. 4-5 days 
after AAV-2 transduction), the cultured neurons were subjected to indirect 
immunofluorescence assay. The coverslips with primary hippocampal neurons were rinsed 
with PBS and fixed by incubation in 4% formaldehyde for 10 min at room temperature. After 
washing 2 times for 5 min with PBS the cells were subjected to permeabilization procedure by 
incubation with ice-cold acetone at -20°C for 5 min. Following a second washing with PBS (3 
x 5 min), blocking solution (10% NGS in PBS) was applied for 30 min at room temperature to 
block unspecific binding of the antibodies. Incubation with a primary antibody (all anti-tag 
antibodies were used in a dilution of 1:500) was performed for 1 h at 37°C. The cells were 
rinsed with PBS 3 x 5 min and then incubated for 1 h at room temperature with a secondary 
antibody coupled to a fluorescent reporter cy3 (1:200). The cells were washed again 3 x 5 min 
with PBS and mounted on the glass slides embedded in Moviol mounting medium (16 % 
Moviol in 30 % Glycerol/ PBS, 0.02 % sodium azide) to protect immunofluorescence from 
bleaching. 
 
2.2.4. Animal procedures 
Adult female Wistar rats (University Hospital Animal Facility, Göttingen) of 250-
280g of weight were housed at 12h/12h of light/dark cycle, provided with food and water ad 
libitum.  Animals were deeply anaesthetised by 7% chloral hydrate intraperitoneally 
(340mg/kg) before the respective surgery. All animal procedures were performed in 
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accordance to German guidelines for care and use of laboratory animals and to the respective 
European Community Council Directive 86/609/EEC. 
 
2.2.4.1. Stereotaxic injection into the rat brain 
The head of the rat was fixed by ear bars and a jaw holder in a stereotaxic frame 
(“Kopf” Instruments) after the appropriate anaesthesia. A skin covering the skull was 
longitudinally cut from the imaginary line connecting the eyes in front till the imaginary line 
connecting the auditory channels in the back.  Remaining connective tissue was carefully 
removed aside by scalpel in order to achieve appropriate visualisation of the skull sutures and 
to define the bregma (a crossing point of parasaggital with coronal sutures) on the surface of 
the skull as “zero” or “start” point. After achieving flat positioning of the skull, the coordinates 
for the injection were calculated related to bregma. For the injection into the SNpc, the 
following coordinates were used according to Paxinos and Watson atlas of a rat brain: antero-
posterior (AP): -0.53; medio-lateral (ML): +0.22; dorso-ventral (DV): -0.78. The coordinates 
for the injection into the LMFB were the following: AP: -0.2; ML: +0.2; DV: -0.85; into the 
striatum: AP: +0.2 mm; ML: -2.8 mm; DV: -5.6 mm; and into hippocampus: AP: -4.3; ML: 
+3.0; DV: -3.4 mm. Glass capillaries (World Precision Instruments, WPI), filled with mineral 
oil and the solution for the injection were attached to the nanoliter injector (WPI).  The injector 
was connected to a microprocessor-based controller, Micro4 smart controller (WPI), which 
allows for setting the operating parameters, such as the volume and the speed (nl/min) of the 
injection. AAV-vectors were injected into SNpc in a volume of 2 µl and in the striatum in a 
volume of 2-4 µl depending on the original infectious titre of the virus. The volume 3 µl of 
5mg/ml of 6-hydroxydopamine hydrochloride in 0.2% ascorbic acid/PBS was injected in 
LMFB to produce the unilateral PD lesion model. The speed for all injections was set to 
500nl/min. 
 
2.2.4.2. Intravitreal injections and optic nerve axotomy 
Wistar rats of 200-270g were anesthetized with 7% chloral hydrate (340mg/kg body 
weight). Pupillary dilatation for better visualisation of the lens was achieved with subsequent 
surface application of 1% tropicamide and 2% mepivacaine. Injections into the eye were 
performed by a fine bore glass capillary with a tip diameter of 30 µm attached to a catheter on 
a Hamilton syringe. 2 µl (1 x 105 transducing units of SFV, 1 x 107 transducing units of AAV) 
of viral suspension were injected intravitreally by puncturing the eyeball below the cornea-
sclera junction. Due to pupillary dilatation, the tip could be observed during the injection and 
care was taken to avoid contact with the lens. Vector injections were performed 3 weeks before 
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the optic nerve axotomy. After skin incision close to the superior orbital rim, the orbita was 
opened and lacrimal gland was partially removed to achieve a better visualisation of the optical 
nerve and surrounding vessels. Following the spreading of superior extraocular muscle by a 
small retractor, the optical nerve was exposed by longitudinal incision of the perineurium. 
Optic nerve was transected at a distance of ca. 2 mm from the posterior pole of the eye leaving 
the retinal blood supply intact. Retrograde fluorogold (FG) labelling of RGCs was performed 
by putting a small sponge soaked with FG tracer onto the proximal to the eyeball optic nerve 
stump. Animals with retinal ischemia, as verified after the surgery fundoscopically, have been 
excluded from the study. 
 
2.2.4.3. Transcardial perfusion and brain tissue processing 
Transcardial perfusion under terminal anaesthesia is a commonly used method for 
tissue fixation in immunohistochemical protocols. This method takes advantage of the animal’s 
circulatory system to deliver the fixative solution evenly throughout the body tissues, with 
optimal penetration of the brain. Fixation preserves the ultrastructure, stabilizes protein and 
peptide conformation so that antibodies can bind to antigen sites. We used 4% 
paraformaldehyde (PFA) in phosphate buffer solution (PBS) as a fixative since it is optimal for 
visualization using fluorescent dyes.  
After a deep anaesthesia with 7% chloral hydrate (800 mg/ml) the rat was fixed on 
rack, the abdominal cavity was opened with sharp scissors, and the diaphragm was cut to allow 
access to the thorax. With large scissors, blunt side down, ribs were bilaterally cut and the rib 
cage was open to allow access to the heart. While holding heart steady, the left ventricle was 
cut and the catheter blunt-ended needle inserted through the ventricle and atrium into aorta. 
Needle position was secured by clamping in place. The liver was cut then to allow a large part 
of blood volume to leave the body. The abdominal aorta was clamped to restrict perfusion to 
the upper par of the body. The nose was cut for the control of procedure. Thus, if fluid was 
flowing freely from the cut nose the needle was considered to be appropriately positioned. The 
syringe containing ice-cold PBS and connected to the catheter was operated with a speed of 
15–20 ml/min. When blood has been cleared from body (ca. 200 ml of PBS is usually 
required), PBS was replaced with ice-cold 4% PFA solution (200 ml). The rat was decapitated 
and the brain carefully removed from the skull and placed into 4% PFA overnight at 4°C for 
post-fixation. The brain was cryoprotected by dehydration in 30% sucrose solution in PBS, 
frozen on dry ice and cut on a cryostat (Leica CM 3050 S) to 18 µm coronary sections.  




2.2.4.4. Preparation of the brain tissue lysates for Western Blotting 
Rats were sacrificed by an overdose of chloral hydrate (1mg/kg) and transcardially 
perfused with 150 ml ice-cold PBS. The brain was removed and quickly frozen on dry ice. 3 
mm thick coronal section containing the substantia nigra was cut out and subjected to biopsy 
in the SNpc region by using a small biopsy needle with 2 mm inner diameter. The excised 
tissue was weighted and homogenized in a tissue lysis buffer by sonication and incubated on 
ice for 15 min. The lysates were then centrifuged twice at 4°C with maximum speed for 15 min 
to remove the debris. The supernatants were aliquoted and kept frozen at -20°C. 
 
2.2.5. Indirect immunofluorescence on brain slices 
Brain slices were dried for 1 h at 37°C, then rehydrated in PBS for 45 min and 
exposed to antigen retrieval in TBS (pH 9.0) for 5 h in a water bath at 60°C. While regular 
antigen retrieval destroys EGFP fluorescence, this procedure allows for keeping it intact. The 
slides were shortly washed with PBS and incubated in a blocking solution for 30 min at room 
temperature to avoid unspecific binding of the antibodies. Incubation with primary antibody 
(anti-TH, 1:600; anti-calbindin 1:1000, anti-GFAP, 1:500; anti-NeuN 1:200; all anti-tag 
antibodies were used in 1:500 dilution after testing different dilutions, ranging from 1:200 to 
1:5,000) was performed overnight at 4°C in incubation solution -1 for IF. After washing 3 x 5 
min with PBS the secondary cy3-coupled antibody (1:250 in incubation solution -2 for IF) was 
applied for 1 h at room temperature. The secondary antibody was washed out with PBS (3 x 5 
min). Slides were embedded in Moviol, coated by coverslips and kept at 4°C until microscopy. 
 
2.2.6. Protein handling procedures 
Western Blotting or immunoblotting allows for determination, with a specific primary 
antibody, the relative amounts of the protein present in different samples. Briefly, 1) samples 
are prepared from tissues or cells that are homogenized in a buffer that protects the protein of 
interest from degradation; 2) the sample is separated using SDS-PAGE and then transferred to 
a membrane for detection; 3) the membrane is incubated with a generic protein (such as milk 
proteins) to bind to any remaining sticky places on the membrane. A primary antibody is then 
added to the solution which is able to bind to its specific protein; 4) a secondary antibody-
enzyme conjugate, which recognizes the primary antibody, is added to find locations where the 






2.2.6.1. Protein concentration determination 
Protein concentration was determined by Bradford assay. The assay is based on the 
observation that the absorbance maximum for an acidic solution of Coomassie Brilliant Blue 
G-250 shifts from 465 nm to 595 nm when binding to protein occurs. Both hydrophobic and 
ionic interactions stabilize the anionic form of the dye, causing a visible colour change. The 
reaction was performed in a 96-well plate at room temperature. Protein standards were 
prepared in PBS in a concentration range between 0.1-1.4 mg/ml. Unknown protein samples 
were diluted to 1:2, 1:10 and 1:100. 5 µl of protein standards or diluted unknowns were mixed 
with 250 µl of Bradford reagent in each well and incubated for 15 min. The absorbance of the 
samples was measured at 595 nm on a TECAN Rainbow plate reader using the easyWINbasic 
software (SLT Company). Plotting of the absorbance vs. the protein concentration for protein 
standards to obtain a standard curve and calculation of the unknown samples protein 
concentration was done using the Microsoft Office 2003 Excel software. 
 
2.2.6.2. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is based on separation of a large range of proteins of varying molecular 
weights and charges under the influence of the electrical field within the continuous cross-
linked polymer matrix polyacrylamide/ bis-acrylamide (Rothiphorese). Cross-linking is 
catalysed by free radicals produced upon addition of ammonium peroxide and TEMED. Two-
phase gels were used for collection and separation of the proteins according to their molecular 
weight. Usually, 12% resolving gel and 5% stacking gel were used to separate the proteins of 
interest. To define a molecular weight of loaded proteins the molecular weight marker was 
loaded and separated in parallel. The protein concentration in the samples was adjusted by 
dilution of more concentrated samples in PBS. Equal volumes of protein samples and 2 x SDS-
loading buffer were mixed, subjected to heating at 95°C for 5 min, chilled on ice and loaded in 
the gel combs. SDS-PAGE was run at 4°C in ice-cold electrophoresis buffer. All equipment 
used for SDS-PAGE and WB was purchased from Bio-Rad. Electric field of 70 V was applied 
for 15 min to allow samples to enter the gel and collect without a smearing and then increased 
to 100 V and kept constant until the bromophenol blue reached the bottom of the resolving gel.   
 
2.2.6.3. Immune blotting 
For the western blot procedure a Mini Trans-Blot Cell setup (Bio-Rad) was 
employed. After electrophoresis completion the polyacrylamide gel was placed between two 
sheets of Whatman filter paper and a nitrocellulose membrane (Protran), all preliminary soaked 
in transfer buffer. Two additional Whatman filter papers were placed on the top on the 
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membrane and the “sandwich” was placed in the Mini Tans-Blot Cell. A voltage of 100 V was 
applied for 1 h at 4°C.  
After the completion of the transfer the membrane was treated with blocking solution 
for 1 h at room temperature to avoid unspecific binding of the antibody. Incubation with both 
primary and secondary antibodies was performed in 2% Milk/TBS-T solution for 1 h at room 
temperature. The membrane was washed 3 x 10 min with TBS-T between primary and 
secondary antibody application and 3 x 15 min with TBS-T after the incubation with secondary 
antibody. The following dilutions of the primary antibodies were used: anti-EGFP, 1:1,000; 
anti-FLAG 1:500; anti BclX, 1:2,000.  All secondary antibodies coupled to HRP were used in 
dilution 1:3000. Together with a secondary antibody streptavidin peroxidase was applied in 
dilution 1:3000 to allow for later visualization of biotinylated molecular weight protein marker 
(Sigma). For developing the membrane equal volumes of ECL-1 and ECL-2 reagents were 
mixed, applied for 1 min in the dark onto the membrane and imaged at Fluor-S-Max Gel 
Imager (Bio-Rad) and Quantity One software (version 4.2.1). 
 
2.2.7. GDNF-ELISA 
Quantification of GDNF tissue levels in transduced and contralateral SNpc was 
determined by ELISA (GDNF Emax® ImmunoAssay System, Promega) according to the 
instructions of the manufacturer. Tissue samples of SNpc were obtained from 3 mm thick 
tissue slices by means of small biopsy needles with inner diameter of 2 mm and lysed 
according to the procedure described in section 2.2.4.4. After an overnight coating of a 96 well 
plate, the specific protein is detected using an antibody sandwich format. To this purpose 96 
well plates are coated with anti-GDNF monoclonal antibody, which binds soluble GDNF. The 
captured GDNF is then bound by a second, specific polyclonal antibody. After several washing 
steps, the amount of specifically bound polyclonal antibody is detected using a species-specific 
antibody conjugated to horseradish peroxidase as a tertiary reactant. The unbound conjugate is 
removed by washing, and after incubation with a chromogenic substrate, the colour change is 
detected. The amount of GDNF in the test solutions corresponds to the colour generated in the 
oxidation-reduction reaction. Using this system, GDNF in tissue culture supernatants or tissue 
homogenates can be quantitatively measured.  
 
2.2.8. Microscopy and image analysis 
Fluorescence from tissue sections and fixed cultured cells was recorded on a Zeiss 
Axioplan-2 microscope equipped with a 16 bit greyscale CCD camera (Zeiss). Narrow band 
filter sets specific for EGFP and cy3 fluorescence were used. For all recorded EGFP images 
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exposure time was 3 000 ms, except for pictures taken from HA-tag transduced sections which 
are labelled EGFP x 5. These images were recorded with an exposure time of 15,000ms. cy3 
fluorescence was recorded with an exposure time of 500 ms. Images from individual 
fluorescences were recorded separately as greyscales. Pseudo-colouring of images, generation 
of overlays and quantification of EGFP / cy3 co-localization was performed with AxioVision 3 
software package (Zeiss).  
  
2.2.9. Quantification of neuroprotection in 6-OHDA rat model of PD 
At the respective time points after 6-OHDA injection into medial forebrain bundle 
(MFB), rats (n = 5 per condition) were sacrificed by an overdose of chloral hydrate and 
transcardially perfused with 4% PFA. Brains were processed to 18 µm slices, and 
immunofluorescent visualization of dopaminergic neurons in SNpc was performed with 
primary rabbit antibody against tyrosine hydroxylase (anti-TH, 1:500, Advanced 
ImmunoChemicals Inc., USA; overnight incubation at 4°C) followed by 1h incubation at RT 
with secondary cy3-conjugated goat anti-rabbit antibody (Dianova). Images of brain sections 
were recorded as described above. TH-immunoreactive (TH-IR) cells were counted in every 8th 
brain section in the region anatomically correspondent to SNpc. TH-IR cells of the ventral 
tegmental area (VTA) area were excluded from counting. To obtain the corresponding total 
DA cell numbers the counted values were multiplied by 8, assuming that the average diameter 
of the adult rat DA-neuron is 16-18µm (Juraska, J. M. et al., 1977). 
 
2.2.10. Rotational behaviour test 
One of the most simple to perform and widely used test for evaluation of the 
unilateral 6-hydroxydopamine lesion is drug-induced rotational behaviour test (Ungerstedt, U. 
et al., 1970). Disbalance in dopamine secretion in the brain results in preferable turning of the 
animal to the side of the lesion.  When the rat is challenged with certain drugs (apomorphine, 
amphetamine), this rotation tendency is greatly increased and leads to a typical “rotational 
behaviour” when an animal “tries to catch its own tail”.  The more complete the lesion is- the 
more complete rotations to one side per min will be counted. To evaluate the degree of the 
lesion of dopaminergic system each rat was subjected to intraperitoneal apomorphine 
hydrochloride injection (0.2 mg/kg, Teclafarm) at 2 weeks after the lesion. If a rat exhibited 5 
or more rotations per min toward the contralateral to the lesion side during one hour after 
apomorphine injection, the lesion was considered to be complete. This typically corresponded 
to the ≥ 80 % loss of dopaminergic neurons in SNpc and almost absolute loss of dopaminergic 
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RGC and TH-IR cell counts are presented as means ± standard deviations. For each 
time point and experimental condition n = 5 were used. For retinas, 3 independent fields per 
retina were counted, for TH-IR cells of SNpc region at least 13 sections were counted per 
animal. Statistical significance was assessed by split-plot analysis of variance and alpha-
adjusting for multiplicity (Bonferroni-Holm sequentially rejective procedure) and, at the 1% 
level, revealed p < 0.001 for either BclXL or GDNF transduced areas vs. untransduced and 
versus the control AAV-EGFP-transduced SNpc at all time points. Analysis of variance (factor 
1 - BclXL, factor 2 - GDNF, interaction 1 / 2 = BclXL + GDNF) revealed that interaction was 
not additive (p<0.001), but more than additive (= synergistic) for retina, but not for the brain, 
where it is additive at 2 weeks, but not significant at 6 weeks after lesion when compared to the 
GDNF-treated group. Pairwise comparisons of values were performed by paired, one-tailed 
Student’s t-test.  
 
          





















3.1. Development of AAV vectors for targeting different cell types of CNS  
3.1.1. Construction of AAV vectors 
AAV vectors hold a great promise as tools for long-term gene transfer in the brain. 
Specific targeting of transgene expression to either neurons or glial cells would expand the 
usability of AAV vectors. In this study, in order to produce AAV vectors with different 
expression profiles in CNS cells several strategies have been employed.  
First, to overcome the inherent limitations of AAV vectors for transgene 
accommodation, small transcriptional regulatory elements have been used.  The fluorescent 
reporter gene was expressed from either short neuron-specific hSyn1 gene promoter or 
ubiquitously active murine cytomegalovirus immediate early promoter (mCMV). In figure 
3.1.1 vector genomes as used in this study are schematically depicted: here, small 
trancriptional control elements allowed for the construction of bi-cistronic vectors, which 
express both a functional transgene and a fluorescent reporter gene, and thus demarkate 
successfully transduced cells.  
Second, we cross-packaged AAV-2 vector genomes in AAV-5 capsid shell, since 
these two AAV serotypes require different cell-surface receptors for successful entry into the 
cell, and thus are being predicted to have different transduction patterns (Davidson, B. L. et al., 
2000;Di Pasquale, G. et al., 2003;Walters, R. W. et al., 2001;Opie, S. R. et al., 2003).  
  
 
Fig.3.1.1. Schematic representation of bi-cistronic vector genomes used in this study. 
Vectors used for the expression of a functional transgene also carry a second, independent expression 
cassette for a reporter gene EGFP (green fluorescent protein) or DsRed2 (red fluorescent protein). 
Functional transgenes expressed from these bi-cistronic vectors may be up to 1500 bp in size.  ITR, 
inverted terminal repeats of AAV-2; hSyn1, human synapsin 1 gene promoter; mCMV, murine 
cytomegalovirus immediate early promoter; Int, 146 bp chimeric intron, WPRE, woodchuck hepatitis 
virus posttranscriptional control element; SV40, simian virus 40 derived polyadenylation site; bGH, 






3.1.2. In vitro transduction of brain cells by AAV vectors 
Following the construction of recombinant AAV vectors, we first investigated their 
transduction properties in primary hippocampal cultures. As shown in figure 3.1.2, different 
combinations of AAV serotypes and promoters allow for targeting the transgene expression 
either exclusively to neurons or to astrocytes. Types of cells transduced by the respective virus 
vector were identified by typical morphology and confirmed by immunofluorescent co-labeling 
with either NeuN or GFAP (data not shown). 
In order to achieve quantitative transduction of cultured neurons (90 - 95 % 
transduction efficacy), cells were grown on coverslips in 24 well plates. Transduction was 
performed at 12 hours after seeding, in a culture volume of 250 µl. 1.5 - 3 x 109 vector 
genomes as determined by quantitative PCR are used for each well. This corresponds to 0.5 - 1 
x 108 transducing vector units, as the ratio of infective vs. total viral particles routinely 
obtained was 1:30. After overnight incubation, culture medium was filled up to 750 µl. This 
procedure allows for the generation of "transgenic" cultures of primary brain cells (Fig. 3.1.2 d, 
e), which are routinely maintained for about 4 weeks without any signs of cytotoxicity (Kügler, 
S. et al., 2003b).  
The onset of transgene expression after AAV vector transduction is often claimed to 
be “slow”, supposedly due to the necessity of conversion of the single stranded genome into 
double-stranded DNA, especially in non-dividing cells. However, when primary hippocampal 
cultures were infected by AAV-2-hSyn-EGFP vectors at the time of seeding, readily detectable 
transgene expression emerged in neurons at 2-3 days after transduction, reaching almost 100% 
transduction efficacy at 5-7 days after transduction (Fig. 3.1.2 a).  
Transgene expression was also completely restricted to neurons as identified by anti-
NeuN staining if the AAV-2 vector genomes containing the expression cassettes were cross-
packaged into the AAV-5 capsid. However, expression levels were substantially reduced (Fig. 
3.1.2 b), indicating that receptors for AAV-5 capsids (PDGFR and sialic acids (Di Pasquale, G. 
et al., 2003)) are less abundant on primary hippocampal neurons as compared to the receptors 
necessary for AAV-2 entry (heparansulphate proteoglycan moieties (Opie, S. R. et al., 2003)). 
Intriguingly, replacing the hSyn1 gene promoter by the mCMV promoter in the AAV-5 vector 
ndrastically changed the transgene expression pattern: rapid onset of transgene expression is 
detected in fibrous astrocytes as identified by anti-GFAP immunofluorescence (Fig. 3.1.2 c) 
and remained confined to this cell type throughout the lifetime of the culture. Thus, AAV-5 
vectors can transduce both neurons and astrocytes in primary cultures, and can be efficiently 





Fig.3.1.2. Neuron- or astrocyte-specific transduction of primary neuronal cultures. AAV vectors 
expressing EGFP from different promoters, packaged into either AAV-2 or AAV-5 capsids, were used to 
transduce primary hippocampal neurons at times of preparation (DIV 0). Transduction of astrocytes was 
performed at DIV 7 of the same culture. EGFP fluorescence of living cultures was recorded at an inverse 
fluorescent microscope at either day 3 or day 8 after transduction for neurons, or at day 1 or day 3 after 
transduction for astrocytes. Parts (a) to (c) show high power magnifications of cultures transduced with (a) 
an AAV-2 vector expressing EGFP from the hSyn1 promoter, (b) an AAV-5 vector expressing EGFP from 
the hSyn1 promoter, and (c) an AAV-5 vector expressing EGFP from the mCMV promoter. Low power 
micrographs showing quantitative transduction of either neurons or astrocytes derived from the same 
culture are shown in (d) and (e). Scale bar, 100µm in c, 400µm in e. 
 
 
3.1.3. In vivo application of AAV vectors 
As discussed above, AAV vectors packaged into the serotype-5 capsid are relatively 
inefficient in transducing neurons in primary hippocampal cultures but are excellent for 
astrocyte-specific transgene expression. Since the production of neurotrophins may be more 
effective if secreted from astrocytes in the brain (e.g. in model systems of neuronal de- and 
regeneration), the AAV-5-mCMV-EGFP vector was tested for its transduction properties in the 
adult rat brain. In contrast to the results obtained in cultured cells prepared from the embryonic 
rat brain, we detected striatal transgene expression mainly in cells which co-localized with 
neither the astrocyte specific GFAP marker, nor with the neuron specific NeuN marker (Fig 






Fig.3.1.3. AAV-5 vector targeting in the brain. An attempt to target transgene 
expression from an AAV-5 vector to astrocytes in the rat brain is shown in (a) and (b). EGFP 
expression driven by the mCMV promoter is shown as an overlay with the astrocyte-specific anti-
GFAP stain (red (a)) or the neuron-specific anti-NeuN stain (red (b)). Note that EGFP expression 
(green) was only rarely co-localized (yellow) with these markers. However, AAV-5 vectors 
expressing EGFP from the hSyn1 promoter very efficiently expressed EGFP in neurons of the 
striatum (c). This expression was neuron specific as demonstrated by the co-localization of 
EGFP expression with the neuronal marker NeuN (e - g). An AAV-2 vector used at the same titre 
showed transgene expression closely confined to the injection tract (arrows). V = ventricle, CC = 
corpus callosum, Cx = cortex, CPu = caudate putamen. Scale bar, 200µm in b, 500µm in d, 




Although the combination of mCMV promoter and serotype-5 capsid failed to do the 
intended task in the brain, AAV-5 vector in combination with hSyn1 promoter offered very 
promising features. While AAV vectors packaged into the most widely used serotype-2 capsid 
show transduction of brain tissue fairly restricted to areas near the injection site (Fig. 3.1.3 d), a 
much larger transduction area was obtained when the serotype-5 capsid was used (Fig. 3.1.3 c). 
In combination with the neuron specific hSyn1 promoter, transgene expression was found 
exclusively in neurons (Fig. 3.1.3 e-g), over large areas in the striatum. Quantification of 
transduced neurons versus total neuron number (as revealed by NeuN staining) showed that in 
a volume of ca. 15 mm3 about 40% of the striatal neurons expressed the transgene EGFP after 
a single injection of 2 µl containing 1 x 108 transducing vector units (3 x 109 genomes). While 
the AAV-5-mCMV-EGFP vector demonstrated that AAV-5 is not a neuron specific vector per 
se, targeting the vector to neurons by the hSyn promoter allowed for efficient and wide spread 
neuronal transduction. 
Since co-expression of several interacting proteins may be desirable, AAV genome 
size may constitute restrictions even if small transcriptional control units are used. Therefore, 
we demonstrate that this problem may be readily overcome by the use of a double transduction 
approach: after stereotaxic injection of two different AAV-2 vectors, one expressing EGFP, the 
other DsRed (1 x 108 transducing units / 3 x 109 genomes each) the majority of neurons 
(>90%) was found to express both transgenes (more details are given in section 3.3, Fig. 3.3.2) 
 
3.2. Evaluation of epitope tags suitability for CNS gene transfer studies 
3.2.1. Expression constructs of epitope tags used for in vivo gene transfer  
Although the vector genomes used in this study contained the fluorescent reporter 
gene to demarcate the transduced cells, unambiguous detection of transgenic protein 
expression may be required. This may become necessary when reporter gene has to be 
removed to increase the capacity for accomodation of relatively large transgene, or when the 
intracellular localization of the transgenic protein has to be determined. 
Since in this study we aimed to overexpress proteins that are endogenously present in 
the brain, discrimination of the transgenic protein from the endogenously expressed is 
necessary and can be successfully accomplished by the epitope-tagging. Although extensively 
used in vitro, little information is currently available on the effective detection of the 
established epitopes by available antibodies. In order to investigate epitope tags and respective 
antibodies in tissue sections, the short peptide sequences were fused to the fluorescent protein 
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EGFP for demarcation of the transduced cells. Gene transfer of the respective constructs was 
achieved by viral vectors based on either Semliki-Forest virus (SFV) or adeno-associated virus 
(AAV). If EGFP fluorescence was detected in cells not recognized by the epitope-specific 
antibody, then sensitivity of tag detection was considered to be insufficient. If 
immunoreactivity was detected in cells not transduced by the vector (EGFP negative) then 
specificity of the tag detection was considered to be inappropriate.  
 
3.2.2. Structural influence of the epitope tags  
Denaturing SDS-PAGE revealed that epitopes might have considerable influence on 
the tagged protein (Fig. 3.2.1). First, fusion of the cMyc- and the FLAG-tags to EGFP resulted 
in more pronounced gel mobility retardation than could be expected from addition of the 
respective amino acids alone (EGFP = 26.9 kDa; expected for cMyc-EGFP-FLAG = 29.4 kDa, 
observed for cMyc-EGFP-FLAG = 34 kDa). Analysis of the amino acid sequences of the cMyc 
and the FLAG-tags by the neural network trained NetPhos 2.0 server (Blom, N. et al., 2004) 
revealed that  (cMyc : EQKLISEEDL) or a tyrosine (FLAG : DYKDDDDK) residue, which 
both have a high probability to be phosphorylated in the context of the EGFP fusion protein 
(scores = 0.997 for serine in cMyc and 0.937 for tyrosine in FLAG, with 1.0 being the highest 
probability score possible). Although tyrosine residues are present in the HA-, AU1-, IRS- and 
EE-tags as well, their scores were close to or significantly lower than a threshold value of 0.5 
and thus, phosphorylation of these residues is unlikely to occur (first and second tyrosine in 
HA below 0.1, third tyrosine in HA = 0.515; tyrosine in AU1 = 0.671; tyrosine in IRS = below 
0.1; tyrosine in EE = 0.564). 
Second, fusion of the HA-tag to EGFP resulted in distinctly different migration 
patterns, depending on whether the tag was fused to either the amino- or the carboxy-terminus. 
Two distinct protein bands were detected with the amino-terminal HA-tag, by using two 
independent constructs (HA-EGFP and HA-EGFP-IRS). Conversely, only one protein band 
was detected after the expression of the carboxy-terminally fused HA-tag. Intriguingly, all HA-
tagged EGFP constructs also showed "functional" impairment: regardless of the position of the 
HA-tag at either the amino- or the carboxy-terminus of EGFP, fluorescence of EGFP was 
reduced considerably as compared to EGFP alone or to EGFP fused to the other epitope tags. 
Using the same exposure time for recording EGFP fluorescence from all tagged constructs, we 
found that the HA-tagged EGFP yielded only 20 - 25 % of the brightness that was obtained 
from EGFP tagged with the other epitopes. Only when we used 5 times longer exposure time 
for recording EGFP fluorescence (i.e. 15,000 vs. 3,000 ms), the greyscale fluorescence level of 
HA - tagged EGFP reached that of the other constructs, suggesting a roughly 4 to 5 fold 
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reduction of EGFP fluorescence due to the fusion to the HA-tag (compare Fig. 3.2.2 c with a, b 




Fig.3.2.1.  Analysis of the various tag-EGFP constructs by SDS-PAGE. Cell lysates of 
SFV-vector transduced primary neuron cultures were consecutively probed on the same 
membrane with an anti-tubulin antibody for loading and migration control and with an anti-EGFP 
antibody to demonstrate different gel retardation properties of the respective EGFP-tag fusion 




3.2.3. Evaluation of epitope tags in the central nervous system 
For in vivo CNS applications, epitope tags were evaluated in striatum and retina. 
Injection of 2 x 105 infective particles of recombinant SFV vectors into striatum of adult rats 
resulted in transgene expression in different cell types. These were categorized by 
morphological criteria (Kügler, S. et al., 2003a) to be predominantly neurons, some 
oligodendroglia (inside striosomes) and some astrocytes or resting microglial cells (heavily 
ramified cells). Brains were preparated at 16h after transduction in order to avoid 
inappropriately high levels of transgene expression due to the self-replication of SFV genomes, 
and to prevent any possible adverse tissue reactions due to vector administration. No such 
tissue reactions were observed, either by DAPI staining to detect cellular infiltrates or by 
staining for activated microglia (not shown).   
In a series of pilot experiments, the dilution of antibodies that resulted in the best 
signal-to-noise ratio (typically in the range of 1:500 – 1:1,000) was determined first. All 
pictures were taken using the optimal dilution for the respective antibody.  
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3.2.4. Evaluation of "established" epitope tags (HA, cMyc, FLAG) 
The FLAG-tag is readily detected in SFV-cMyc-EGFP-FLAG transduced cells (Fig. 
3.2.2 c). However, in control brain transduced with SFV-EGFP or without any transduction, 
the anti-FLAG M2 antibody moderately but reproducibly stained the cytoplasm of cells with 
neuronal morphology (Fig. 3.2.2 a). Even more pronounced background staining was observed 
using anti-FLAG M2 antibody in the retinal ganglion cell layer (Fig. 3.2.2 b). Further dilution 
of the antibody reduced both background staining and specific signal detection, but did not 
enhance signal-to-noise ratio. Despite sensitive detection of the FLAG epitope in the brain, we 
noticed that a subpopulation (about 10-20%) of EGFP expressing cells was not stained by anti-
FLAG antibody (Fig. 3.2.2 c).  
Detection of the cMyc-tag was highly sensitive and specific in the brain, but not in 
the retina, where we noticed that about 20-30% of cells, which showed cMyc immunoreactivity 
were not EGFP-positive (Fig. 3.2.2 d). This finding suggests that endogenous cMyc protein (of 
which 10 amino acids represent the cMyc epitope peptide, corresponding to residues 423 - 432 
of human cMyc or residues 424 - 433 of rat cMyc) was detected in these cells rather than the 
vector expressed cMyc epitope tagged transgene. Since cMyc is a protein crucial for cell cycle 
progression but also is upregulated in several paradigms of neuronal degeneration (Qin, Z. H. 
et al., 1999;Di Giovanni, S. et al., 2003), our finding emphasizes that physiological tissue 
reactions may readily result in the false-positive detection of the cMyc-tag.  
The anti-HA antibody sensitively and specifically detected the HA-tag, however, 
EGFP fluorescence of the fusion proteins (HA-EGFP, HA-EGFP-IRS, EGFP-HA) was 
considerably reduced in brain sections and in cultured brain cells as compared to other tagged 
EGFP constructs (compare Fig. 3.2.2 e with a-d and f). Regardless, the remaining EGFP 
fluorescence was still sufficient to detect the fusion protein by using longer exposure times 
(approximately 5 times longer than for the other constructs).  
Taken together, all "established" epitope tag / antibody combinations allowed for 
sensitive detection of the expressed transgene, although we also document either structural 
influence of the epitope  tag on the fusion partner (HA - tag) or problems with background 
staining, depending on either tissue composition (FLAG - tag) or potential physiological tissue 
reactions as in case of cMyc - tag.  
 
3.2.5. Evaluation of "new" epitope tags (AU1, EE, IRS) 
The very short IRS-tag was detected specifically by its respective antibody. However, 
this detection was limited to cells expressing high levels of EGFP. Cells expressing lower 
levels of EGFP were not detected by the antibody in brain sections (Fig. 3.2.3 a), or in cultured 
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brain cells (Fig. 3.2.3 c). Increasing antibody concentration or changing the permeabilization 
protocol did not improve IRS detection (not shown). 
 
Fig.3.2.2. Evaluation of FLAG-, cMyc-, and HA- tags in striatum and retina. Recombinant SFV-
vectors (2 x 105 infective units each) were either stereotaxically injected into the striatum (a, c, e, f), or into the 
eye (b, d).  Vectors expressed either EGFP alone (a, b), or EGFP coupled to the cMyc- and the FLAG-tags (c, d), 
or EGFP coupled to the HA- and the IRS-tags (e, f). Each sub-panel of the figure shows EGFP fluorescence in 
the left (green), antibody staining (visualized by a cy3-coupled secondary antibody) in the middle part (red) and 
an overlay in the right part. Retinal sections are shown as overlays with nuclear DAPI stain to demonstrate tissue 
composition. Inlays in (a), (b), (d) and (f) show higher magnifications of the respective pictures. Arrows in (b) 
denote a Müller glia cell clearly recognizable by its longitudinal morphology with extended endfeet in the ganglion 
cell layer. Arrows in (c) denote EGFP expressing cells which are not recognized by the anti-FLAG antibody. 
Arrows in (d) denote retinal cells, which are not transduced by the SFV-vectors (EGFP-negative) but positively 
stained for the cMyc antigen. Arrows in (f) denote cells showing levels of EGFP expression barely above 
background but nonetheless properly detected by the anti-HA antibody. Note that (e) and (f) show the same 
specimen, for which in (f) five times longer exposure time (15,000 ms) was used to record EGFP fluorescence 





Fig.3.2.3. Evaluation of IRS-, EE- and AU1- epitope tags in striatum and primary neuron 
cultures. Recombinant SFV-vectors (2 x 105 infective units each) were either stereotaxically injected 
into the striatum ("brain", a, b, e), or used for transduction of primary hippocampal neuron cultures 
("HNC", c, d).  Vectors expressed either EGFP coupled to the IRS-tag (a, c), or EGFP coupled to the 
AU1- and EE-tags (b, d, e). Each sub-panel of the figure shows EGFP fluorescence in the left 
(green), antibody staining (visualized by a cy3-coupled secondary antibody) in the middle part (red) 
and the overlay in the right part, except for (c) and (d), which show EGFP fluorescence in the left and 
cy3 fluorescence in the right part of the panel. Sections in (a) are shown as overlays with nuclear 
DAPI stain to demonstrate that no accumulation of blood-borne immune cells were observed in these 
specimen. Arrows in (a) denote cells expressing EGFP but not stained by the anti-IRS antibody. 
Arrows in (b) denote EGFP expressing cells which are not recognized by the anti-EE antibody. 
Arrows in (d) denote cultured brain cells not transduced by the SFV-vectors (no EGFP fluorescence) 
but positively stained for the EE-antigen. Arrows in (e) denote a few cells expressing EGFP but not 





Since this epitope tag is the shortest  (only 5 amino acids in length) of all epitope peptides 
evaluated in this study, it may not be possible to develop more sensitive antibodies in order to 
increase the otherwise highly specific detection due to its low immunogenicity. 
In contrast, we were unable to determine appropriate conditions for using the anti-EE 
antibody to detect specific immunoreactivity of its respective tag. Brain sections exhibited 
dramatic background staining of fibrous structures and even of those cells which strongly 
express EGFP, only a subset was detected by the anti - EE antibody (Fig. 3.2.3 b). Some cells 
in primary hippocampal cultures were stained by the antibody, however most cells which were 
transduced by the respective SFV-vector, were not detected (Fig. 3.2.3 d). 
Apparently, the best results were achieved by using the anti-AU1 antibody to detect 
the AU1-EGFP-EE fusion protein. In the brain sections the AU1-tagged EGFP was sensitively 
and specifically detected (Fig. 3.2.3 e). EGFP and cy3 co-localization was observed in > 95 % 
of cells as judged from counting respectively labelled cells in sections of SFV-AU1-EGFP-EE-
transduced brain. Taken together, detection of the IRS - and EE - tags was hindered by either 
low sensitivity or a complete lack of specificity. Only the AU1 - tag was detected both 
sensitively and specifically. 
 
3.2.6. Proof-of-principle: discrimination of ectopically from endogenously expressed 
protein 
Gene transfer of proteins with potentially neuroprotective function is a rapidly 
developing field aiming at therapeutic intervention in animal models of neurodegenerative 
diseases. In order to prove efficacy of such attempts it is crucial to target expression of the 
respective protein to the affected neuronal populations, but also to be able to trace transgene 
expression appropriately. As SFV vectors are not suited for long-term gene transfer, we used a 
bicistronic adeno-associated virus vector (AAV-2) to express AU1-tagged calbindin D28K 
together with EGFP (Fig. 3.2.4 a) in the brain hippocampus, where high endogenous level of 
calbindin D28K expression was reported (Lomri, N. et al., 1989). After control vector (AAV-
EGFP) injection or in untransduced hippocampi, pronounced endogenous calbindin D28K 
expression was detected (Fig. 3.2.4 b). Thus, a specific cellular localization of the 
overexpressed protein would be almost impossible by using a calbindin-specific antibody. 
After stereotaxic injection of an AAV-2 vector expressing both, EGFP and AU1-tagged 
calbindin D28K, and after staining with the anti-AU1 antibody, only those cells transduced by 
the vector (as demarcated by EGFP fluorescence) were found to be immunoreactive for AU1-
tagged calbindin D28K (Fig. 3.2.4 c). Appropriate discrimination of endogenous from 
overexpressed calbindin D28K was also achieved by western blotting of the transduced with 
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either AAV-EGFP or AAV-AU1-calbindin-EGFP hippocampal cell lysates by using anti-AU1 
but not by anti-calbindin antibody (Fig. 3.2.4 a).  Thus, proper discrimination of neuronal 
populations endogenously expressing calbindin D28K from those overexpressing the transgene 




Fig.3.2.4. Proof-of-principle: unequivocal discrimination of ectopic and endogenous protein 
expression using AU1-tag after AAV-2 vector mediated transduction of hippocampus. (a) Schematic 
depiction of AAV-calbindin D28K vector genome is shown on the left: TR, inverted terminal repeats; hSyn1, 
human synapsin 1 gene promoter; Int, intron; SV40, SV40 polyadenylation site; WPRE, woodchuck hepatitis 
virus posttranscriptional control element; bGH, bovine growth hormone gene polyadenylation site. Western 
blot showing calbindin D28K expression and detection in cell lysates from AAV-2 transduced primary 
hippocampal neurons is shown on the right. Only anti-AU1 antibody specifically stained the overexpressed 
protein, while anti-calbindin D28K antibody detected both, endogenous and overexpressed protein. AAV-2 
vectors encoding AU1-tagged calbindin D28K plus EGFP were stereotaxically injected into the rat 
hippocampus. Left parts of each panel show tissue sections stained with either anti-calbindin D28K (b) or anti-
AU1 (c) antibodies,  middle parts of the panels show EGFP fluorescence (green), while the right parts of 





3.3. Long-term neuroprotection mediated by AAV gene transfer in the 
complete 6-OHDA rat model of PD 
3.3.1. Targeted transduction of SNpc by stereotaxic injection of AAV-2 vectors 
After establishing effective means for gene transfer in CNS, we overexpressed BclXL 
or GDNF, or BclXL plus GDNF in the substantia nigra pars compacta (SNpc) aiming to 
achieve efficient neuroprotection of DA neurons in rat model of PD. To this purpose, AAV-2 
viral vectors expressing BclXL or GDNF plus a fluorescent reporter protein (EGFP or DsRed2; 
Fig. 3.3.1) have been constructed. Fluorescent reporters simplified tracing of transduced 
neuronal populations. We also constructed a control vector containing a fluorescent reporter 
EGFP but no functional transgene (Fig. 4.3.1). After stereotaxic co-injection of 1.4 x 108 
transducing units (t.u.) of AAV-GDNF-EGFP and AAV-BclXL-DsRed vectors into the 
substantia nigra, we detected highly efficient co-expression from both vectors (Fig. 3.3.2 a-c). 
Efficient transduction of dopaminergic neurons was documented by staining transduced 
sections for tyrosine-hydroxylase immunoreactivity, demonstrating almost quantitative 
transduction of dopaminergic neurons (Fig. 3.3.2 d-f).  
 
Fig.3.3.1. Schematic depiction of the AAV-2 vector genomes. TR, inverted terminal 
repeats; hSyn1, human synapsin 1 gene promoter; BclXL, rat BclXL; GDNF, human glial cell line-
derived neurotrophic factor; EGFP, enhanced green fluorescent protein; DsRed, red fluorescent 
protein 2; Int, intron; SV40, SV40 polyadenylation site; TB, synthetic transcription blocker; WPRE, 
woodchuck hepatitis virus posttranscriptional regulatory element; bGH, bovine growth hormone 






Fig.3.3.2. Transduction of a rat brain.by AAV-2 vectors. Co-transduction of SNpc neurons by 
AAV-GDNF-EGFP (a) and AAV-BclXL-DsRed (b) is shown as an overlay image in (c). Representative 
transduction of SNpc dopaminergic neurons after injection of 1.4 x 108 t.u. of AAV vector as demarkated 
by EGFP-fluorescence (d), where dopaminergic neurons are visualised by TH immunoreactivity (e), is 
shown as an overlay in (f). Scale bar, 100µm in (c) and 400µm in (f).  
 
 
3.3.2. Establishment of the complete 6-OHDA rat model of PD  
Since unilateral 6-OHDA lesion of the nigrostriatal projection was chosen as a model 
system for the evaluation of neuroprotective effects of BclXL and GDNF, the criteria for 
successful surgery and appropriateness of the produced lesion had to be developed first. Wistar 
rats of 250-280g were found to be the best suited for effective and reproducible stereotaxic 
targeting of the medial forebrain bundle. The minimal effective dose of 6-OHDA was used to 
achieve the complete lesion of the nigrostriatal system. In order to evaluate the degree of the 
lesion rotational behaviour test and tyrosine hydroxylase (TH) immunofluorescent staining of 
the brain slices have been performed at different time points after the lesion.  The 6-OHDA 
injected rats were subjected to the apomorphine test at 1, 2, 3 and 4 weeks after brain surgery, 
followed by perfusion and evaluation of remaining TH-immunoreactivity (TH-IR) in the 
striatum and SNpc brain regions. More reproducible data in terms of correlation between the 
number of rotations and the loss of TH-IR have been obtained at 3 and 4 weeks after the lesion. 
Although some rats did not show pronounced rotational behaviour at 2 weeks after the injury 
(e.g. ≤ 3 rotations/min), they often developed a strong response to apomorphine by 3 weeks 
time point which then remained stable. However, those rats which at 2 weeks after the lesion 
showed 5 or more rotations per min typically presented with more than 85 % reduction of TH-
IR cells in the SNpc as well as almost complete loss of TH positive terminals in the striatum. 
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All the rats in the study were subjected to the rotational test at 2 weeks after the 6-OHDA 
lesion to confirm that the lesion was complete and to exclude from the study those rats which 
exhibited less than 5 rotations per min.  
 
3.3.3. BclXL mediated protection of DA cell bodies in 6-OHDA rat model of PD 
In animals injected with a control virus expressing only EGFP, 25% of nigral 
dopaminergic neurons survived for 2 weeks after the 6-OHDA lesion, while only 7% survived 
for 6 weeks following the lesion (Fig. 3.3.4 c, d; Fig. 3.3.5 a and Table 3.3.1). Care was taken 
to exclude TH-positive neurons of the ventral tegmental area (VTA) from counting, as these 
neurons were not directly affected by the lesion. BclXL overexpression significantly improved 
survival of DA neurons, which constituted 61% at 2 weeks after lesion and 31% at 6 weeks 
after lesion (Fig. 3.3.4 f, g; Fig. 3.3.5 a, Table 3.3.1). Importantly, the protection from 
neurodegeneration was restricted predominantly to the DA cell bodies, since the dense neuritic 
network of these neurons present under normal conditions was lost to a large extent (compare 
Fig. 3.3.4 f and g with h). It should be noted that the decline in numbers of TH-positive 
neurons was accompanied by a respective decline in numbers of neurons showing EGFP 
fluorescence in both, EGFP and BclXL / EGFP transduced SNpc. These data indicate that not 
only a downregulation of TH expression, but a real loss of DA neurons was observed after 6-
OHDA lesion in our paradigm. The rate of decline in TH-positive neuron numbers in either 
BclXL / EGFP or in EGFP transduced SNpc was similar, indicating that BclXL overexpression 
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Fig.3.3.3. Schematic schedule for 6-OHDA lesion experiments in the brain given in weeks. 





3.3.4. GDNF protects DA cell bodies and dendritic protrusions from 6-OHDA toxicity 
 At 2 weeks after 6-OHDA lesion, DA neurons in GDNF transduced SNpc were 
substantially protected from degeneration in that 77% survived at this time (Fig. 3.3.4 i, Table 
3.3.1). In contrast to BclXL-mediated neuroprotection, surviving DA neurons showed a dense 
network of dendritic arborisations throughout the SNpc, indicating that GDNF not only 
protects DA cell bodies but also their neurites from 6-OHDA toxicity. At 6 weeks after 6-
OHDA lesion, no significant decline in TH-positive cell numbers has taken place (76% 
surviving DA neurons, Fig. 3.3.4 j, Table 3.3.1), indicating that GDNF can inhibit and not only 
postpone 6-OHDA-induced neurodegeneration. No obvious difference in the density of neuritic 
arborisations of TH-positive neurons in either unlesioned controls or GDNF transduced SNpc 
at 2 or 6 weeks after 6-OHDA lesion were detectable (Fig. 3.3.4 j-k).  
As it was demonstrated earlier, high levels of GDNF expression may result in 
disturbances of dopaminergic metabolism and some aberrant sprouting of dopaminergic fibres 
(Georgievska, B. et al., 2002b). Therefore, the GDNF expression cassette used in our vector 
construct did not contain transcriptional control elements which strongly enhance transgene 
expression, such as the WPRE. GDNF expression levels in AAV-EGFP and in AAV-GDNF 
transduced SNpc quantified by ELISA were 11pg/mg and 190pg/mg, respectively.  
 
3.3.5. BclXL and GDNF co-expression has additive neuroprotective effects at 2 weeks 
after 6-OHDA lesion 
Co-expression of BclXL and GDNF resulted in almost complete protection of SNpc 
DA neurons from 6-OHDA toxicity at 2 weeks after lesion: 96 % of DA neurons survive at this 
time (Fig. 3.3.4 l; Table 3.3.1). When compared to 77 % surviving neurons through GDNF 
alone and 61 % surviving neurons through BclXL alone, these data represent a statistically 
significant additive neuroprotective effect (p < 0.001; Fig. 3.3.4; Table 3.3.1).  Moreover, no 
obvious morphological differences were detected between unlesioned control DA neurons and 
DA neurons under combination therapy (Fig. 3.3.4 l, n). 
 
 
Table 3.3.1. Quantification of surviving TH+-neurons in SNpc at 2 and 6 weeks after 6-OHDA lesion of 
MFB. The numbers of surviving TH+-neurons in AAV-BclXL, -GDNF, -BclXL +GDNF transduced SNpc 
regions are presented along with the numbers of surviving TH+-neurons in a control-vector (AAV-EGFP) 








  Fig.3.3.4. TH-immunoreactivity in rat brain after unilateral 6-OHDA lesion. Representative CPu 
regions show the TH-immunoreactive projections of the DA-neurons (a) at 3 weeks after 6-OHDA injection into 
MFB and, (b) on contralateral (unlesioned) side. The insets in (a) and (b) depict the magnified views on the TH+-
fibre density in the corresponding areas. Immunohistochemical visualisation of surviving DA-neurons by TH-
immunostaining in AAV-transduced SNpc (c, d, f, g, i, j, l, m) at 2 and 6 weeks after the MFB lesion compared to 
the unlesioned side of the same animal (e, h, k, n) at 6 weeks after the lesion. The AAV-EGFP transduced SNpc 
is shown at 2 and 6 weeks after 6-OHDA lesion in (c) and (d). TH+ neurons transduced by AAV-BclXL are shown 
in (f), at 2 weeks after lesion, and in (g), at 6 weeks after lesion. The inset in (g) shows the predominant 
morphology of surviving DA-neurons transduced by AAV-BclXL at 6 weeks after the lesion. Note that most cell 
bodies of the remaining TH+-neurons are devoid of processes. The AAV-GDNF transduced nigrae are shown at 
2 and 6 weeks after the 6-OHDA lesion in (i) and (j); the S. nigrae co-transduced with AAV-GDNF and AAV-
BclXL at 2 and 6 weeks after the MFB lesion are shown in (l) and (m).  The inset in (j) shows the morphology of 
the majority of surviving DA-neurons in AAV-GDNF transduced SNpc at 6 weeks after the 6-OHDA lesion, while 
the inset in (k) depicts the native morphology of neurons in untreated SNpc. Note that the fibre density of the DA-
neurons protected by GDNF at 6 weeks after the 6-OHDA lesion (inset in (j)) is indistinguishable from that of 
unlesioned side (inset in (k)). Scale bar, 200µm in (b) and 400µm in (n). 
  
3.3.6. Co-expression of BclXL with GDNF has no beneficial effect on dopaminergic 
neuron survival at 6 weeks after 6-OHDA lesion 
Although BclXL expression alone resulted in significant neuroprotection from 6-
OHDA toxicity at 6 weeks after lesion, its co-expression with GDNF at this time did not result 
in any additive neuroprotective effect. It rather appeared that the neuroprotection at this time is 
exclusively mediated by GDNF, since the numbers of TH-positive (TH+) neurons in the GDNF 
group were almost identical to the numbers in the GDNF plus BclXL group (Fig. 3.3.5 a; Table 
3.3.1). In order to rule out that 6-OHDA lesion might have any effect on BclXL expression 
from the viral vector genome, AAV-BclXL transduced nigrae were stained for BclXL. In DA-
neurons surviving for up to 6 weeks after 6-OHDA intoxication we detected the same level of 
immunoreactivity for BclXL as in unlesioned controls (Fig. 3.3.5 b-d). In contrast, we could not 
detect any obvious upregulation of BclXL (Fig. 3.3.5 e-g) or bcl-2 expression (not shown) in 
AAV-GDNF transduced DA-neurons. These latter results demonstrate that the long-lasting 
neuroprotective effect of GDNF on survival of DA-neurons was independent from BclXL. 
 
3.3.7. Effects of delayed AAV-GDNF administration in the rat striatum after the 
complete 6-OHDA lesion of the MFB  
In agreement with several other studies (Björklund, A. et al., 1997;Eslamboli, A. et 
al., 2003;Georgievska, B. et al., 2002b) we have shown here that the overexpression of GDNF 
alone allows for sustained protection of dopaminergic cell bodies of SNpc as well as their 
neuritic arbour from 6-OHDA toxicity. However, the primary pathologic background that 
results in movement disorders typically observed in PD patients is believed to be a disbalance 
in dopamine release in the striatum. 
Therefore, we overexpressed GDNF in the lesioned striatum late after the complete 
lesion of nigrostriatal projections was achieved. To this purpose, we first induced the lesion by 
6-OHDA injection in the MFB and introduced GDNF three weeks after the lesion by 
stereotaxic injection of the AAV-5-hSyn-GDNF into the ipsilateral to the lesion striatum (for 
schematic timetable see Fig. 3.3.6 a). AAV-5 serotype was used in this experiment for GDNF 
delivery since it allows for transduction of a large area in the brain (Fig. 3.1.3 c). Neither at 6 
weeks nor at 4 months after the AAV injection we observed behavioural or 
immunohistochemical recovery in lesioned animals. The striatum on the side of the lesion was 
almost completely devoid of TH-immunoreactive terminals in both GDNF- and EGFP-







Fig.3.3.5. Quantification of DA-neuron survival in SNpc after 6-OHDA lesion. In (a) the 
number of surviving TH+-neurons was determined after the control vector injection (AAV-EGFP) and 
after the injection of AAV-BclXL, or AAV-GDNF, or AAV-BclXL plus AAV-GDNF (gray bars). Dark-gray 
bars represent the mean values of surviving TH+-neurons in SNpc at 2 weeks after 6-OHDA lesion, 
light-gray bars represent mean values of surviving TH+-neurons at 6 weeks after 6-OHDA lesion. The 
mean number of TH+-neurons in unlesioned SNpc is shown by black bar. Bars represent mean 
values ± standard deviations (***p < 0.001, n.s., non-significant). Immunohistochemical staining for 
BclXL in SNpc neurons transduced by AAV-BclXL confirmed that BclXL expression is not 
downregulated in the course of the experiment (b - d). Immunohistochemical staining for BclXL was 
also used to demonstrate that GDNF expression did not result in BclXL upregulation in SNpc neurons 





These data suggest that GDNF alone is not sufficient to induce resprouting of a few 
remaining after the lesion of the nigrostriatal projections. Neurorestorative effect of GDNF 





Fig.3.3.6. Delayed delivery of GDNF into the rat striatum by AAV-5 vectors after the 
complete unilateral 6-OHDA lesion. The schematic schedule of the course of the experiment given in 
weeks is shown in (a). TH-immunoreactivity in a 6-OHDA lesioned rat striatum is shown at 3 months 
after stereotaxic application of AAV-5-EGFP (b) or AAV-5-GDNF-EGFP (c). Area transduced by AAV-
5 vector is represented by EGFP fluorescence (green) in the left panel, TH-immunoreactivity 
represented by cy3 fluorescence (red) in the middle and the overlay of both images is given in the 










In the work presented here the following aims have been pursued: 1) to evaluate the 
neuroprotective and neurorestorative properties of BclXL and GDNF in the rat model of 
Parkinson’s disease; 2) to develop appropriate adeno-associated viral vectors for efficient gene 
transfer to the target regions in the brain; 3) to improve detection the transgene for ongoing and 
future gene transfer studies by epitope-tagging approach. 
 
4.1. AAV vector targeting  
In this study we aimed to overexpress BclXL and GDNF in the substantia nigra and 
GDNF in the striatum. The purpose of nigral gene transfer was to achieve efficient and long-
lasting neuroprotection of DA cells. AAV-2 serotype was employed as a gene transfer tool, 
since it preferentially transduces neurons in the CNS and has especially high affinity to DA 
neurons of SNpc (Paterna, J. C. et al., 2004). This property of AAV-2 vectors can be explained 
by high density of HSPG receptors, necessary for virus entry, on nigral neurons (Fuxe, K. et 
al., 1994). To further restrict the expression of the transgene to neurons, hSyn1 promoter was 
used.  However, protecting the DA cell bodies in SNpc may not be sufficient for maintenance 
of the basal ganglia circuit in the brain. To achieve reconstruction of functional connections of 
DA cell bodies to the striatum, striatal overexpression of GDNF may be required (Kirik, D. et 
al., 2004). GDNF was found to be expressed primarily from astrocytes in the brain. Therefore, 
we attempted to redirect the AAV-mediated transgene expression from neurons to astrocytes. 
Previous studies aiming to restrict the transduction by AAV vectors to either astrocytes or 
oligodendroglia using the glial cell type specific promoters GFAP and myelin basic protein 
promoter failed (Peel, A. L. et al., 1997;Peel, A. L. et al., 2000). In this study we used 
ubiquitously active mCMV promoter which has been shown to target the transgene expression 
to astrocytes after adenoviral transduction of the CNS (Kügler, S. et al., 2001). Moreover we 
made use of the AAV-5 capsid for packaging since this AAV serotype was shown to equally 
transduce neurons and astrocytes (Tenenbaum, L. et al., 2004). With this approach, efficient 
astroglia-specific transgene expression was achieved in primary hippocampal culture. 
Incorporation of EGFP into AAV vector genome greatly simplified visualization of the 
transduced cells. However, when the same promoter/capsid (mCMV/AAV-5) combination was 
utilized for AAV-mediated gene transfer into the brain, a different cellular transduction pattern 
was observed as compared to in vitro results. Instead of predominant localization of EGFP to 
astrocytes as it would be expected after the in vitro experiments, some neurons and cells of 
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unidentified origin, which were negative to both astroglial and microglial immunological 
markers have been transduced.  These apparently divergent data obtained from in vitro and in 
vivo studies on AAV vector targeting may be explained by variable expression of receptors 
required for successful entry of the recombinant virus into the cell in embryonic and adult 
brain. In neonatal mice intraventricular brain injection of AAV-2 or AAV-1 has been shown to 
result in widespread neuronal transduction, whereas AAV-5 injection led to a very limited 
transgene expression (Passini, M. A. et al., 2003). In the brain of adult animals, however, 
AAV-2 transduction is localized while AAV-5 transgene expression is typically widespread 
(Davidson, B. L. et al., 2000;Shevtsova, Z. et al., 2005). Moreover, the extracellular 
environment and tissue composition which may contribute to the successful entry of the virus 
into the cell are very different in primary cultures and in the living organism. For example, in 
addition to glycosamynoglycans AAV-2 serotype requires fibroblast growth factor receptor 
and integrins as co-receptors for effective transduction (Qing, K. et al., 1999;Summerford, C. 
et al., 1999), which appear to be differentially expressed in neonate and adult brain. On the 
contrary, AAV-5 mediated transduction does not require heparan sulfate proteoglycan (HSPG), 
but α-2,3- or α-2,6-N-linked sialic acid (Kaludov, N. et al., 2001;Walters, R. W. et al., 2001) 
and platelet-derived growth factor receptor (PDGFR) (Di Pasquale, G. et al., 2003). In 
addition, mCMV promoter activity in mature and in non-differentiated CNS cells may also 
influence the observed difference in expression patterns. 
Consistent with the results obtained by others (Burger, C. et al., 2004), the area of 
virus transduction in the brain was restricted to the injection site after stereotaxic application of 
AAV-2 vector and was spread beyond the striatum borders (ca. 10x larger) after injecting the 
same titre of AAV-5 vector. These serotype properties of AAV can define the choice of the 
vector for gene transfer: when the transduction of a relatively small-size region is intended, the 
use of AAV-2 serotype is appropriate. For effective transduction of a large structure in the brain 
(e.g. striatum), AAV-5 would be the vector of choice. Thus, AAV-2 serotype was selected for 
gene transfer into the small nucleus SNpc whereas AAV-5 was used to deliver GDNF into the 
striatum. 
  
4.2. Epitope-tagging for in vivo transgene detection 
Difficulties in detection of transgenic protein expression by respective antibodies and 
in its discrimination from the endogenously expressed analogue in a living organism (Weise, J. 
et al., 2000;Wagenknecht, B. et al., 1999) necessitate the search for alternative confirmation of 
transgene expression.  Advanced viral gene transfer systems have made it possible to express 
almost every protein of interest not only in rodent but also in the more complex primate brain 
 74
  
(Gerdes, C. A. et al., 2000;Kirik, D. et al., 2003). Gene transfer studies directed towards 
therapeutic interventions in disease models or towards basic research on protein functions 
require the unambiguous verification of the transgene expression. An antibody, specific for the 
respective protein may be used, but this antibody might not be able to discriminate intrinsically 
expressed proteins from the ectopically or overexpressed one. Additionally, for dominant-
negative or constitutively activated variants of a protein, or for splice variants as well as for 
many proteins investigated for the first time specific antibodies may not be available. Thus, 
epitope tags, short peptides which can be fused to the protein under investigation and 
specifically detected by well-characterized antibodies, appear to be an attractive alternative. 
Although proven to be useful for protein tracing in cell-free systems or in cultured cells in vitro 
(Terpe, K., 2003), thus far there has been no systematic attempt to characterize different epitope 
tags for in vivo gene transfer applications. 
The study presented here is the first systematic evaluation of different epitope tags in 
the CNS. The data demonstrate that all "established" tags (HA-, cMyc-, FLAG-tag) were 
detected by their respective antibodies with high sensitivity, but in all cases significant 
drawbacks have also been observed. The anti-FLAG and the anti-cMyc antibodies showed 
significant background staining of distinct CNS structures, and at least one of these tags was 
responsible for pronounced gel mobility retardation of the tagged EGFP, probably due to the 
introduction of an odd phosphorylation site. Fusion of the HA-tag to EGFP resulted in 
pronounced reduction of EGFP fluorescence, and the N-terminally tagged EGFP showed altered 
mobility in SDS gel electrophoresis while the C-terminally tagged version did not. Among the 
"new" tags evaluated, the very short IRS tag (5 amino acids in length) was specifically detected, 
but not with sufficient sensitivity for routine use. In contrast, the antibody used to detect the EE-
tag proved to be inoperative in brain sections due to tremendous background staining. Only 
AU1-tag detection was accomplished with high specificity and sensitivity, both on brain 
sections and in cultured neurons, and did not show any obvious influence on the tagged protein.  
Subtle to moderate changes in protein structure and function due to the addition of extra 
amino acids may be less relevant in cell-free or cell culture experiments, in which super-
physiological amounts of recombinant or overexpressed proteins are used for experiments (e.g. 
co-precipitation assays). However, if functional studies require physiological protein expression 
levels, then the influence of an epitope tag may turn out to affect the results of the study. 
Despite this important issue, only limited information is currently available with respect to the 
influence of epitope tags on the fusion protein. Transgenic mice expressing the wild-type P0-
glycoprotein, which is important for peripheral nerve myelination, and which was N-terminally 
tagged by the cMyc epitope, demonstrated clinical symptoms of Charcot-Marie-Tooth disease 
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solely due to the presence of the cMyc-tag (Previtali, S. C. et al., 2000), although 
crystallographic studies suggest that the N-terminus of this protein is not involved in cis or trans 
interactions (Shapiro, L. et al., 1996). Fusion of the FLAG epitope to the membrane-binding 
subunit of influenza virus haemagglutinin caused the protein to localize to the cytoplasm of cells 
rather than to the membrane (Chen, J. et al., 1998). Tagging the small GTPase H-Ras by the 
FLAG epitope resulted in activity changes as well as in altered mobility in SDS gel 
electrophoresis (Johnson, K. Y. et al., 2002). As such, potential influences of epitope tags must 
be taken into account especially in studies regarding proteins with as-of-yet unknown functions. 
Putative phosphorylation sites as present in the cMyc- and the FLAG-tag amino acids sequences 
may only be post-translationally modified depending on a particular cellular environment. 
Regardless, such modifications may have unpredictable impacts on the protein under 
investigation.  
While some background staining is to be expected if an epitope derived from a cellular 
protein (like the cMyc-tag) is used, epitopes derived from viral proteins should not have 
matching cellular counterparts and thus the respective antibodies should be less likely to result 
in background staining. In the present study, this assumption was found to be correct for the 
influenza hemagglutinin (HA-) tag (Wilson, I. A. et al., 1984) and for the AU1-tag, which is 
derived from the bovine papilloma virus capsid protein L1 (Lim, P. S. et al., 1990), but not for 
the EE (or Glu-Glu) tag, which is derived from polyoma virus medium T-antigen 
(Grussenmeyer, T. et al., 1985). This latter result together with the finding of FLAG - antibody 
background staining clearly demonstrates the need to evaluate potential epitope tags and their 
respective antibodies in the tissue under study, since it can not be excluded that epitope tag - 
specific antibodies bind to unexpected cellular antigenes. SFV vectors appear to be an attractive 
tool for such evaluation due to their property of fast and efficient transduction of broad 
specificity. 
In a proof-of-principle experiment we used an AAV-2 based viral vector for 
demonstration of the functionality of the AU1-tag in an in vivo gene transfer approach. The 
AAV vector genome was designed in a way that EGFP is co-expressed with calbindin D28K, 
clearly demarcating the transduced areas. It should be noted that the approach of co-expressing a 
reporter gene with the transgene under investigation is a valuable, but indirect way of proving 
transgene expression. It may fail if detailed sub-cellular localisation of the transgene has to be 
documented, if the transgene is expressed with different kinetics, or if it is processed or 
secreted. Therefore, epitope-tagging may be a more reliable methodological approach in 
targeting transgenic protein expression. Despite robust endogenous calbindin D28K expression in 
several retinal neuron populations, it was possible to unequivocally trace the expression of the 
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vector derived AU1-tagged calbindin D28K, clearly discriminating endogenous from 
overexpressed protein. These results demonstrate the usefulness of this epitope and of epitope-
tagging techniques for in vivo studies in general. However, this data also clearly demonstrated 
that a careful pre-evaluation of epitope tags and their respective antibodies is necessary for 
different types of tissues and transduction paradigms, in order to avoid problems with 
background detection and unexpected influences of the epitope tags on the protein under 
investigation.  
In this study we have chosen to tag the calcium buffering protein calbindin D28K as its 
role in neurodegeneration has yet to be clarified. It remains unclear whether localized rather 
than general increase in cytosolic free calcium is critical for cell death (Rizzuto, R. et al., 
1999;Mattson, M. P. et al., 2003). In ongoing experiments we aim to investigate the role of 
calcium and calbindin D28K in two models of neurodegeneration: optic nerve axotomy and 6-
OHDA nigrostriatal lesion. Since relatively high expression of calbindin in retina and certain 
brain regions was detected in a series of preliminary experiments, appropriate detection of 
overexpressed calbindin by using the AU1-tag may prove to be useful.   
 
4.3. Neuroprotective therapy of PD as evaluated in the complete 6-OHDA lesion model 
Neurodegenerative diseases are characterized by slow and multifactorial progression, 
and potential therapeutic treatment is difficult due to diagnosis at relatively late stages of life. 
After diagnosis patients have one or more decades of life expectation, which would necessitate a 
long-lasting therapeutical intervention in order to halt, or at least significantly postpone the 
neurodegenerative processes. Any potential therapeutic intervention should thus be confirmed to 
be effective over longer periods of time. Furthermore, the multifactorial nature of 
neurodegeneration in its later stages suggests that   therapeutic approaches targeting more than 
one neurodegenerative mechanism might be more effective than mono-specific attempts.  
In this study we have evaluated such combination gene transfer in a widely used animal 
model of neurodegeneration induced by oxidative stress, 6-OHDA lesion of the nigrostriatal 
system. The unilateral 6-OHDA lesion model of PD offers certain advantages in that it allows 
the immunohistological analysis of the lesioned hemisphere in comparison to the unaffected 
brain hemisphere of the same animal as an internal control. Furthermore, an easy-to-perform 
apomorphine induced rotational behaviour test reflects the degree of assymetry in striatal 
dopamine content and can be used to verify the successful lesioning surgery. In order to produce 
the unilateral toxic model of PD, 6-OHDA is typically injected either into the striatum or into the 
medial forebrain bundle (MFB) (Blum, D. et al., 2001;Deumens, R. et al., 2002). Multiple 
striatal injections are usually required to induce the degeneration of more than 50-60% of the DA 
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neurons in SNpc which increase the time and traumatisation of the surgery (Deumens, R. et al., 
2002).  An alternative way to achieve the selective degeneration of the nigrostriatal DA neurons 
in SNpc is to deliver the 6-OHDA toxin directly into the nigrostriatal projection, the MFB. 
Injection of 6-OHDA into the MFB represents a more severe oxidative stress lesion of DA 
neurons than the striatal 6-OHDA injection or systemic MPTP application (Deumens, R. et al., 
2002;Dauer, W. et al., 2003). Therefore, molecules, able to counteract neurodegeneration in this 
model may have high potential for therapeutic benefit in PD, in which degeneration of DA 
neurons occurs at much slower rates.  
 
4.4. BclXL mediated neuroprotection 
The data obtained in this study demonstrate that BclXL overexpression can promote the 
survival of 61% of dopaminergic neurons at 2 weeks and 31% at 6 weeks after the 6-OHDA 
lesion of the medial forebrain bundle. The numbers of remaining neurons in AAV-2-BclXL 
injected group are significantly higher (p<0.001) than those transduced with the AAV-2-EGFP 
control virus (25% at 2 weeks and 7% at 6 weeks). However, a decline in DA cell numbers from 
2 to 6 weeks post-lesion was observed, and thus, stable neuroprotection could not be achieved 
through BclXL overexpression alone.  
Several studies have focused on the role of bcl-2, another anti-apoptotic protein of the 
same family as BclXL, in the protection of CNS neurons from cell death. In the partial 6-OHDA 
toxicity model of PD, herpes virus mediated overexpression of bcl-2 supported the survival of 
approximately 50% of nigral neurons at 2 weeks after the lesion (Yamada, M. et al., 1999). Also, 
transgenic mice expressing human bcl-2 under the neuron-specific enolase promoter have been 
found to be more resistant to MPTP and 6-OHDA toxicity (Offen, D. et al., 1998). However, 
both experiments were estimating only the short-term effects of the bcl-2 on DA cell survival.  
Moreover, the toxic lesions performed in either of the studies were relatively mild as compared 
to the complete unilateral lesion paradigm (Deumens, R. et al., 2002;Dauer, W. et al., 2003).  
In this study, overexpression of BclXL but not bcl-2 was chosen mainly for two 
reasons. First, BclXL has been shown to be more potent in inhibiting mitochondrial membrane 
potential breakdown than bcl-2 (Kim, R., 2005), probably due to its more efficient targeting to 
mitochondria (Kaufmann, T. et al., 2003). Second, BclXL but not bcl-2 can inhibit TNFα-
activated TRAIL mediated apoptotic and non-apoptotic cell death (necrosis and autophagy) 
(Kim, I. K. et al., 2003;Kim, R., 2005;Keogh, S. A. et al., 2000), which play important roles in 
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several neurodegenerative paradigms (Anglade, P. et al., 1997;Hirsch, E. C. et al., 
2003;Cacquevel, M. et al., 2004). 
Taken together, BclXL overexpression failed to finally preserve neurons from 
degeneration after severe unilateral lesion of nigrostriatal system, with a 50% decrease of 
surviving neuron numbers late after lesion as compared to the early time of analysis. Moreover, 
BclXL failed to preserve the DA neurites, protecting only the cell bodies of DA neurons. Thus, 
maintenance of mitochondrial integrity may be essential for neuronal survival early after lesion 
but appeared to be less important for the long-term survival of deafferentiated neurons and 
insufficient for the maintenance of the functional DA connections.  
 
4.5. Combination of BclXL and GDNF for neuroprotection of DA neurons 
In order to achieve sustained and complete protection of nigrostriatal neurons, a 
combination of mitochondrial integrity protection by BclXL overexpression with neurotrophic 
support by GDNF expression was used. To this purpose a mixture of two AAV-2 vectors each 
carrying a functional transgene (BlcXL or GDNF) and a fluorescent reporter gene (DsRed or 
EGFP) was stereotaxically applied into the SNpc. The presence of the fluorescent transgenes 
was required to prove the efficient co-transduction of nigral DA neurons upon co-injection of the 
AAV vectors. As it has been shown before for retinal ganglion cells (Michel, U. et al., 2005), 
double transduction of the vast majority of DA neurons (>90%) by two different AAV-2 vectors 
could be accomplished.  
When used in combination, BclXL and GDNF provided almost complete 
neuroprotection (96%) in the 6-OHDA lesion paradigm at early time after lesion. The combined 
effect of these two molecules was found to be additive indicating the important role for targeting 
multiple pathways in neurodegenerative diseases. The results obtained in the short-term 
experiments are in coincidence with previous studies demonstrating that a combination of 
expression of GDNF with the anti-apoptotic bcl-2 or XIAP proteins had additive neuroprotective 
effects in several other lesion models (Natsume, A. et al., 2002;Natsume, A. et al., 2001;Straten, 
G. et al., 2002;Eberhardt, O. et al., 2000). Altogether, this strengthens the notion that aiming to 
prevent neurodegeneration through different pathways may be a more effective approach to slow 
down the progression of neurodegenerative processes than by targeting single cellular pathways. 
In the model system evaluated in this study, the BclXL plus GDNF co-expression 
resulted in the most effective short-term prevention from neurodegeneration reported so far. 
While the mode of action for BclXL is relatively well-defined (Kim, R., 2005), this does not hold 
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true for the neurotrophin GDNF. GDNF may exert its beneficial effects through several receptor 
systems, including its prototype receptors GFRα and Ret, but also NCAM and heparansulphate-
proteoglycans like syndecan-3 (Sariola, H. et al., 2003). Dopaminergic neurons of the SNpc 
express high levels of GDNF receptors (Trupp, M. et al., 1996), and thus may be responsive to 
the neurotrophin without a delay, explaining the stable and efficient protection mediated by 
GDNF expression.  
Nevertheless, at later time after lesions co-expressed BclXL and GDNF failed to 
demonstrate any additive effect of on DA neuronal survival. This outcome may be partially 
explained by the fact that GDNF may induce the upregulation of bcl-2 and BclXL expression 
(Ghribi, O. et al., 2001;Cheng, H. et al., 2002) and further AAV mediated overexpression of 
BclXL may not be beneficial. However, immunofluorescence did not reveal any GDNF-induced 
upregulation of BclXL or bcl-2 levels in transduced nigral neurons. 
 In many neurodegenerative paradigms axonal damage precedes the loss of neuronal 
cell bodies (Dauer, W. et al., 2003;Stokin, G. B. et al., 2005;Li, H. et al., 2001;Gunawardena, S. 
et al., 2005). This principle is at least partially recapitulated in the model system used in this 
study, since DA neurons of SNpc are lesioned primarily by the axonal damage. In this paradigm 
protection of mitochondrial integrity was substantially more effective at early time after lesion, 
but no stable prevention of neurodegeneration over time was achieved by BclXL expression. 
These data suggest that in deafferentiated CNS neurons degeneration can only be postponed by 
targeting mitochondria mediated pathways. Further neuroprotective signalling by GDNF may 
then be necessary to inhibit neurodegeneration in its later stages.  These results should have 
important implications for the design of therapeutic neuroprotective approaches.   
Taken together, it was demonstrated in this work that BclXL and GDNF act additively  
in protecting DA cells of SNpc at early time points after lesion, however loose this combinatorial 
effect when investigated at later time points. This data suggest that the actual potency of the 
therapeutic approach could only be revealed over long-term experiments suggesting that studies 
aiming to define neuroprotective strategies should be generally performed over longer periods of 
time.  
 
4.6. GDNF mediated neurorestorative therapy 
The highly efficient neuroprotection of DA cell bodies in SNpc reported in this study 
does not, however, preserve their striatal projections. Therefore, the ultimate goal to restore the 
balance in nigrostriatal DA system could not be achieved due to the model system outlay. 
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GDNF appears to become the molecule of choice for restoration of the dopaminergic 
projection network in the striatum. Striatal delivery of GDNF was proven to be effective in 
protecting both nigral dopamine (DA) neurons and their axons in the striatum accompanied by 
recovery of spontaneous sensorimotor behaviors in various animal models (Chao, C. C. et al., 
2003;Georgievska, B. et al., 2002b;Jollivet, C. et al., 2004;Rosenblad, C. et al., 2000). 
Sprouting of the lesioned axons was documented along the nigrostriatal pathway, precisely 
corresponding to the areas containing anterogradely transported GDNF (Georgievska, B. et al., 
2002b). First successful phase 1 clinical trials on intraputamenal delivery of GDNF reported to 
improve motor symptoms and striatal dopamine content in human patients (Nutt, J. G. et al., 
2003;Gill, S. S. et al., 2003). However, recent results from a double-controlled clinical study 
delivering the recombinant GDNF directly into brain did not demonstrate efficacy and safety of 
such a treatment (Lang, A. E. et al., 2006). Various methodological reasons could contribute to 
this outcome, such as surgical procedure of peptide delivery, the development of immune 
response to the recombinant protein, and overall dosage of the GDNF. It may therefore be 
premature to conclude the ineffectiveness of GDNF trophic support therapy for PD patients. 
Nevertheless, before proceeding with any further clinical trials, the safety issues regarding the 
tools for efficient GDNF delivery, the dosages and therapeutic indications have to be carefully 
re-evaluated. More preclinical studies in animal models will be required to fulfil these 
requirements. Future approaches, such as gene therapy or cells engineered to produce GDNF 
(Kishima, H. et al., 2004;Behrstock, S. et al., 2006), or viral vector mediated GDNF expression 
(Eslamboli, A. et al., 2003) may prove more effective for providing local and sustained 
delivery of GDNF than simple direct brain infusion.  
In this work the question was posed on whether GDNF may contribute to the re-
sprouting and behavioural recovery after the complete nigrostriatal lesion which may reflect 
the situation at the very late stages of PD, when more than 90% of DA innervation is lost. The 
appropriate dose of GDNF may be crucial for beneficial outcome. Long-term striatal 
overexpression of GDNF was shown to selectively downregulate tyrosine hydroxylase in intact 
nigral neurons (Rosenblad, C. et al., 2003) and may induce aberrant neuritic sprouting 
(Georgievska, B. et al., 2002a). To avoid the overdose effect, GDNF was expressed from the 
hSyn1 promoter which typically allows for physiological levels of protein expression (Kügler, 
S. et al., 2003a).  
In contrast to the data showing that delayed delivery of AAV-GDNF promoted 
functional recovery in the partial 6-OHDA lesion of the nigrostriatal system (Wang, L. et al., 
2002), it failed to produce such effect in the complete lesion model in the study presented here. 
This result favours the hypothesis that GDNF requires the presence of sufficient remaining DA 
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projections in the striatum (as in partial lesion model) in order to exert its neurorestorative 













































Gene transfer to the brain is a promising therapeutic strategy for a variety of 
neurodegenerative disorders including Parkinson’s disease (PD). PD is characterized by a 
progressive degeneration of the nigrostriatal dopaminergic system. By using adeno-associated 
viral (AAV) vector that allows for long-term and stable transgene expression, a single 
intervention rather than continuous pharmacological treatment may provide a therapeutic effect.  
In this study, BclXL and GDNF have been evaluated separately and in combination as 
prospective neuroprotective molecules for gene therapy in the complete 6-hydroxydopamine 
lesion model of PD. Efficiency of gene therapy is dependent on the effective transduction of the 
selected regions in the brain. AAV-2 serotype is known to preferentially transduce 
dopaminergic neurons in substantia nigra (SN) and therefore was chosen for BclXL and/or 
GDNF gene transfer into this region. Wide-spread transduction of the rat striatum for GDNF 
delivery could be achieved by cross-packaging of the AAV-2 genome into the AAV-5 capsid. 
Attempts to restrict GDNF transgene expression to astrocytes, as it is naturally secreted from 
glial cells, by using murine cytomegalovirus (mCMV) promoter and AAV-5 serotype, were 
successful in vitro but not in vivo. In order to facilitate tracing of the transgenic protein 
expression in vivo, epitope-tagging technique has been employed. The first systematic 
evaluation of six different epitope/antibody combinations for in vivo application is presented in 
this study and reveals the AU1 epitope tag as the best suited for detection of the transgenic 
protein in the central nervous system. 
 AAV-2-mediated overexpression of BclXL in substantia nigra of rat brain mediated 
the survival of 61% of dopaminergic neurons at 2 weeks and 31% at 6 weeks after the lesion as 
compared to 25% and 7%, respectively, in the control-virus transduced SN. Co-expression of 
BclXL and GDNF resulted in the most effective protection of dopaminergic neurons at 2 weeks 
after the 6-OHDA lesion reported so far (96% surviving DA neurons). At this time point of 
analysis, additive neuroprotective effects of BclXL and GDNF were evident. At 6 weeks after 
the lesion, however, no additive effect of BclXL to GDNF-mediated neuroprotection was 
observed. Therefore, long-term studies should be generally performed to determine the actual 
potency of particular gene transfer. 
Aiming for delayed restoration of dopaminergic projections, AAV-5-GDNF 
transduction of the striatum was performed after the complete lesion of nigrostriatal system. 
Failure to observe any behavioural or histo-morphological improvement at 3 months after the 
AAV injection into the lesioned striatum favours the conclusion that sufficient remaining 






I would like to express my gratitude to all people who have supported me during the work on 
the PhD thesis, especially to 
 
Dr. Sebastian Kügler, for his excellent supervision, fruitful discussions and guiding me 
through the every-day-experiments, for creating nice and friendly atmosphere in the laboratory  
 
Prof. Mathias Bähr, for financial and mental support, for closely following my progress on the 
project 
 
My PhD Committee Members, Prof. Reinhard Jahn and Prof. Markus Missler, for the 
feedback on the project and supervision during the years of PhD 
 
My colleagues and friends in the laboratory, Dr. Malik Ibrahim, Manuel Garrido, Dr. Uwe 
Michel, Ulrike Schöll and Veronique Planchamp, for their helping hands and open hearts, for 
making my time in the laboratory and outside full of great memories 
 
My dear friends, Elena Kvachnina, Rocio Finol and Nataliya Korogod, always being there to 
share wonderful and sad moments, giving warmth and understanding like only family can give 
 
To all my friends in Göttingen, Ukraine and all-round-the-world for their helping hands and 
open minds 
 
Last, but not least, I want to thank my parents, for continuous support and love in every 

















Abou-Sleiman, P. M., Muqit, M. M., and Wood, N. W. (2006). Expanding insights of 
mitochondrial dysfunction in Parkinson's disease. Nat.Rev.Neurosci. 7: 207-219. 
Addison, C. L., Hitt, M., Kunsken, D., and Graham, F. L. (1997). Comparison of the human 
versus murine cytomegalovirus immediate early gene promoters for transgene expression by 
adenoviral vectors. J.Gen.Virol. 78 ( Pt 7): 1653-1661. 
Airaksinen, M. S. and Saarma, M. (2002). The GDNF family: signalling, biological functions 
and therapeutic value. Nat.Rev.Neurosci. 3: 383-394. 
Andersen, J. K. (2004). Oxidative stress in neurodegeneration: cause or consequence? 
Nat.Med. 10 Suppl: S18-S25. 
Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M. T., Michel, P. P., Marquez, J., Mouatt-
Prigent, A., Ruberg, M., Hirsch, E. C., and Agid, Y. (1997). Apoptosis and autophagy in 
nigral neurons of patients with Parkinson's disease. Histol.Histopathol. 12: 25-31. 
Arenas, E., Trupp, M., Akerud, P., and Ibanez, C. F. (1995). GDNF prevents degeneration 
and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 15: 1465-1473. 
Atkins, G. J., Sheahan, B. J., and Liljestrom, P. (1999). The molecular pathogenesis of 
Semliki Forest virus: a model virus made useful? J.Gen.Virol. 80 ( Pt 9): 2287-2297. 
Auricchio, A., Kobinger, G., Anand, V., Hildinger, M., O'Connor, E., Maguire, A. M., 
Wilson, J. M., and Bennett, J. (15-12-2001). Exchange of surface proteins impacts on viral 
vector cellular specificity and transduction characteristics: the retina as a model. 
Hum.Mol.Genet. 10: 3075-3081. 
Azzouz, M., Hottinger, A., Paterna, J. C., Zurn, A. D., Aebischer, P., and Bueler, H. (22-3-
2000). Increased motoneuron survival and improved neuromuscular function in transgenic 
ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. 
Hum.Mol.Genet. 9: 803-811. 
Bantel-Schaal, U., Delius, H., Schmidt, R., and zur, H. H. (1999). Human adeno-associated 
virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. 
J.Virol. 73: 939-947. 
Beal, M. F. (2005). Mitochondria take center stage in aging and neurodegeneration. 
Ann.Neurol. 58: 495-505. 
Bear, M. F., Connors, B. W., and Paradiso, M. A. Neuroscience: Exploring the Brain. [2nd 
ed.]. 2001.  Williams and Wilkins.  
 
Behrstock, S., Ebert, A., McHugh, J., Vosberg, S., Moore, J., Schneider, B., Capowski, E., 
Hei, D., Kordower, J., Aebischer, P., and Svendsen, C. N. (2006). Human neural progenitors 
deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. 
Gene Ther. 13: 379-388. 
Beilina, A., Van Der, B. M., Ahmad, R., Kesavapany, S., Miller, D. W., Petsko, G. A., and 
Cookson, M. R. (19-4-2005). Mutations in PTEN-induced putative kinase 1 associated with 
 85
  
recessive parkinsonism have differential effects on protein stability. 
Proc.Natl.Acad.Sci.U.S.A 102: 5703-5708. 
Ben Shachar, D., Zuk, R., and Glinka, Y. (1995). Dopamine neurotoxicity: inhibition of 
mitochondrial respiration. J.Neurochem. 64: 718-723. 
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and 
Greenamyre, J. T. (2000). Chronic systemic pesticide exposure reproduces features of 
Parkinson's disease. Nat.Neurosci. 3: 1301-1306. 
Björklund, A., Rosenblad, C., Winkler, C., and Kirik, D. (1997). Studies on neuroprotective 
and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. 
Neurobiol.Dis. 4: 186-200. 
Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S., and Brunak, S. (2004). Prediction 
of post-translational glycosylation and phosphorylation of proteins from the amino acid 
sequence. Proteomics. 4: 1633-1649. 
Blum, D., Torch, S., Lambeng, N., Nissou, M., Benabid, A. L., Sadoul, R., and Verna, J. M. 
(2001). Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: 
contribution to the apoptotic theory in Parkinson's disease. Prog.Neurobiol. 65: 135-172. 
Braak, H. and Braak, E. (2000). Pathoanatomy of Parkinson's disease. J.Neurol. 247 Suppl 2: 
II3-10. 
Buller, R. M., Janik, J. E., Sebring, E. D., and Rose, J. A. (1981). Herpes simplex virus types 
1 and 2 completely help adenovirus-associated virus replication. J.Virol. 40: 241-247. 
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., 
Reier, P. J., Mandel, R. J., and Muzyczka, N. (2004). Recombinant AAV viral vectors 
pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and 
cell tropism after delivery to different regions of the central nervous system. Mol.Ther. 10: 
302-317. 
Cacquevel, M., Lebeurrier, N., Cheenne, S., and Vivien, D. (2004). Cytokines in 
neuroinflammation and Alzheimer's disease. Curr.Drug Targets. 5: 529-534. 
Cadet, J. L., Zhu, S. M., and Angulo, J. A. (1992). Quantitative in situ hybridization evidence 
for differential regulation of proenkephalin and dopamine D2 receptor mRNA levels in the 
rat striatum: effects of unilateral intrastriatal injections of 6-hydroxydopamine. Brain 
Res.Mol.Brain Res. 12: 59-67. 
Cearley, C. N. and Wolfe, J. H. (2006). Transduction characteristics of adeno-associated 
virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol.Ther. 13: 
528-537. 
Chang, L. K., Putcha, G. V., Deshmukh, M., and Johnson, E. M., Jr. (2002). Mitochondrial 
involvement in the point of no return in neuronal apoptosis. Biochimie 84: 223-231. 
Chao, C. C., Ma, Y. L., Chu, K. Y., and Lee, E. H. (2003). Integrin alphav and NCAM 
mediate the effects of GDNF on DA neuron survival, outgrowth, DA turnover and motor 
activity in rats. Neurobiol.Aging 24: 105-116. 
 86
  
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., and Walsh, C. E. (2000). Several 
log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype 
vectors. Mol.Ther. 2: 619-623. 
Chen, J., Skehel, J. J., and Wiley, D. C. (29-9-1998). A polar octapeptide fused to the N-
terminal fusion peptide solubilizes the influenza virus HA2 subunit ectodomain. 
Biochemistry 37: 13643-13649. 
Cheng, E. H., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., and 
Korsmeyer, S. J. (2001). BCL-2, BCL-X(L) sequester BH3 domain-only molecules 
preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol.Cell 8: 705-711. 
Cheng, H., Wu, J. P., and Tzeng, S. F. (1-8-2002). Neuroprotection of glial cell line-derived 
neurotrophic factor in damaged spinal cords following contusive injury. J.Neurosci.Res. 69: 
397-405. 
Dauer, W. and Przedborski, S. (11-9-2003). Parkinson's disease: mechanisms and models. 
Neuron 39: 889-909. 
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, 
J., Ghodsi, A., and Chiorini, J. A. (28-3-2000). Recombinant adeno-associated virus type 2, 
4, and 5 vectors: transduction of variant cell types and regions in the mammalian central 
nervous system. Proc.Natl.Acad.Sci.U.S.A 97: 3428-3432. 
Dawson, T. M., Dawson, V. L., Gage, F. H., Fisher, L. J., Hunt, M. A., and Wamsley, J. K. 
(1991). Functional recovery of supersensitive dopamine receptors after intrastriatal grafts of 
fetal substantia nigra. Exp.Neurol. 111: 282-292. 
de Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa, S., 
Manubens-Bertran, J. M., Alperovitch, A., and Rocca, W. A. (1997). Prevalence of 
parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative 
Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. 
J.Neurol.Neurosurg.Psychiatry 62: 10-15. 
Deumens, R., Blokland, A., and Prickaerts, J. (2002). Modeling Parkinson's disease in rats: 
an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp.Neurol. 175: 303-317. 
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P., and 
Marsden, C. D. (1989a). Basal lipid peroxidation in substantia nigra is increased in 
Parkinson's disease. J.Neurochem. 52: 381-389. 
Dexter, D. T., Wells, F. R., Lees, A. J., Agid, F., Agid, Y., Jenner, P., and Marsden, C. D. 
(1989b). Increased nigral iron content and alterations in other metal ions occurring in brain in 
Parkinson's disease. J.Neurochem. 52: 1830-1836. 
Di Giovanni, S., Knoblach, S. M., Brandoli, C., Aden, S. A., Hoffman, E. P., and Faden, A. I. 
(2003). Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. 
Ann.Neurol. 53: 454-468. 
Di Pasquale, G., Davidson, B. L., Stein, C. S., Martins, I., Scudiero, D., Monks, A., and 
Chiorini, J. A. (2003). Identification of PDGFR as a receptor for AAV-5 transduction. 
Nat.Med. 9: 1306-1312. 
 87
  
Dong, J. Y., Fan, P. D., and Frizzell, R. A. (10-11-1996). Quantitative analysis of the 
packaging capacity of recombinant adeno-associated virus. Hum.Gene Ther. 7: 2101-2112. 
Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., and Engelhardt, 
J. F. (1998). Circular intermediates of recombinant adeno-associated virus have defined 
structural characteristics responsible for long-term episomal persistence in muscle tissue. 
J.Virol. 72: 8568-8577. 
Duan, D., Yue, Y., and Engelhardt, J. F. (2001). Expanding AAV packaging capacity with 
trans-splicing or overlapping vectors: a quantitative comparison. Mol.Ther. 4: 383-391. 
Eberhardt, O., Coelln, R. V., Kügler, S., Lindenau, J., Rathke-Hartlieb, S., Gerhardt, E., 
Haid, S., Isenmann, S., Gravel, C., Srinivasan, A., Bähr, M., Weller, M., Dichgans, J., and 
Schulz, J. B. (15-12-2000). Protection by synergistic effects of adenovirus-mediated X-
chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene 
transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. 
J.Neurosci. 20: 9126-9134. 
Ehrengruber, M. U., Renggli, M., Raineteau, O., Hennou, S., Vähä-Koskela, M. J., 
Hinkkanen, A. E., and Lundstrom, K. (2003). Semliki Forest virus A7(74) transduces 
hippocampal neurons and glial cells in a temperature-dependent dual manner. J.Neurovirol. 
9: 16-28. 
Elston, T., Wang, H., and Oster, G. (29-1-1998). Energy transduction in ATP synthase. 
Nature 391: 510-513. 
Eslamboli, A., Cummings, R. M., Ridley, R. M., Baker, H. F., Muzyczka, N., Burger, C., 
Mandel, R. J., Kirik, D., and Annett, L. E. (2003). Recombinant adeno-associated viral vector 
(rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common 
marmoset monkey (Callithrix jacchus). Exp.Neurol. 184: 536-548. 
Esselink, R. A., de Bie, R. M., de Haan, R. J., Lenders, M. W., Nijssen, P. C., Staal, M. J., 
Smeding, H. M., Schuurman, P. R., Bosch, D. A., and Speelman, J. D. (27-1-2004). 
Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized 
trial. Neurology 62: 201-207. 
Ewing, B. and Green, P. (2000). Analysis of expressed sequence tags indicates 35,000 human 
genes. Nat.Genet. 25: 232-234. 
Feany, M. B. and Bender, W. W. (23-3-2000). A Drosophila model of Parkinson's disease. 
Nature 404: 394-398. 
Fearnley, J. M. and Lees, A. J. (1991). Ageing and Parkinson's disease: substantia nigra 
regional selectivity. Brain 114 ( Pt 5): 2283-2301. 
Fleming, S. M., Fernagut, P. O., and Chesselet, M. F. (2005). Genetic mouse models of 
parkinsonism: strengths and limitations. NeuroRx. 2: 495-503. 
Floor, E. and Wetzel, M. G. (1998). Increased protein oxidation in human substantia nigra 
pars compacta in comparison with basal ganglia and prefrontal cortex measured with an 
improved dinitrophenylhydrazine assay. J.Neurochem. 70: 268-275. 
 88
  
Flotte, T. R., Afione, S. A., and Zeitlin, P. L. (1994). Adeno-associated virus vector gene 
expression occurs in nondividing cells in the absence of vector DNA integration. 
Am.J.Respir.Cell Mol.Biol. 11: 517-521. 
Flotte, T. R., Solow, R., Owens, R. A., Afione, S., Zeitlin, P. L., and Carter, B. J. (1992). 
Gene expression from adeno-associated virus vectors in airway epithelial cells. 
Am.J.Respir.Cell Mol.Biol. 7: 349-356. 
Foley, P. and Riederer, P. (1999). Pathogenesis and preclinical course of Parkinson's disease. 
J.Neural Transm.Suppl 56: 31-74. 
Fornai, F., Schluter, O. M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., 
Busceti, C. L., Pontarelli, F., Battaglia, G., Pellegrini, A., Nicoletti, F., Ruggieri, S., 
Paparelli, A., and Sudhof, T. C. (1-3-2005). Parkinson-like syndrome induced by continuous 
MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. 
Proc.Natl.Acad.Sci.U.S.A 102: 3413-3418. 
Forno, L. S. (1996). Neuropathology of Parkinson's disease. J.Neuropathol.Exp.Neurol. 55: 
259-272. 
Fuxe, K., Chadi, G., Tinner, B., Agnati, L. F., Pettersson, R., and David, G. (4-2-1994). On 
the regional distribution of heparan sulfate proteoglycan immunoreactivity in the rat brain. 
Brain Res. 636: 131-138. 
Gagnon, C., Bedard, P. J., Rioux, L., Gaudin, D., Martinoli, M. G., Pelletier, G., and Di 
Paolo, T. (6-9-1991). Regional changes of striatal dopamine receptors following denervation 
by 6-hydroxydopamine and fetal mesencephalic grafts in the rat. Brain Res. 558: 251-263. 
Gandhi, S. and Wood, N. W. (15-9-2005). Molecular pathogenesis of Parkinson's disease. 
Hum.Mol.Genet. 14: 2749-2755. 
Georgievska, B., Kirik, D., and Björklund, A. (2002a). Aberrant sprouting and 
downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced 
by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by 
lentiviral gene transfer. Exp.Neurol. 177: 461-474. 
Georgievska, B., Kirik, D., Rosenblad, C., Lundberg, C., and Björklund, A. (21-1-2002b). 
Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a 
lentiviral vector. Neuroreport 13: 75-82. 
Gerdes, C. A., Castro, M. G., and Löwenstein, P. R. (2000). Strong promoters are the key to 
highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery 
into the brain in vivo. Mol.Ther. 2: 330-338. 
Ghribi, O., Herman, M. M., Forbes, M. S., DeWitt, D. A., and Savory, J. (2001). GDNF 
protects against aluminum-induced apoptosis in rabbits by upregulating Bcl-2 and Bcl-XL 
and inhibiting mitochondrial Bax translocation. Neurobiol.Dis. 8: 764-773. 
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, 
D. J., Svendsen, C. N., and Heywood, P. (2003). Direct brain infusion of glial cell line-
derived neurotrophic factor in Parkinson disease. Nat.Med. 9: 589-595. 
Gotz, M. E., Dirr, A., Burger, R., Janetzky, B., Weinmuller, M., Chan, W. W., Chen, S. C., 
Reichmann, H., Rausch, W. D., and Riederer, P. (15-2-1994). Effect of lipoic acid on redox 
 89
  
state of coenzyme Q in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 
diethyldithiocarbamate. Eur.J.Pharmacol. 266: 291-300. 
Graham, D. G., Tiffany, S. M., Bell, W. R., Jr., and Gutknecht, W. F. (1978). Autoxidation 
versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-
hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. 
Mol.Pharmacol. 14: 644-653. 
Grondin, R. and Gash, D. M. (1998). Glial cell line-derived neurotrophic factor (GDNF): a 
drug candidate for the treatment of Parkinson's disease. J.Neurol. 245: 35-42. 
Grussenmeyer, T., Scheidtmann, K. H., Hutchinson, M. A., Eckhart, W., and Walter, G. 
(1985). Complexes of polyoma virus medium T antigen and cellular proteins. 
Proc.Natl.Acad.Sci.U.S.A 82: 7952-7954. 
Gunawardena, S. and Goldstein, L. S. (2005). Polyglutamine diseases and transport 
problems: deadly traffic jams on neuronal highways. Arch.Neurol. 62: 46-51. 
Hald, A. and Lotharius, J. (2005). Oxidative stress and inflammation in Parkinson's disease: 
is there a causal link? Exp.Neurol. 193: 279-290. 
Hauck, B., Chen, L., and Xiao, W. (2003). Generation and characterization of chimeric 
recombinant AAV vectors. Mol.Ther. 7: 419-425. 
Henderson, C. E., Phillips, H. S., Pollock, R. A., Davies, A. M., Lemeulle, C., Armanini, M., 
Simmons, L., Moffet, B., Vandlen, R. A., Simpson LC [corrected to Simmons, and . (11-11-
1994). GDNF: a potent survival factor for motoneurons present in peripheral nerve and 
muscle. Science 266: 1062-1064. 
Hengartner, M. O. (12-10-2000). The biochemistry of apoptosis. Nature 407: 770-776. 
Hildinger, M., Auricchio, A., Gao, G., Wang, L., Chirmule, N., and Wilson, J. M. (2001). 
Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene 
transfer. J.Virol. 75: 6199-6203. 
Hirsch, E. C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A., and Michel, P. P. (2003). 
The role of glial reaction and inflammation in Parkinson's disease. Ann.N.Y.Acad.Sci. 991: 
214-228. 
Hristova, A. H. and Koller, W. C. (2000). Early Parkinson's disease: what is the best 
approach to treatment. Drugs Aging 17: 165-181. 
Hughes, A. J., Ben Shlomo, Y., Daniel, S. E., and Lees, A. J. (2001). What features improve 
the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. 
Neurology 57: S34-S38. 
Ibanez, C. F. (1998). Emerging themes in structural biology of neurotrophic factors. Trends 
Neurosci. 21: 438-444. 
Jin, J., Meredith, G. E., Chen, L., Zhou, Y., Xu, J., Shie, F. S., Lockhart, P., and Zhang, J. 
(24-3-2005). Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy 
body formation and Parkinson's disease. Brain Res.Mol.Brain Res. 134: 119-138. 
 90
  
Johnson, K. Y., Liu, L., and Vincent, T. S. (2002). Minimal FLAG sequence useful in the 
functional epitope tagging of H-Ras. Biotechniques 32: 1270, 1272-6, 1278, 1280. 
Jollivet, C., Aubert-Pouessel, A., Clavreul, A., Venier-Julienne, M. C., Remy, S., Montero-
Menei, C. N., Benoit, J. P., and Menei, P. (2004). Striatal implantation of GDNF releasing 
biodegradable microspheres promotes recovery of motor function in a partial model of 
Parkinson's disease. Biomaterials 25: 933-942. 
Juraska, J. M., Wilson, C. J., and Groves, P. M. (15-4-1977). The substantia nigra of the rat: 
a Golgi study. J.Comp Neurol. 172: 585-600. 
Kaludov, N., Brown, K. E., Walters, R. W., Zabner, J., and Chiorini, J. A. (2001). Adeno-
associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for 
hemagglutination and efficient transduction but differ in sialic acid linkage specificity. 
J.Virol. 75: 6884-6893. 
Kandel, E. R., Schwartz, J. H., and Jessell, T. M. Principles of Neural Science. [ 4th ed.]. 
2000. New York, McGraw-Hill.  
 
Kaufmann, T., Schlipf, S., Sanz, J., Neubert, K., Stein, R., and Borner, C. (6-1-2003). 
Characterization of the signal that directs Bcl-x(L), but not Bcl-2, to the mitochondrial outer 
membrane. J.Cell Biol. 160: 53-64. 
Keogh, S. A., Walczak, H., Bouchier-Hayes, L., and Martin, S. J. (7-4-2000). Failure of Bcl-
2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Lett. 471: 
93-98. 
Kermer, P., Klöcker, N., and Bähr, M. (1999). Long-term effect of inhibition of ced 3-like 
caspases on the survival of axotomized retinal ganglion cells in vivo. Exp.Neurol. 158: 202-
205. 
Kim, I. K., Jung, Y. K., Noh, D. Y., Song, Y. S., Choi, C. H., Oh, B. H., Masuda, E. S., and 
Jung, Y. K. (24-3-2003). Functional screening of genes suppressing TRAIL-induced 
apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2. Br.J.Cancer 88: 910-917. 
Kim, R. (29-7-2005). Unknotting the roles of Bcl-2 and Bcl-xL in cell death. 
Biochem.Biophys.Res.Commun. 333: 336-343. 
Kirik, D., Annett, L. E., Burger, C., Muzyczka, N., Mandel, R. J., and Bjorklund, A. (4-3-
2003). Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression 
of human alpha-synuclein: a new primate model of Parkinson's disease. 
Proc.Natl.Acad.Sci.U.S.A 100: 2884-2889. 
Kirik, D., Georgievska, B., and Björklund, A. (2004). Localized striatal delivery of GDNF as 
a treatment for Parkinson disease. Nat.Neurosci. 7: 105-110. 
Kirik, D., Rosenblad, C., and Björklund, A. (1998). Characterization of behavioral and 
neurodegenerative changes following partial lesions of the nigrostriatal dopamine system 
induced by intrastriatal 6-hydroxydopamine in the rat. Exp.Neurol. 152: 259-277. 
Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, 
R. J., and Björklund, A. (1-4-2002). Parkinson-like neurodegeneration induced by targeted 
overexpression of alpha-synuclein in the nigrostriatal system. J.Neurosci. 22: 2780-2791. 
 91
  
Kish, S. J., Morito, C., and Hornykiewicz, O. (5-8-1985). Glutathione peroxidase activity in 
Parkinson's disease brain. Neurosci.Lett. 58: 343-346. 
Kishima, H., Poyot, T., Bloch, J., Dauguet, J., Conde, F., Dolle, F., Hinnen, F., Pralong, W., 
Palfi, S., Deglon, N., Aebischer, P., and Hantraye, P. (2004). Encapsulated GDNF-producing 
C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. 
Neurobiol.Dis. 16: 428-439. 
Klein, R. L., King, M. A., Hamby, M. E., and Meyer, E. M. (20-3-2002). Dopaminergic cell 
loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. 
Hum.Gene Ther. 13: 605-612. 
Kügler, S., Kilic, E., and Bähr, M. (2003a). Human synapsin 1 gene promoter confers highly 
neuron-specific long-term transgene expression from an adenoviral vector in the adult rat 
brain depending on the transduced area. Gene Ther. 10: 337-347. 
Kügler, S., Lingor, P., Schöll, U., Zolotukhin, S., and Bähr, M. (20-6-2003b). Differential 
transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small 
transcriptional control units. Virology 311: 89-95. 
Kügler, S., Meyn, L., Holzmuller, H., Gerhardt, E., Isenmann, S., Schulz, J. B., and Bähr, M. 
(2001). Neuron-specific expression of therapeutic proteins: evaluation of different cellular 
promoters in recombinant adenoviral vectors. Mol.Cell Neurosci. 17: 78-96. 
Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., 
Moro, E., Heywood, P., Brodsky, M. A., Burchiel, K., Kelly, P., Dalvi, A., Scott, B., Stacy, 
M., Turner, D., Wooten, V. G., Elias, W. J., Laws, E. R., Dhawan, V., Stoessl, A. J., 
Matcham, J., Coffey, R. J., and Traub, M. (2006). Randomized controlled trial of 
intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. 
Ann.Neurol. 59: 459-466. 
Lang, A. E. and Lozano, A. M. (15-10-1998). Parkinson's disease. Second of two parts. 
N.Engl.J.Med. 339: 1130-1143. 
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, 
M. J., Jonnalagada, S., Chernova, T., Dehejia, A., Lavedan, C., Gasser, T., Steinbach, P. J., 
Wilkinson, K. D., and Polymeropoulos, M. H. (1-10-1998). The ubiquitin pathway in 
Parkinson's disease. Nature 395: 451-452. 
Li, H., Li, S. H., Yu, Z. X., Shelbourne, P., and Li, X. J. (1-11-2001). Huntingtin aggregate-
associated axonal degeneration is an early pathological event in Huntington's disease mice. 
J.Neurosci. 21: 8473-8481. 
Liljestrom, P. and Garoff, H. (1991). A new generation of animal cell expression vectors 
based on the Semliki Forest virus replicon. Biotechnology (N.Y.) 9: 1356-1361. 
Lim, P. S., Jenson, A. B., Cowsert, L., Nakai, Y., Lim, L. Y., Jin, X. W., and Sundberg, J. P. 
(1990). Distribution and specific identification of papillomavirus major capsid protein 
epitopes by immunocytochemistry and epitope scanning of synthetic peptides. J.Infect.Dis. 
162: 1263-1269. 
Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S., and Collins, F. (21-5-1993). GDNF: a glial 




Liu, S. and Altman, R. B. (15-8-2003). Large scale study of protein domain distribution in 
the context of alternative splicing. Nucleic Acids Res. 31: 4828-4835. 
Lo, B. C., Deglon, N., Pralong, W., and Aebischer, P. (2004). Lentiviral nigral delivery of 
GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. 
Neurobiol.Dis. 17: 283-289. 
Lomri, N., Perret, C., Gouhier, N., and Thomasset, M. (1-8-1989). Cloning and analysis of 
calbindin-D28K cDNA and its expression in the central nervous system. Gene 80: 87-98. 
Lotharius, J. and Brundin, P. (1-10-2002a). Impaired dopamine storage resulting from alpha-
synuclein mutations may contribute to the pathogenesis of Parkinson's disease. 
Hum.Mol.Genet. 11: 2395-2407. 
Lotharius, J. and Brundin, P. (2002b). Pathogenesis of Parkinson's disease: dopamine, 
vesicles and alpha-synuclein. Nat.Rev.Neurosci. 3: 932-942. 
Love, S., Plaha, P., Patel, N. K., Hotton, G. R., Brooks, D. J., and Gill, S. S. (2005). Glial cell 
line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat.Med. 11: 
703-704. 
Lundstrom, K. (2005). Biology and application of alphaviruses in gene therapy. Gene Ther. 
12 Suppl 1: S92-S97. 
Lundstrom, K., Abenavoli, A., Malgaroli, A., and Ehrengruber, M. U. (2003). Novel Semliki 
Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term 
enhancement of transgene expression. Mol.Ther. 7: 202-209. 
Malik, J. M., Shevtsova, Z., Bähr, M., and Kügler, S. (2005). Long-term in vivo inhibition of 
CNS neurodegeneration by Bcl-XL gene transfer. Mol.Ther. 11: 373-381. 
Marini, P., Jendrossek, V., Durand, E., Gruber, C., Budach, W., and Belka, C. (2003). 
Molecular requirements for the combined effects of TRAIL and ionising radiation. 
Radiother.Oncol. 68: 189-198. 
Marjama-Lyons, J. M. and Koller, W. C. (2001). Parkinson's disease. Update in diagnosis 
and symptom management. Geriatrics 56: 24-30, 33. 
Mastakov, M. Y., Baer, K., Symes, C. W., Leichtlein, C. B., Kotin, R. M., and During, M. J. 
(2002). Immunological aspects of recombinant adeno-associated virus delivery to the 
mammalian brain. J.Virol. 76: 8446-8454. 
Mattson, M. P. and Chan, S. L. (2003). Calcium orchestrates apoptosis. Nat.Cell Biol. 5: 
1041-1043. 
Melov, S. (2004). Modeling mitochondrial function in aging neurons. Trends Neurosci. 27: 
601-606. 
Michel, U., Malik, I., Ebert, S., Bähr, M., and Kügler, S. (14-1-2005). Long-term in vivo and 
in vitro AAV-2-mediated RNA interference in rat retinal ganglion cells and cultured primary 
neurons. Biochem.Biophys.Res.Commun. 326: 307-312. 
Moskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., 
and Patel, S. D. (2000). Epitope mapping of human anti-adeno-associated virus type 2 
 93
  
neutralizing antibodies: implications for gene therapy and virus structure. J.Virol. 74: 1761-
1766. 
Motoyama, N., Wang, F., Roth, K. A., Sawa, H., Nakayama, K., Nakayama, K., Negishi, I., 
Senju, S., Zhang, Q., Fujii, S., and . (10-3-1995). Massive cell death of immature 
hematopoietic cells and neurons in Bcl-x-deficient mice. Science 267: 1506-1510. 
Nakajima, A., Kataoka, K., Hong, M., Sakaguchi, M., and Huh, N. H. (25-11-2003). BRPK, 
a novel protein kinase showing increased expression in mouse cancer cell lines with higher 
metastatic potential. Cancer Lett. 201: 195-201. 
Natsume, A., Mata, M., Goss, J., Huang, S., Wolfe, D., Oligino, T., Glorioso, J., and Fink, D. 
J. (2001). Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to 
protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp.Neurol. 169: 231-
238. 
Natsume, A., Mata, M., Wolfe, D., Oligino, T., Goss, J., Huang, S., Glorioso, J., and Fink, D. 
J. (2002). Bcl-2 and GDNF delivered by HSV-mediated gene transfer after spinal root 
avulsion provide a synergistic effect. J.Neurotrauma 19: 61-68. 
Newmeyer, D. D. and Ferguson-Miller, S. (21-2-2003). Mitochondria: releasing power for 
life and unleashing the machineries of death. Cell 112: 481-490. 
Nutt, J. G., Burchiel, K. J., Comella, C. L., Jankovic, J., Lang, A. E., Laws, E. R., Jr., 
Lozano, A. M., Penn, R. D., Simpson, R. K., Jr., Stacy, M., and Wooten, G. F. (14-1-2003). 
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. 
Neurology 60: 69-73. 
Offen, D., Beart, P. M., Cheung, N. S., Pascoe, C. J., Hochman, A., Gorodin, S., Melamed, 
E., Bernard, R., and Bernard, O. (12-5-1998). Transgenic mice expressing human Bcl-2 in 
their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- 
tetrahydropyridine neurotoxicity. Proc.Natl.Acad.Sci.U.S.A 95: 5789-5794. 
Olanow, C. W. and Stocchi, F. (13-1-2004). COMT inhibitors in Parkinson's disease: can 
they prevent and/or reverse levodopa-induced motor complications? Neurology 62: S72-S81. 
Opie, S. R., Warrington, K. H., Jr., Agbandje-McKenna, M., Zolotukhin, S., and Muzyczka, 
N. (2003). Identification of amino acid residues in the capsid proteins of adeno-associated 
virus type 2 that contribute to heparan sulfate proteoglycan binding. J.Virol. 77: 6995-7006. 
Paratcha, G., Ledda, F., and Ibanez, C. F. (27-6-2003). The neural cell adhesion molecule 
NCAM is an alternative signaling receptor for GDNF family ligands. Cell 113: 867-879. 
Parker, W. D., Jr., Boyson, S. J., and Parks, J. K. (1989). Abnormalities of the electron 
transport chain in idiopathic Parkinson's disease. Ann.Neurol. 26: 719-723. 
Passini, M. A., Watson, D. J., Vite, C. H., Landsburg, D. J., Feigenbaum, A. L., and Wolfe, J. 
H. (2003). Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in 
neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total 
long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. 
J.Virol. 77: 7034-7040. 
 94
  
Patel, N. K., Bunnage, M., Plaha, P., Svendsen, C. N., Heywood, P., and Gill, S. S. (2005). 
Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year 
outcome study. Ann.Neurol. 57: 298-302. 
Paterna, J. C., Feldon, J., and Bueler, H. (2004). Transduction profiles of recombinant adeno-
associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. 
J.Virol. 78: 6808-6817. 
Peel, A. L. and Klein, R. L. (1-6-2000). Adeno-associated virus vectors: activity and 
applications in the CNS. J.Neurosci.Methods 98: 95-104. 
Peel, A. L., Zolotukhin, S., Schrimsher, G. W., Muzyczka, N., and Reier, P. J. (1997). 
Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-
associated virus vectors containing cell type-specific promoters. Gene Ther. 4: 16-24. 
Perrelet, D., Ferri, A., MacKenzie, A. E., Smith, G. M., Korneluk, R. G., Liston, P., Sagot, 
Y., Terrado, J., Monnier, D., and Kato, A. C. (2000). IAP family proteins delay motoneuron 
cell death in vivo. Eur.J.Neurosci. 12: 2059-2067. 
Picada, J. N., Roesler, R., and Henriques, J. A. (2005). Genotoxic, neurotoxic and 
neuroprotective activities of apomorphine and its oxidized derivative 8-oxo-apomorphine. 
Braz.J.Med.Biol.Res. 38: 477-486. 
Previtali, S. C., Quattrini, A., Fasolini, M., Panzeri, M. C., Villa, A., Filbin, M. T., Li, W., 
Chiu, S. Y., Messing, A., Wrabetz, L., and Feltri, M. L. (27-11-2000). Epitope-tagged P(0) 
glycoprotein causes Charcot-Marie-Tooth-like neuropathy in transgenic mice. J.Cell Biol. 
151: 1035-1046. 
Qin, Z. H., Chen, R. W., Wang, Y., Nakai, M., Chuang, D. M., and Chase, T. N. (15-5-1999). 
Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during 
NMDA receptor-mediated apoptosis in rat striatum. J.Neurosci. 19: 4023-4033. 
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., and Srivastava, A. (1999). Human 
fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. 
Nat.Med. 5: 71-77. 
Rabinowitz, J. E., Bowles, D. E., Faust, S. M., Ledford, J. G., Cunningham, S. E., and 
Samulski, R. J. (2004). Cross-dressing the virion: the transcapsidation of adeno-associated 
virus serotypes functionally defines subgroups. J.Virol. 78: 4421-4432. 
Ramer, M. S., Priestley, J. V., and McMahon, S. B. (20-1-2000). Functional regeneration of 
sensory axons into the adult spinal cord. Nature 403: 312-316. 
Rideout, H. J. and Stefanis, L. (2001). Caspase inhibition: a potential therapeutic strategy in 
neurological diseases. Histol.Histopathol. 16: 895-908. 
Riederer, P. and Wuketich, S. (1976). Time course of nigrostriatal degeneration in 
parkinson's disease. A detailed study of influential factors in human brain amine analysis. 
J.Neural Transm. 38: 277-301. 
Rioux, L., Gaudin, D. P., Gagnon, C., Di Paolo, T., and Bedard, P. J. (1991). Decrease of 
behavioral and biochemical denervation supersensitivity of rat striatum by nigral transplants. 
Neuroscience 44: 75-83. 
 95
  
Rizzuto, R., Pinton, P., Brini, M., Chiesa, A., Filippin, L., and Pozzan, T. (1999). 
Mitochondria as biosensors of calcium microdomains. Cell Calcium 26: 193-199. 
Rosenblad, C., Georgievska, B., and Kirik, D. (2003). Long-term striatal overexpression of 
GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine 
system. Eur.J.Neurosci. 17: 260-270. 
Rosenblad, C., Kirik, D., and Björklund, A. (2000). Sequential administration of GDNF into 
the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting 
but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. 
Exp.Neurol. 161: 503-516. 
Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. [2nd 
ed.]. 1989. Cold Spring Harbor, Cold Spring Harbor Laboratory Press.  
 
Samulski, R. J., Chang, L. S., and Shenk, T. (1989). Helper-free stocks of recombinant 
adeno-associated viruses: normal integration does not require viral gene expression. J.Virol. 
63: 3822-3828. 
Sariola, H. and Saarma, M. (1-10-2003). Novel functions and signalling pathways for GDNF. 
J.Cell Sci. 116: 3855-3862. 
Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, 
H. S., Shuker, S. B., Chang, B. S., Minn, A. J., Thompson, C. B., and Fesik, S. W. (14-2-
1997). Structure of Bcl-xL-Bak peptide complex: recognition between regulators of 
apoptosis. Science 275: 983-986. 
Schaar, D. G., Sieber, B. A., Dreyfus, C. F., and Black, I. B. (1993). Regional and cell-
specific expression of GDNF in rat brain. Exp.Neurol. 124: 368-371. 
Schapira, A. H. (1994). Evidence for mitochondrial dysfunction in Parkinson's disease--a 
critical appraisal. Mov Disord. 9: 125-138. 
Schapira, A. H., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., and Marsden, C. D. 
(1990). Mitochondrial complex I deficiency in Parkinson's disease. J.Neurochem. 54: 823-
827. 
Schapira, A. H., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., and Marsden, C. D. (3-6-
1989). Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1269. 
Schmidt, R. H., Björklund, A., Stenevi, U., Dunnett, S. B., and Gage, F. H. (1983). 
Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral 
suspension implants as assessed by measurements of dopamine synthesis and metabolism. 
Acta Physiol Scand.Suppl 522: 19-28. 
Seniuk, N. A., Tatton, W. G., and Greenwood, C. E. (10-9-1990). Dose-dependent 
destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 527: 
7-20. 
Shapiro, L., Doyle, J. P., Hensley, P., Colman, D. R., and Hendrickson, W. A. (1996). 
Crystal structure of the extracellular domain from P0, the major structural protein of 
peripheral nerve myelin. Neuron 17: 435-449. 
 96
  
Shevtsova, Z., Malik, J. M., Michel, U., Bähr, M., and Kügler, S. (2005). Promoters and 
serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central 
nervous system in vitro and in vivo. Exp.Physiol 90: 53-59. 
Shindler, K. S., Latham, C. B., and Roth, K. A. (1-5-1997). Bax deficiency prevents the 
increased cell death of immature neurons in bcl-x-deficient mice. J.Neurosci. 17: 3112-3119. 
Sian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy-Agid, F., Jenner, P., and 
Marsden, C. D. (1994). Alterations in glutathione levels in Parkinson's disease and other 
neurodegenerative disorders affecting basal ganglia. Ann.Neurol. 36: 348-355. 
Sofic, E., Lange, K. W., Jellinger, K., and Riederer, P. (17-8-1992). Reduced and oxidized 
glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci.Lett. 142: 
128-130. 
Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G., and 
Youdim, M. B. (1988). Increased iron (III) and total iron content in post mortem substantia 
nigra of parkinsonian brain. J.Neural Transm. 74: 199-205. 
Srivastava, A., Lusby, E. W., and Berns, K. I. (1983). Nucleotide sequence and organization 
of the adeno-associated virus 2 genome. J.Virol. 45: 555-564. 
Staniek, K., Gille, L., Kozlov, A. V., and Nohl, H. (2002). Mitochondrial superoxide radical 
formation is controlled by electron bifurcation to the high and low potential pathways. Free 
Radic.Res. 36: 381-387. 
Stieger, K., Le Meur, G., Lasne, F., Weber, M., Deschamps, J. Y., Nivard, D., Mendes-
Madeira, A., Provost, N., Martin, L., Moullier, P., and Rolling, F. (24-1-2006). Long-term 
doxycycline-regulated transgene expression in the retina of nonhuman primates following 
subretinal injection of recombinant AAV vectors. Mol.Ther. 
Stokes, A. H., Hastings, T. G., and Vrana, K. E. (15-3-1999). Cytotoxic and genotoxic 
potential of dopamine. J.Neurosci.Res. 55: 659-665. 
Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount, S. L., Raman, 
R., Davies, P., Masliah, E., Williams, D. S., and Goldstein, L. S. (25-2-2005). Axonopathy 
and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282-
1288. 
Straten, G., Schmeer, C., Kretz, A., Gerhardt, E., Kügler, S., Schulz, J. B., Gravel, C., Bähr, 
M., and Isenmann, S. (2002). Potential synergistic protection of retinal ganglion cells from 
axotomy-induced apoptosis by adenoviral administration of glial cell line-derived 
neurotrophic factor and X-chromosome-linked inhibitor of apoptosis. Neurobiol.Dis. 11: 
123-133. 
Strauss, J. H. and Strauss, E. G. (1994). The alphaviruses: gene expression, replication, and 
evolution. Microbiol.Rev. 58: 491-562. 
Strauss, K. M., Martins, L. M., Plun-Favreau, H., Marx, F. P., Kautzmann, S., Berg, D., 
Gasser, T., Wszolek, Z., Muller, T., Bornemann, A., Wolburg, H., Downward, J., Riess, O., 
Schulz, J. B., and Krüger, R. (1-8-2005). Loss of function mutations in the gene encoding 
Omi/HtrA2 in Parkinson's disease. Hum.Mol.Genet. 14: 2099-2111. 
 97
  
Strelau, J. and Unsicker, K. (1999). GDNF family members and their receptors: expression 
and functions in two oligodendroglial cell lines representing distinct stages of 
oligodendroglial development. Glia 26: 291-301. 
Sulzer, D., Sonders, M. S., Poulsen, N. W., and Galli, A. (2005). Mechanisms of 
neurotransmitter release by amphetamines: a review. Prog.Neurobiol. 75: 406-433. 
Sulzer, D. and Zecca, L. (2000). Intraneuronal dopamine-quinone synthesis: a review. 
Neurotox.Res. 1: 181-195. 
Summerford, C., Bartlett, J. S., and Samulski, R. J. (1999). AlphaVbeta5 integrin: a co-
receptor for adeno-associated virus type 2 infection. Nat.Med. 5: 78-82. 
Sun, L., Li, J., and Xiao, X. (2000). Overcoming adeno-associated virus vector size limitation 
through viral DNA heterodimerization. Nat.Med. 6: 599-602. 
Takahashi, M. (2001). The GDNF/RET signaling pathway and human diseases. Cytokine 
Growth Factor Rev. 12: 361-373. 
Tenenbaum, L., Chtarto, A., Lehtonen, E., Velu, T., Brotchi, J., and Levivier, M. (2004). 
Recombinant AAV-mediated gene delivery to the central nervous system. J.Gene Med. 6 
Suppl 1: S212-S222. 
Terpe, K. (2003). Overview of tag protein fusions: from molecular and biochemical 
fundamentals to commercial systems. Appl.Microbiol.Biotechnol. 60: 523-533. 
Thress, K., Kornbluth, S., and Smith, J. J. (1999). Mitochondria at the crossroad of apoptotic 
cell death. J.Bioenerg.Biomembr. 31: 321-326. 
Tretter, L., Sipos, I., and Adam-Vizi, V. (2004). Initiation of neuronal damage by complex I 
deficiency and oxidative stress in Parkinson's disease. Neurochem.Res. 29: 569-577. 
Trupp, M., Arenas, E., Fainzilber, M., Nilsson, A. S., Sieber, B. A., Grigoriou, M., Kilkenny, 
C., Salazar-Grueso, E., Pachnis, V., and Arumae, U. (27-6-1996). Functional receptor for 
GDNF encoded by the c-ret proto-oncogene. Nature 381: 785-789. 
Trupp, M., Scott, R., Whittemore, S. R., and Ibanez, C. F. (23-7-1999). Ret-dependent and -
independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal 
cells. J.Biol.Chem. 274: 20885-20894. 
Ungerstedt, U. (1968). 6-Hydroxy-dopamine induced degeneration of central monoamine 
neurons. Eur.J.Pharmacol. 5: 107-110. 
Ungerstedt, U. and Arbuthnott, G. W. (18-12-1970). Quantitative recording of rotational 
behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. 
Brain Res. 24: 485-493. 
Unoki, M. and Nakamura, Y. (27-7-2001). Growth-suppressive effects of BPOZ and EGR2, 
two genes involved in the PTEN signaling pathway. Oncogene 20: 4457-4465. 
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., Ali, 
Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., Albanese, A., Nussbaum, R., Gonzalez-
Maldonado, R., Deller, T., Salvi, S., Cortelli, P., Gilks, W. P., Latchman, D. S., Harvey, R. J., 
 98
  
Dallapiccola, B., Auburger, G., and Wood, N. W. (21-5-2004). Hereditary early-onset 
Parkinson's disease caused by mutations in PINK1. Science 304: 1158-1160. 
van Adel, B. A., Kostic, C., Deglon, N., Ball, A. K., and Arsenijevic, Y. (20-1-2003). 
Delivery of ciliary neurotrophic factor via lentiviral-mediated transfer protects axotomized 
retinal ganglion cells for an extended period of time. Hum.Gene Ther. 14: 103-115. 
Van Den Eeden, S. K., Tanner, C. M., Bernstein, A. L., Fross, R. D., Leimpeter, A., Bloch, 
D. A., and Nelson, L. M. (1-6-2003). Incidence of Parkinson's disease: variation by age, 
gender, and race/ethnicity. Am.J.Epidemiol. 157: 1015-1022. 
von Bohlen und Halbach O., Schober, A., and Krieglstein, K. (2004). Genes, proteins, and 
neurotoxins involved in Parkinson's disease. Prog.Neurobiol. 73: 151-177. 
Wagenknecht, B., Glaser, T., Naumann, U., Kügler, S., Isenmann, S., Bähr, M., Korneluk, 
R., Liston, P., and Weller, M. (1999). Expression and biological activity of X-linked inhibitor 
of apoptosis (XIAP) in human malignant glioma. Cell Death.Differ. 6: 370-376. 
Walters, R. W., Yi, S. M., Keshavjee, S., Brown, K. E., Welsh, M. J., Chiorini, J. A., and 
Zabner, J. (8-6-2001). Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is 
required for gene transfer. J.Biol.Chem. 276: 20610-20616. 
Wang, H. Y., Baxter, C. F., Jr., and Schulz, H. (1991). Regulation of fatty acid beta-oxidation 
in rat heart mitochondria. Arch.Biochem.Biophys. 289: 274-280. 
Wang, L., Muramatsu, S., Lu, Y., Ikeguchi, K., Fujimoto, K., Okada, T., Mizukami, H., 
Hanazono, Y., Kume, A., Urano, F., Ichinose, H., Nagatsu, T., Nakano, I., and Ozawa, K. 
(2002). Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes 
functional recovery in a rat model of Parkinson's disease. Gene Ther. 9: 381-389. 
Weise, J., Isenmann, S., Klöcker, N., Kügler, S., Hirsch, S., Gravel, C., and Bähr, M. (2000). 
Adenovirus-mediated expression of ciliary neurotrophic factor (CNTF) rescues axotomized 
rat retinal ganglion cells but does not support axonal regeneration in vivo. Neurobiol.Dis. 7: 
212-223. 
Wilson, I. A., Niman, H. L., Houghten, R. A., Cherenson, A. R., Connolly, M. L., and 
Lerner, R. A. (1984). The structure of an antigenic determinant in a protein. Cell 37: 767-
778. 
Wong, L. F., Ralph, G. S., Walmsley, L. E., Bienemann, A. S., Parham, S., Kingsman, S. M., 
Uney, J. B., and Mazarakis, N. D. (2005). Lentiviral-mediated delivery of Bcl-2 or GDNF 
protects against excitotoxicity in the rat hippocampus. Mol.Ther. 11: 89-95. 
Woo, Y. J., Zhang, J. C., Taylor, M. D., Cohen, J. E., Hsu, V. M., and Sweeney, H. L. (28-4-
2005). One year transgene expression with adeno-associated virus cardiac gene transfer. 
Int.J.Cardiol. 100: 421-426. 
Yamada, M., Oligino, T., Mata, M., Goss, J. R., Glorioso, J. C., and Fink, D. J. (30-3-1999). 
Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-




Zhang, J., Perry, G., Smith, M. A., Robertson, D., Olson, S. J., Graham, D. G., and Montine, 
T. J. (1999). Parkinson's disease is associated with oxidative damage to cytoplasmic DNA 
and RNA in substantia nigra neurons. Am.J.Pathol. 154: 1423-1429. 
Zhang, L., Shimoji, M., Thomas, B., Moore, D. J., Yu, S. W., Marupudi, N. I., Torp, R., 
Torgner, I. A., Ottersen, O. P., Dawson, T. M., and Dawson, V. L. (15-7-2005). 
Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for 





















































Name:                 Zinayida Shevtsova 
Citizenship:        Ukrainian 
Date of birth:      12 August 1978 
Place of birth:     Dnipropetrovsk, Ukraine 




1993-1995 High school N 23, Dnipropetrovsk, Ukraine 
Graduation with honours 
1995-2001 Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine 
Diploma in general medicine with honours 
1999/ Oct-Dec   Clinical clerkship rotation, University of Rochester  
                           School of Medicine and Dentistry, USA 
2001-2002          International MSc/MD/PhD program in Neurosciences, Göttingen, Germany  
                           Completion of the 1st MSc year, admission to the PhD  
2002-2006          Department of Neurology, University Hospital, Göttingen, Germany 
                           PhD project in the framework of the International MSc/MD/PhD 












Shevtsova, Z., Malik, I. J. M., Michel, U., Bähr, M., and Kügler, S. (2005). Promoters and 
serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central 
nervous system in vitro and in vivo. Exp.Physiol 90: 53-59. 
Shevtsova, Z., Malik, J. M. I., Michel, U., Schöll, U., Bähr, M., Kügler, S. (2006). 
Evaluation of epitope tags for protein detection after in vivo CNS gene transfer. EJN 
(accepted for publication, Feb 2006)  
 
Shevtsova, Z., Malik, I. J. M., Garrido, M., Schöll, U., Bähr, M., and Kügler, S. (2006). 
Potentiation of in vivo neuroprotection by BclXL and GDNF co-expression depends on 
post-lesion time in deafferentiated CNS neurons. (submitted) 
 
Malik, J. M., Shevtsova, Z., Bähr, M., and Kügler, S. (2005). Long-term in vivo inhibition of 
CNS neurodegeneration by Bcl-XL gene transfer. Mol.Ther. 11: 373-381. 
 
 102
